PARP-1 Cleavage Patterns: Decoding the Molecular Signatures of Apoptosis vs. Necrosis

Abstract

This article provides a comprehensive analysis of the distinct proteolytic cleavage patterns of poly(ADP-ribose) polymerase-1 (PARP-1) during apoptosis and necrosis, two fundamentally different cell death pathways. Tailored for researchers and drug development professionals, we explore the foundational biology, detailing how specific proteases—caspases in apoptosis and lysosomal proteases like cathepsins in necrosis—generate unique PARP-1 fragments that serve as biochemical hallmarks. The content covers methodological approaches for detecting these signatures, addresses common challenges in experimental interpretation, and validates findings through comparative analysis across models. Understanding these patterns is crucial for accurate cell death assessment, elucidating disease mechanisms, and developing targeted therapeutic strategies that can influence cell fate decisions in cancer, neurodegeneration, and other pathologies.

The Fundamental Biology of PARP-1 Cleavage in Cell Death Pathways

Poly(ADP-ribose) polymerase-1 (PARP-1) is a highly abundant nuclear enzyme that serves as a critical molecular sensor for DNA damage, playing essential roles in DNA repair, genomic integrity maintenance, and cell death signaling pathways [1] [2]. This multifunctional protein exhibits a modular domain architecture that couples DNA damage detection to poly(ADP-ribosyl)ation activity, a unique post-translational modification involved in various nuclear processes [3]. PARP-1's structure enables it to participate in base excision repair (BER), single-strand break repair (SSBR), and alternative non-homologous end joining pathways [2]. Beyond its DNA repair functions, PARP-1 also influences chromatin structure, transcriptional regulation, and serves as a key substrate for proteolytic cleavage during different forms of cell death [2] [4]. Understanding the relationship between PARP-1's structural domains and their functions provides critical insights for developing PARP-1-targeted cancer therapies and understanding cellular stress responses.

Structural Domains of PARP-1: A Three-Zone Architecture

PARP-1 consists of three primary functional regions that work in concert to detect DNA damage and initiate appropriate cellular responses. The precise arrangement and coordination of these domains enable PARP-1 to function as an efficient molecular sensor for DNA integrity.

Table 1: Primary Structural Domains of Human PARP-1

Domain Name	Molecular Weight	Key Structural Features	Primary Functions
DNA-Binding Domain (DBD)	24 kDa	Three zinc finger motifs (Zn1, Zn2, Zn3), nuclear localization signal (NLS)	Recognizes and binds to DNA strand breaks, facilitates nuclear localization
Automodification Domain (AMD)	22 kDa	BRCT (BRCA1 C-terminus) fold, multiple glutamate residues	Serves as primary target for auto-poly(ADP-ribosyl)ation, mediates protein-protein interactions
Catalytic Domain (CAT)	54 kDa	Helical subdomain (HD), ART subdomain, NAD+ binding site	Catalyzes poly(ADP-ribose) polymer formation from NAD+ substrate

The DNA-binding domain (DBD) located at the N-terminus contains two zinc fingers (Zn1 and Zn2) that specifically recognize DNA strand breaks, with Zn2 playing a predominant role in binding DNA single-strand breaks [5]. A third zinc finger (Zn3) has a distinct structure and function from Zn1 and Zn2, contributing to interdomain interactions essential for PARP-1 activation [1]. The DBD facilitates PARP-1's tight binding to various DNA lesions including single-strand breaks, double-strand breaks, and cruciform structures [2].

The central automodification domain (AMD) contains a BRCT fold that is found in many DNA repair proteins and facilitates protein-protein interactions [2]. This domain bears the major sites for PARP-1 automodification, including glutamate residues 488, 491 and serine residues 499, 507, and 519, which serve as acceptors for ADP-ribose units [6]. Automodification negatively regulates PARP-1's DNA binding affinity and facilitates the recruitment of other DNA repair proteins to damage sites [4].

The C-terminal catalytic domain (CAT) is composed of two key subdomains: the helical subdomain (HD) and the ADP-ribosyl transferase (ART) subdomain [1]. The ART subdomain contains conserved amino acids involved in catalysis and NAD+ binding, while the HD plays a regulatory role in PARP-1 activation [1] [6]. The WGR domain, named for its conserved Trp-Gly-Arg sequence, serves as a central component that interacts with Zn1, Zn3, CAT, and DNA, forming a bridge between the DNA damage interface and the catalytic domain [1].

Diagram 1: PARP-1 domain architecture showing the linear arrangement of functional domains and key subdomains. The DBD contains zinc fingers for DNA damage recognition, while the CAT domain comprises specialized subdomains for catalytic function.

DNA Damage-Induced Activation Mechanism

PARP-1 activation represents a sophisticated molecular mechanism that transforms DNA damage detection into catalytic activity. In the absence of DNA damage, PARP-1 maintains a basal level of activity, but binding to DNA strand breaks increases its catalytic activity by more than 500-fold [6]. Structural studies reveal that PARP-1 engages DNA damage as a monomer, with the Zn1, Zn3, and WGR domains collectively binding to DNA to form a network of interdomain contacts that link the DNA damage interface to the catalytic domain [1].

The activation mechanism involves significant conformational changes in PARP-1 upon DNA binding. The WGR domain serves as a central hub, interacting with Zn1, Zn3, CAT, and DNA simultaneously [1]. Key interfacial contacts include a salt bridge between Asp45 of Zn1 and Arg591 of WGR, with Arg591 additionally interacting with the HD subdomain [1]. This interdomain networking results in structural distortions that destabilize the helical subdomain (HD) of the CAT domain, particularly affecting its hydrophobic core [1]. This destabilization increases CAT domain dynamics, which underlies the DNA-dependent activation mechanism rather than directly affecting NAD+ access to the active site [1].

Mutation studies confirm the importance of these interdomain contacts, with mutations at key interfacial residues causing severe to moderate defects in DNA-dependent PARP-1 activity [1]. Interestingly, specific mutations targeting the HD hydrophobic core (such as L713F) can simulate DNA-induced HD distortions and increase DNA-independent PARP-1 activity by up to 20-fold, demonstrating the critical role of HD destabilization in PARP-1 activation [1].

PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

PARP-1 serves as a hallmark substrate for various proteases during cell death, with distinct cleavage patterns characterizing different cell death pathways. These specific proteolytic signatures provide valuable biomarkers for identifying particular forms of cell death and understanding their underlying mechanisms.

Table 2: Comparative Analysis of PARP-1 Cleavage Patterns in Cell Death Pathways

Characteristic	Apoptosis	Necrosis
Primary Proteases	Caspase-3 and Caspase-7	Lysosomal proteases (cathepsins B, D, G)
Characteristic Fragments	89 kDa (CAD) and 24 kDa (DBD)	50 kDa (major), 89 kDa, 40 kDa, 35 kDa
Caspase Inhibitor Sensitivity	Inhibited by zVAD-fmk	Not inhibited by zVAD-fmk
DNA Degradation Pattern	Internucleosomal laddering	Random, diffuse degradation
Functional Consequences	Inactivation of PARP-1 to conserve energy	Extensive proteolytic degradation

During apoptosis, PARP-1 is cleaved specifically by caspase-3 and caspase-7 at the DEVD216↓G217 motif located within the AMD domain, producing characteristic fragments of 89 kDa and 24 kDa [2] [7]. The 89 kDa fragment contains the automodification and catalytic domains but has greatly reduced DNA binding capacity and is liberated from the nucleus into the cytosol [2]. The 24 kDa fragment, comprising the DBD with its two zinc finger motifs, remains in the nucleus where it irreversibly binds to damaged DNA and acts as a trans-dominant inhibitor of BER by blocking access of intact PARP-1 and other DNA repair enzymes to strand breaks [2]. This cleavage event serves to conserve cellular ATP pools during the execution phase of apoptosis and represents one of the most recognized biomarkers for apoptotic cell death [2].

In contrast, necrosis involves a different proteolytic processing of PARP-1 mediated by lysosomal proteases. Treatment of HL-60 cells with necrotic inducers such as H₂O₂, ethanol, or HgCl₂ results in the formation of a major PARP-1 fragment at approximately 50 kDa along with minor fragments of 40 kDa and 35 kDa, in addition to the 89 kDa fragment [8] [7]. This necrotic cleavage pattern is not inhibited by the broad-spectrum caspase inhibitor zVAD-fmk, distinguishing it from apoptotic cleavage [8]. Isolated lysosomal-rich fractions and purified lysosomal proteases (cathepsins B and G) can reproduce this distinctive cleavage pattern in vitro, confirming the role of lysosomal proteases in necrotic PARP-1 processing [8]. The extensive degradation of PARP-1 during necrosis reflects the uncontrolled proteolytic environment characteristic of this inflammatory cell death pathway.

Diagram 2: PARP-1 cleavage pathways in apoptosis versus necrosis. Apoptosis involves specific cleavage by caspases into defined fragments, while necrosis results in more extensive degradation by lysosomal proteases.

Experimental Approaches for PARP-1 Cleavage Analysis

Cell Culture and Death Induction Protocols

Research investigating PARP-1 cleavage patterns typically employs established cell lines (e.g., HL-60 human promyelocytic leukemia cells) treated with specific inducters to trigger different death pathways [8] [7]. For apoptosis induction, cells are commonly treated with 50-100 μM etoposide (VP-16) or 1 μM staurosporine for 4-16 hours [8] [2]. For necrosis induction, protocols include treatment with 0.1% H₂O₂, 10% ethanol, or 100 μM HgCl₂ for similar durations [8]. To distinguish caspase-dependent apoptosis from other death pathways, researchers often pre-treat cells with 50-100 μM zVAD-fmk, a broad-spectrum caspase inhibitor, for 1-2 hours before applying death inducers [8].

PARP-1 Cleavage Detection Methods

Western Blot Analysis represents the primary method for detecting PARP-1 cleavage fragments. Standard protocols involve separating cellular proteins by SDS-PAGE (6-12% gels) followed by transfer to PVDF or nitrocellulose membranes [8] [2]. Primary antibodies specific for PARP-1 N-terminal (for detecting 24 kDa fragment) or C-terminal epitopes (for detecting 89 kDa fragment) are used at dilutions ranging from 1:1,000 to 1:5,000 [2]. The characteristic fragments are identified by comparing their molecular weights to pre-stained protein markers: 89 kDa and 24 kDa for apoptosis, and 50 kDa, 40 kDa, and 35 kDa fragments in addition to the 89 kDa fragment for necrosis [8] [7].

Activity-Western Blot Techniques combine nonisotopic activity detection with immunoblotting to simultaneously assess PARP-1 fragmentation and catalytic function [2]. This approach involves in vitro PAR synthesis assays using NAD+ as substrate followed by detection with specific anti-PAR antibodies, allowing researchers to determine which cleavage fragments retain catalytic activity [2].

Flow Cytometric Analysis of PARP-1 cleavage can be performed in conjunction with other cell death markers (e.g., annexin V staining for phosphatidylserine exposure, propidium iodide uptake for membrane integrity) to correlate PARP-1 cleavage patterns with specific death phenotypes [7]. This multi-parameter approach helps distinguish between apoptotic and necrotic populations within heterogeneous cell samples.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for PARP-1 Cleavage Studies

Reagent/Category	Specific Examples	Research Applications	Experimental Function
Cell Death Inducers	Etoposide (VP-16), Staurosporine, H₂O₂, Ethanol, HgCl₂	Induction of apoptosis vs. necrosis	Trigger specific cell death pathways for PARP-1 cleavage analysis
Protease Inhibitors	zVAD-fmk (caspase inhibitor), E64d (cysteine protease inhibitor), Pepstatin A (aspartyl protease inhibitor)	Pathway specificity determination	Distinguish between caspase-dependent and independent cleavage events
PARP-1 Antibodies	N-terminal specific, C-terminal specific, anti-PAR antibodies	Detection of cleavage fragments by Western blot	Identify specific PARP-1 fragments and determine cleavage patterns
Lysosomal Preparations	Lysosomal-rich fractions, purified cathepsins B, D, G	In vitro cleavage assays	Reproduce necrotic cleavage patterns and identify responsible proteases
Activity Assay Components	NAD+, histone substrates, PARG inhibitors	Catalytic function of cleavage fragments	Assess functional consequences of PARP-1 cleavage

Implications for Cancer Therapy and Drug Development

The distinct cleavage patterns of PARP-1 have significant implications for cancer therapy and drug development. PARP-1 inhibitors (PARPi) represent a promising class of anticancer agents that exploit synthetic lethality in tumors with deficient DNA repair pathways, particularly BRCA-mutated cancers [3] [9]. Understanding PARP-1's structure and cleavage behavior provides critical insights for developing these therapeutic approaches.

PARP-1's role as a DNA damage sensor and its involvement in multiple DNA repair pathways make it an attractive target for combination therapies [3]. The differential cleavage of PARP-1 during cell death pathways serves as an important pharmacodynamic biomarker for assessing treatment efficacy and understanding mechanisms of action of anticancer therapies [2] [7]. Additionally, the development of PARP-1 inhibitors has evolved through multiple generations, with current research focusing on dual-targeted inhibitors and combination strategies to overcome resistance mechanisms that cancer cells develop [9].

The structural insights into PARP-1's domain organization and activation mechanism have been instrumental in rational drug design [1] [9]. Understanding how PARP-1 engages DNA damage and undergoes conformational changes has enabled the development of inhibitors that trap PARP-1 on DNA, creating cytotoxic lesions that enhance therapeutic efficacy [1] [3]. Furthermore, the characterization of PARP-1 cleavage fragments in different cell death contexts provides valuable biomarkers for monitoring treatment response and understanding whether cancer cell death occurs primarily through apoptotic or necrotic mechanisms following therapy [2] [7].

The proteolytic cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) is a well-established biochemical hallmark of programmed cell death. This nuclear enzyme, crucial for DNA repair and genome maintenance, becomes a key substrate for specific proteases during cell death initiation and execution. Among these processes, apoptotic cleavage by caspases generates distinctive 89 kDa and 24 kDa signature fragments that serve as definitive biomarkers for identifying caspase-dependent apoptosis in experimental and clinical contexts. Within the broader thesis comparing PARP-1 cleavage patterns across different cell death pathways, this signature stands in sharp contrast to the fragmentation patterns observed during necrosis, parthanatos, and other caspase-independent death mechanisms. The specific cleavage of PARP-1 not only inactivates its DNA repair function but also generates fragments with potential signaling roles, making it a critical event in the commitment to cellular demise [2] [10].

Molecular Anatomy of PARP-1 and Its Caspase Cleavage Site

PARP-1 is a modular protein containing several functional domains that dictate its activity and fate during cell death. The DNA-binding domain (DBD), located at the N-terminus, contains two zinc finger motifs that facilitate its attachment to DNA strand breaks. The central auto-modification domain (AMD) serves as a target for covalent poly(ADP-ribosyl)ation, while the C-terminal catalytic domain (CD) carries the enzyme's poly(ADP-ribose) polymerase activity [2].

During apoptosis, executioner caspases-3 and -7 recognize and cleave PARP-1 at a specific DEVD214↓G motif (located between aspartic acid 214 and glycine 215), situated within the nuclear localization signal near the DNA-binding domain [2] [10]. This proteolytic event separates the N-terminal DNA-binding domain (24 kDa) from the C-terminal fragment (89 kDa) containing the AMD and catalytic domains [2]. The table below summarizes the characteristics of these signature fragments:

Table 1: PARP-1 Signature Fragments Generated by Caspase Cleavage

Fragment Size	Domains Contained	Cellular Localization Post-Cleavage	Functional Consequences
24 kDa	DNA-binding domain (DBD) with two zinc finger motifs	Remains tightly bound to DNA in the nucleus	Acts as a trans-dominant inhibitor of DNA repair by blocking access of intact PARP-1 and other repair enzymes to DNA strand breaks
89 kDa	Auto-modification domain (AMD) and catalytic domain (CD)	Liberated from nucleus into the cytosol	Has greatly reduced DNA binding capacity; may function as a cytoplasmic PAR carrier in parthanatos

This cleavage event is considered a hallmark of apoptosis because it effectively inactivates PARP-1's DNA repair function, conserving cellular ATP pools that would otherwise be depleted by excessive PARP-1 activation, and thus facilitating the apoptotic process [2] [10].

Comparative Analysis of PARP-1 Cleavage Across Cell Death Pathways

The cleavage of PARP-1 occurs in multiple forms of cell death, but the proteases responsible, the cleavage sites, and the resulting fragments differ substantially. This creates distinctive molecular signatures that researchers can use to identify the specific cell death pathway activated in experimental systems or pathological conditions.

Table 2: PARP-1 Cleavage Patterns Across Different Cell Death Pathways

Cell Death Pathway	Key Proteases Involved	Characteristic PARP-1 Fragments	Inhibitor Sensitivity	Functional Outcome
Apoptosis	Caspases-3 and -7	89 kDa and 24 kDa	zVAD-fmk sensitive	Inactivation of DNA repair; conservation of ATP; facilitation of apoptotic program
Necrosis	Lysosomal proteases (cathepsins B and G)	50 kDa (major), ~40 kDa, ~35 kDa, and 89 kDa	zVAD-fmk insensitive	Unclear functional significance; may reflect general proteolytic degradation
Parthanatos	(PARP-1 overactivation without proteolytic cleavage as initial trigger)	(No characteristic cleavage fragments)	(PARP inhibitors prevent)	PAR-mediated AIF release from mitochondria; large-scale DNA fragmentation

The differential cleavage of PARP-1 provides researchers with critical diagnostic tools for distinguishing between apoptosis and necrosis, particularly in experimental systems where both death modalities may be present. The appearance of the 89 kDa and 24 kDa fragments strongly indicates caspase activation and apoptosis, while the presence of a predominant 50 kDa fragment suggests necrotic death mediated by lysosomal proteases [8] [11].

Experimental Protocols for Detecting PARP-1 Cleavage

Standard Workflow for Induction and Detection of Apoptotic PARP-1 Cleavage

The following diagram illustrates a generalized experimental workflow for inducing apoptosis and detecting PARP-1 cleavage:

Key Methodological Details

Cell Culture and Apoptosis Induction: Commonly used cell lines include HL-60 human promyelocytic leukemia cells and Jurkat T-cells. Apoptosis is typically induced using staurosporine (0.1-1 µM), etoposide (VP-16, 10-100 µM), or actinomycin D (0.5-5 µg/mL) for varying durations (2-24 hours) depending on the cell type and inducer concentration [8] [11].

Sample Preparation and Western Blotting: Cells are lysed using RIPA or similar buffers containing protease inhibitors. Protein samples are separated by SDS-PAGE (8-12% gels) and transferred to PVDF or nitrocellulose membranes. PARP-1 cleavage fragments are detected using specific antibodies recognizing different PARP-1 epitopes. The 89 kDa fragment is typically detected with antibodies against the catalytic domain, while the 24 kDa fragment requires antibodies targeting the DNA-binding domain [8] [11].

Caspase Activity Assays: DEVD-ase activity (caspases-3 and -7) is measured using colorimetric (acetyl-Asp-Glu-Val-Asp-p-nitroanilide) or fluorogenic substrates. Activity peaks approximately 6 hours after apoptosis induction in Jurkat cells, preceding maximal PARP-1 cleavage [12].

Inhibitor Controls: Specificity of apoptotic cleavage is confirmed using the broad-spectrum caspase inhibitor zVAD-fmk (20-100 µM), which should prevent generation of the 89 kDa and 24 kDa fragments but not affect necrosis-associated cleavage [8].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Studying PARP-1 Cleavage

Reagent Category	Specific Examples	Experimental Function	Application Notes
Apoptosis Inducers	Staurosporine, Etoposide (VP-16), Actinomycin D	Trigger intrinsic apoptosis pathway leading to caspase activation	Concentration and time course must be optimized for each cell type
Caspase Inhibitors	zVAD-fmk (pan-caspase), Z-DEVD-fmk (caspase-3/7 specific)	Confirm caspase-dependent cleavage; distinguish apoptosis from necrosis	Use 20-100 µM concentration, pre-incubate 1-2 hours before apoptosis inducer
Necrosis Inducers	Hydrogen Peroxide (0.1%), Ethanol (10%), Mercuric Chloride (100 µM)	Induce necrotic cell death for comparative studies	Generate 50 kDa PARP-1 fragment via lysosomal proteases
PARP-1 Antibodies	Anti-catalytic domain, Anti-DNA-binding domain, Anti-full length	Detect specific PARP-1 fragments by Western blot	Antibody selection critical for identifying specific fragments (e.g., 24 kDa requires DBD-specific antibodies)
Activity Assays	DEVD-pNA (colorimetric), DEVD-AFC (fluorogenic)	Measure caspase-3/7 activity	Correlate enzymatic activity with PARP-1 cleavage pattern
Cell Death Markers	Annexin V/PI staining, LDH release, Hoechst staining	Confirm and quantify apoptosis vs necrosis	Provide orthogonal validation of cell death modality

Caspase-Mediated PARP-1 Cleavage in Pathological Contexts

Caspase-mediated PARP-1 cleavage has significant implications in various pathological conditions, particularly in neurological diseases and cancer. In cerebral ischemia, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and excitotoxicity, PARP-1 cleavage serves as a marker of apoptotic neuronal death [2] [13] [14]. The extent of PARP-1 cleavage often correlates with disease severity and progression, making it a potential biomarker for therapeutic monitoring.

In cancer biology, PARP-1 cleavage patterns provide insights into treatment responses. Many chemotherapeutic agents induce apoptosis in cancer cells, with PARP-1 cleavage serving as an early marker of treatment efficacy [2]. Interestingly, recent research has revealed that during secondary necrosis following chemotherapy, active caspases-3 and -7 can be released into the extracellular space where they may contribute to extracellular proteolytic networks in the tumor microenvironment [12].

The interconnected nature of cell death pathways is exemplified by the finding that caspase-generated 89 kDa PARP-1 fragments with covalently attached PAR polymers can translocate to the cytoplasm and facilitate apoptosis-inducing factor (AIF) release from mitochondria, creating a molecular bridge between apoptosis and parthanatos [10].

The apoptotic cleavage of PARP-1 into characteristic 89 kDa and 24 kDa fragments remains a cornerstone biomarker for identifying caspase-dependent apoptosis in experimental and clinical contexts. The precise molecular signature of this event—distinct from necrosis-associated PARP-1 cleavage—provides researchers with a critical diagnostic tool for differentiating cell death modalities. As our understanding of PARP-1's roles in various cell death pathways continues to evolve, the detection and interpretation of its cleavage fragments will remain essential for basic research, drug discovery, and therapeutic monitoring across a spectrum of human diseases.

The cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) serves as a critical molecular signature distinguishing different forms of cell death. While its caspase-mediated cleavage during apoptosis is well-characterized, the necrotic cleavage of PARP-1 presents a distinct proteolytic pattern driven by lysosomal proteases. This review systematically compares PARP-1 cleavage patterns in apoptosis versus necrosis, highlighting the prominent 50 kDa fragment generated during necrosis through the action of cathepsins and other lysosomal enzymes. We provide comprehensive experimental data, detailed methodologies, and visual schematics to guide researchers in identifying and interpreting these cleavage events, offering valuable insights for drug development targeting specific cell death pathways.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a 113 kDa nuclear enzyme crucial for DNA repair and maintenance of genomic integrity. Beyond its physiological roles, PARP-1 serves as a key substrate for various proteases activated during different cell death programs. The specific cleavage patterns of PARP-1 have emerged as reliable biomarkers for distinguishing between apoptosis and necrosis, two fundamentally distinct cellular demise processes with different implications for health and disease [2].

During apoptosis, a programmed and regulated cell death process, PARP-1 is cleaved by caspases into characteristic 89 kDa and 24 kDa fragments. In contrast, necrosis involves a different proteolytic cascade resulting in a prominent 50 kDa fragment along with other cleavage products [8] [11]. This necrotic cleavage is mediated not by caspases but by lysosomal proteases released during cellular disruption, particularly cathepsins B and G [8]. Understanding these distinct cleavage patterns provides researchers with critical tools for identifying specific cell death mechanisms in experimental models and pathological conditions.

Comparative Analysis of PARP-1 Cleavage Patterns

The cleavage of PARP-1 occurs at different sites and through different enzymatic mechanisms in apoptosis versus necrosis, resulting in functionally distinct fragments.

Apoptotic Cleavage of PARP-1

In apoptosis, PARP-1 is primarily cleaved by effector caspases-3 and -7 at a specific aspartic acid residue within the nuclear localization signal (NLS) located between the DNA-binding domain (DBD) and the automodification domain (AMD) [2] [15]. This proteolytic event produces two well-defined fragments:

• An 89 kDa fragment containing the automodification domain (AMD) and catalytic domain (CD)
• A 24 kDa fragment containing the DNA-binding domain (DBD) with two zinc finger motifs [2]

The 89 kDa fragment, which retains the catalytic domain, can be poly(ADP-ribosyl)ated and has been recently found to translocate to the cytoplasm under certain conditions, where it may function as a poly(ADP-ribose) (PAR) carrier to induce apoptosis-inducing factor (AIF)-mediated cell death [15]. The 24 kDa fragment remains nuclear-bound, where it acts as a trans-dominant inhibitor of DNA repair by irreversibly binding to DNA strand breaks, thereby preventing recruitment of DNA repair machinery and conserving cellular ATP pools [2].

Necrotic Cleavage of PARP-1

During necrosis, PARP-1 undergoes a completely different cleavage pattern mediated by lysosomal proteases rather than caspases. This process generates multiple fragments, with the most prominent being:

• A major 50 kDa fragment
• Additional fragments at ∼89, 40, and 35 kDa [8] [11]

This cleavage pattern is not inhibited by broad-spectrum caspase inhibitors like zVAD-fmk, confirming the non-caspase-mediated nature of this proteolytic event [8]. The 50 kDa fragment represents a signature cleavage product specific to necrotic cell death, making it a valuable diagnostic marker for distinguishing necrosis from apoptosis.

Table 1: Comparative Analysis of PARP-1 Cleavage in Apoptosis vs. Necrosis

Feature	Apoptosis	Necrosis
Primary Cleavage Fragments	89 kDa and 24 kDa	50 kDa (major), plus 89, 40, and 35 kDa
Responsible Proteases	Caspases-3 and -7	Cathepsins B and G (lysosomal proteases)
Caspase Inhibitor Sensitivity	Sensitive to zVAD-fmk	Insensitive to zVAD-fmk
DNA-binding Fragment	24 kDa fragment binds irreversibly to DNA	Multiple fragments with different DNA binding properties
Catalytic Fragment	89 kDa fragment with reduced activity	Various fragments with potentially modified activities
Subcellular Localization	24 kDa nuclear, 89 kDa nuclear/cytoplasmic	Fragments distributed according to size and properties

Table 2: PARP-1 Domains and Their Functions

Domain	Size	Location	Function
DNA-Binding Domain (DBD)	46 kDa	N-terminus	Contains two zinc finger motifs; recognizes and binds to DNA breaks
Auto-Modification Domain (AMD)	22 kDa	Central region	Target for covalent auto-modification; contains BRCT fold for protein-protein interactions
Catalytic Domain (CD)	54 kDa	C-terminus	Polymerizes poly(ADP-ribose) units from NAD+ onto target proteins

Lysosomal Proteases in Necrotic PARP-1 Cleavage

Mechanisms of Lysosomal Protease Release

Necrosis is characterized by the loss of lysosomal membrane integrity, resulting in the release of various cathepsins and other hydrolytic enzymes into the cytosol. These proteases, normally compartmentalized within lysosomes, gain access to nuclear substrates like PARP-1 during necrotic cell death [8]. Multiple necrotic inducers can trigger this process, including:

• Oxidative stress (e.g., 0.1% H₂O₂)
• Chemical toxins (e.g., 100 μM HgCl₂)
• Metabolic disruptors (e.g., 10% EtOH) [8]

The temporal sequence of events places PARP-1 cleavage early in the necrotic process, coinciding with other flow cytometric changes but preceding extensive DNA degradation [11].

Specific Lysosomal Proteases Involved

Research using lysosomal rich-fractions from Jurkat T cells has identified several specific cathepsins responsible for PARP-1 cleavage during necrosis:

• Cathepsin B: Generates fragments corresponding to those observed in intact cells treated with necrotic inducers
• Cathepsin G: Produces similar cleavage patterns to cathepsin B
• Other lysosomal proteases: Likely contribute to the complete necrotic cleavage pattern [8]

The in vitro cleavage of affinity-purified bovine PARP-1 by these purified enzymes produces fragments matching those observed in necrotic cells, confirming their direct role in this process [8].

Experimental Models and Methodologies

Cell Culture Models for Studying Necrotic Cleavage

Several well-established cell models have been utilized to characterize PARP-1 cleavage during necrosis:

• HL-60 cells (human promyelocytic leukemia): Treated with cytochalasin B to induce necrosis [11]
• Jurkat T cells: Treated with H₂O₂, ethanol, or HgCl₂ as necrotic inducers [8]
• HK-2 cells (human kidney proximal tubular): Treated with doxorubicin to study PARP-1-mediated necrosis [16]

These models provide reproducible systems for analyzing the distinct 50 kDa PARP-1 fragment that serves as a hallmark of necrotic cleavage.

Key Experimental Protocols

Induction and Assessment of Necrosis

• Cell Treatment: Expose cells to necrotic inducers (e.g., 0.1% H₂O₂, 10% EtOH, 100 μM HgCl₂, or 50 μM cytochalasin B) for specified durations
• Viability Assessment: Measure cell viability using trypan blue exclusion or propidium iodide uptake to confirm necrotic death
• Caspase Inhibition: Include caspase inhibitors (e.g., zVAD-fmk) to confirm caspase-independent cell death
• Morphological Analysis: Assess cellular and nuclear swelling characteristic of necrosis [8] [16] [11]

Lysosomal Protease Isolation and Analysis

• Lysosomal Rich-Fraction Preparation:

  • Homogenize cells in isotonic sucrose buffer
  • Separate lysosomal fractions using Percoll or sucrose density gradient centrifugation
  • Confirm purity through marker enzyme assays (e.g., β-N-acetyl-D-glucosaminidase) [8]

• In Vitro Cleavage Assay:

  • Incubate affinity-purified PARP-1 with lysosomal fractions or purified cathepsins
  • Use appropriate buffer conditions (e.g., CAPS buffer pH 11 for cathepsin D)
  • Analyze cleavage products by SDS-PAGE and Western blotting [8]

PARP-1 Cleavage Fragment Detection

• Protein Extraction: Prepare whole cell or nuclear extracts at various time points after treatment
• Western Blotting:
  • Separate proteins using 8-12% SDS-PAGE
  • Transfer to PVDF or nitrocellulose membranes
  • Probe with PARP-1 antibodies recognizing different epitopes
  • Use enhanced chemiluminescence for detection [8] [16]
• Fragment Characterization: Identify specific fragments (24 kDa, 50 kDa, 89 kDa) based on molecular weight markers

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Studying Necrotic PARP-1 Cleavage

Reagent	Function/Application	Examples/Specifications
Necrotic Inducers	Induction of necrotic cell death	H₂O₂ (0.1%), Ethanol (10%), HgCl₂ (100 μM), Cytochalasin B (50 μM)
Caspase Inhibitors	Confirm caspase-independent cleavage	zVAD-fmk (broad-spectrum)
Protease Inhibitors	Specific inhibition of lysosomal proteases	CA-074 (cathepsin B inhibitor), Pepstatin A (cathepsin D inhibitor)
PARP-1 Antibodies	Detection of full-length and cleavage fragments	Epitopes spanning different PARP-1 domains
Lysosomal Isolation Kits	Preparation of lysosomal fractions	Density gradient media (Percoll, sucrose)
Purified Cathepsins	In vitro cleavage assays	Cathepsins B, D, G (species-specific)
Cell Death Assays	Validation of necrotic phenotype	Propidium iodide, LDH release, trypan blue exclusion

Visualization of PARP-1 Cleavage Pathways

The following diagrams illustrate the key pathways and experimental workflows for studying PARP-1 cleavage in necrosis versus apoptosis.

Diagram 1: Comparative Pathways of PARP-1 Cleavage in Apoptosis vs. Necrosis. This schematic illustrates the distinct proteolytic cascades leading to PARP-1 cleavage in apoptosis (blue) versus necrosis (red), highlighting the different enzymes involved and their sensitivity to caspase inhibition.

Diagram 2: Experimental Workflow for Detecting Necrotic PARP-1 Cleavage. This flowchart outlines the key steps in establishing and analyzing PARP-1 cleavage during necrosis, from cell treatment to fragment detection and validation.

Research Implications and Applications

The distinct cleavage patterns of PARP-1 in different cell death pathways have significant implications for both basic research and therapeutic development:

Diagnostic Applications

The 50 kDa PARP-1 fragment serves as a specific biomarker for necrotic cell death in experimental systems. This is particularly valuable for:

• Distinguishing mixed cell death populations in heterogeneous samples
• Validating necrotic mechanisms in disease models
• Screening for compounds that modulate specific cell death pathways [8] [11]

Therapeutic Implications

Understanding PARP-1 cleavage mechanisms opens avenues for therapeutic interventions:

• PARP inhibitors are already employed in cancer therapy, particularly for BRCA-deficient tumors
• Modulating specific cell death pathways could provide neuroprotection in conditions like cerebral ischemia, trauma, and excitotoxicity [2]
• Targeting lysosomal stability might influence necrotic pathology in various disease contexts

Methodological Considerations

Researchers should be aware of several technical considerations:

• The 89 kDa fragment appears in both apoptosis and necrosis, so it should not be used alone to identify cell death mechanisms
• Multiple antibodies targeting different PARP-1 domains may be needed to detect all relevant cleavage fragments
• Time-course experiments are essential, as cleavage patterns evolve throughout cell death progression
• Complementary assays (viability staining, LDH release, caspase activity) should confirm the specific cell death mechanism

The cleavage of PARP-1 during necrosis represents a distinct proteolytic event characterized by the generation of a prominent 50 kDa fragment through the action of lysosomal proteases, particularly cathepsins B and G. This pattern fundamentally differs from the caspase-mediated cleavage observed in apoptosis, providing researchers with a specific molecular signature for identifying necrotic cell death. The experimental methodologies, reagent toolkit, and visual schematics presented here offer a comprehensive resource for investigating these cleavage events in various research contexts. As our understanding of cell death pathways continues to evolve, the precise characterization of PARP-1 cleavage patterns will remain an essential tool for unraveling complex pathophysiological processes and developing targeted therapeutic strategies.

Within the intricate landscape of programmed cell death, proteases act as master executioners, cleaving critical cellular substrates to orchestrate disparate morphological outcomes. This guide provides a comparative analysis of two key protease families: the caspases, specifically caspase-3 and -7, which are hallmarks of apoptosis; and the cathepsins, notably cathepsins B, D, and G, which are increasingly recognized as mediators of necrosis and other lytic cell death pathways. A profound understanding of their distinct mechanisms, substrates, and experimental interrogation is fundamental for research in cancer biology, neurodegenerative disorders, and drug development. A pivotal molecular event distinguishing these pathways is the cleavage of Poly (ADP-ribose) polymerase-1 (PARP-1). During apoptosis, caspases cleave PARP-1 to inactivate it and prevent energy depletion, whereas in necrosis, PARP-1's overactivation can drive the cell death process itself, a distinct pathway known as parthanatos [17]. This comparison will frame the differential roles of these proteases within this specific biochemical context.

Protease Profiles and Functional Mechanisms

Caspase-3 and Caspase-7: Apoptotic Executioners

Caspase-3 and -7 are effector caspases that serve as the central executioners of apoptosis, a non-inflammatory, programmed cell death process characterized by cell shrinkage, chromatin condensation, and the formation of apoptotic bodies [18] [19]. They are synthesized as inactive zymogens and become activated through proteolytic cleavage by initiator caspases (e.g., caspase-8, -9, -10) within multimeric complexes such as the DISC or apoptosome [18]. Once active, they cleave a vast array of cellular substrates, including PARP-1. Caspase-mediated cleavage of PARP-1 inactivates its DNA repair function and serves as a biochemical marker to distinguish apoptosis from other cell death forms [18] [19]. Beyond apoptosis, caspase-3 can also cleave gasdermin E (GSDME), potentially initiating a secondary pyroptotic response [18].

Cathepsins B, D, and G: Mediators of Necrotic and Lytic Pathways

Cathepsins are lysosomal proteases that, upon release into the cytosol due to lysosomal membrane permeabilization (LMP), can trigger various forms of lytic cell death, including necrosis and pyroptosis [20] [21] [22]. Their role is often context-dependent and cell-type-specific.

• Cathepsin B: A cysteine protease implicated in lysosome-mediated necrosis and NLRP3 inflammasome activation [20] [21]. It can promote mitochondrial outer membrane permeabilization by cleaving the pro-apoptotic protein Bid, bridging lysosomal and apoptotic pathways [20].
• Cathepsin D: An aspartic protease that acts upstream in a proteolytic cascade. It is required for the activation of other cathepsins, such as cathepsin C, and is essential for necrosis induced by lysosome-destabilizing agents like Leu-Leu-OMe (LLOMe) [21].
• Cathepsin G: A serine protease stored in neutrophil azurophilic granules. It contributes to neutrophil extracellular trap (NET) formation and can cleave and activate gasdermin D (GSDMD), a key executioner of pyroptosis, illustrating crosstalk between different lytic death pathways [23].

Table 1: Comparative Profile of Key Proteases in Cell Death

Feature	Caspase-3/7	Cathepsin B	Cathepsin D	Cathepsin G
Primary Cell Death Pathway	Apoptosis	Necrosis, Pyroptosis	Necrosis	NETosis, Pyroptosis
Protease Class	Cysteine Aspartase	Cysteine Protease	Aspartic Protease	Serine Protease
Localization	Cytosol	Lysosomal/Cytosol (upon LMP)	Lysosomal	Azurophilic Granules (Neutrophils)
Key Substrates	PARP-1, GSDME, Lamin	Bid, NLRP3?	Pro-Cathepsins	GSDMD, Histones
PARP-1 Cleavage	Inactivates; generates specific fragments	Not typically associated; PARP-1 overactivation in parthanatos	Not typically associated; PARP-1 overactivation in parthanatos	Not typically associated
Primary Function in Cell Death	Execution of apoptotic dismantling	Lysosomal-mitochondrial crosstalk, Inflammasome activation	Master activator in proteolytic cascade	Chromatin decondensation, Pore formation

Experimental Data and Methodologies

Key Experimental Models and Quantitative Data

Research into these proteases relies on specific inducers, inhibitors, and genetic models to delineate their functions. Quantitative data from such experiments highlight their distinct roles.

Table 2: Experimental Models and Reagent Effects on Cell Death

Experimental Context	Protease Targeted	Intervention/Tool	Observed Outcome	Citation
Pyroptosis (LPS/Nigericin)	Cathepsin B	CA-074-Me (10-50 µM)	Blocked cell death	[21]
Lysosome-Mediated Necrosis (LLOMe)	Cathepsin B	CA-074-Me	Blocked cell death in monocytes/DCs, but not neutrophils	[21]
Lysosome-Mediated Necrosis (LLOMe)	Cathepsin C	Genetic knockout (KO)	Blocked cell death in all myeloid cells, including neutrophils	[21]
Lysosome-Mediated Necrosis (LLOMe)	Cathepsin D	Pepstatin A / siRNA knockdown	Blocked cell death	[21]
Alum Adjuvant Immunity	Cathepsins B & S	Genetic knockout (KO)	Impaired alum-mediated necrosis and Th2 immune response	[24]
Apoptosis (Various stimuli)	Caspase-3/7	Pharmacological inhibition or genetic deletion	Abrogation of apoptotic morphology and PARP-1 cleavage	[18] [19]

Detailed Experimental Protocol: Assessing Cathepsin-Dependent Necrosis

The following methodology is adapted from studies investigating lysosome-mediated necrosis, a cathepsin-driven process [21] [24].

• Cell Preparation: Use primary murine bone marrow-derived macrophages (BMDMs) or other relevant myeloid cells. Culture cells in appropriate media in multi-well plates.
• Inhibitor Pre-treatment: Pre-treat cells for 1-2 hours with specific inhibitors:
  • CA-074-Me (10-50 µM): A cell-permeable inhibitor selective for cathepsin B.
  • Pepstatin A (20 µM): An inhibitor of aspartic proteases like cathepsin D.
  • NH4Cl (10-30 mM) or Bafilomycin A1 (100 nM): Lysosomotropic agents that neutralize lysosomal pH, inhibiting overall cathepsin activity.
• Induction of Necrosis: Challenge the pre-treated cells with necrosis inducers:
  • LLOMe (1-2 mM): A lysosomotropic dipeptide ester that induces rapid lysosomal permeabilization and cathepsin-dependent necrosis.
  • Alum (100-200 µg/mL): An adjuvant known to trigger cathepsin B/S-dependent necrosis in myeloid cells.
• Cell Viability Assay: After 4-24 hours of incubation, measure cell death. A common method is the Lactate Dehydrogenase (LDH) release assay, which quantifies the release of this cytoplasmic enzyme upon plasma membrane rupture, a hallmark of necrosis.
• Genetic Validation: Confirm results using siRNA-mediated knockdown or cells from cathepsin-deficient (e.g., Ctsb-/-, Ctsc-/-) mice. The persistence of cell death in Ctsb-/- cells upon LLOMe treatment, for example, indicates the involvement of other cathepsins like cathepsin C [21].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Studying Apoptotic and Necrotic Proteases

Reagent	Function/Application	Specificity
Z-VAD-FMK	Pan-caspase inhibitor; used as a control to distinguish caspase-dependent apoptosis from other death pathways.	Broad-spectrum Caspases
CA-074-Me	Cell-permeable inhibitor used to probe the role of cathepsin B in necrosis and inflammasome activation.	Cathepsin B
Pepstatin A	Inhibitor of aspartic proteases; used to demonstrate the dependency of necrotic pathways on cathepsin D activity.	Cathepsin D
DEVD-CHO (or similar)	Cell-permeable peptide inhibitor targeting the active site of effector caspases; confirms caspase-3/7 involvement.	Caspase-3/7
LLOMe (Leu-Leu-OMe)	Lysosomotropic agent; a standard experimental tool to induce rapid, cathepsin-dependent lysosome-mediated necrosis.	Lysosomal Permeabilization
Anthrax Lethal Toxin / Nigericin	Potent inducers of pyroptosis; used to study inflammatory cell death and the limited role of cathepsins in this pathway.	Pyroptosis Inducers
Anti-Cleaved PARP (Asp214) Antibody	Gold-standard immunoassay to detect caspase-3/7 activity and confirm apoptosis execution.	Caspase-3/7 activity
Lactate Dehydrogenase (LDH) Assay Kit	Colorimetric assay to quantitatively measure plasma membrane rupture, a key feature of necrotic cell death.	Cell Membrane Integrity

Signaling Pathway Diagrams

The comparative analysis underscores that caspase-3/7 and cathepsins B, D, and G are definitive markers and executors of two fundamentally different cell death paradigms. Caspase-3/7 mediate the orderly, programmed dismantling of apoptosis, with specific cleavage and inactivation of PARP-1 as a key diagnostic event. In contrast, cathepsins act as instigators of lytic death, often in a cell-type-specific and stimulus-dependent manner, and are frequently associated with PARP-1 overactivation in parthanatos. The experimental data and methodologies detailed herein provide a framework for researchers to dissect these pathways accurately. The choice of inducers, selective inhibitors, and genetic models, coupled with the analysis of definitive endpoints like PARP-1 cleavage patterns and LDH release, is critical for unambiguous interpretation of cell death mechanisms in both basic research and drug discovery.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that functions as a critical molecular switch governing cellular fate in response to stress and damage. As a primary DNA damage sensor, PARP-1 activation triggers divergent biological pathways leading to either cell survival or death. The specific proteolytic cleavage patterns of PARP-1 serve as definitive biochemical signatures that distinguish between programmed cell death (apoptosis) and unregulated cellular demise (necrosis). Understanding these distinct cleavage events provides crucial insights for therapeutic development in cancer, neurodegenerative disorders, and other pathological conditions. This guide systematically compares the molecular mechanisms, experimental detection methods, and functional consequences of PARP-1 cleavage in apoptosis versus necrosis, providing researchers with essential tools for navigating this critical field of cell death research.

PARP-1 Cleavage Patterns: Apoptosis vs. Necrosis

The cleavage of PARP-1 produces characteristic fragments that serve as diagnostic markers for different cell death pathways. The table below summarizes the key differences between apoptotic and necrotic PARP-1 cleavage.

Table 1: Comparative Analysis of PARP-1 Cleavage in Apoptosis vs. Necrosis

Characteristic	Apoptotic Cleavage	Necrotic Cleavage
Primary Proteases	Caspases-3 and -7 [2]	Lysosomal proteases (Cathepsins B and G) [8]
Characteristic Fragments	89 kDa (catalytic domain) and 24 kDa (DNA-binding domain) [2]	50 kDa fragment [8]
Caspase Dependence	Dependent (inhibited by zVAD-fmk) [8]	Independent (not inhibited by zVAD-fmk) [8]
Cellular ATP Levels	Maintained [25]	Depleted [25]
Inflammatory Response	Non-inflammatory [26]	Pro-inflammatory [26]
Biological Function	Inactivates PARP-1 to conserve ATP and prevent DNA repair [2]	May represent uncontrolled proteolytic degradation [8]

Molecular Mechanisms and Signaling Pathways

PARP-1 Cleavage in Apoptosis

Apoptotic cleavage of PARP-1 represents a controlled, energy-dependent process that is orchestrated by caspase proteases. During apoptosis, executioner caspases-3 and -7 recognize and cleave PARP-1 at a specific aspartic acid residue within the 216-DEVD-219 motif, generating the characteristic 89 kDa and 24 kDa fragments [2]. The 24 kDa fragment containing the DNA-binding domain remains bound to damaged DNA, acting as a trans-dominant inhibitor that blocks PARP-1 catalytic activity and prevents additional DNA repair [2]. This controlled inactivation conserves cellular ATP pools needed for the orderly execution of the apoptotic program and facilitates the dismantling of the cell without eliciting inflammatory responses [26] [25].

PARP-1 in Necrosis

In contrast to apoptosis, necrotic PARP-1 cleavage occurs through a distinct mechanism driven by lysosomal proteases. Under conditions of severe DNA damage, PARP-1 becomes overactivated, leading to depletion of NAD+ and ATP pools [25]. This energy collapse prevents the execution of apoptosis and instead promotes necrotic cell death. During necrosis, lysosomal membranes become permeabilized, releasing cathepsins B and G into the cytosol [8]. These lysosomal proteases cleave PARP-1 to generate a dominant 50 kDa fragment, representing an unregulated proteolytic process that differs fundamentally from the precise caspase-mediated cleavage observed in apoptosis [8].

Experimental Approaches for PARP-1 Cleavage Analysis

Standardized Methodologies

Researchers have established robust experimental protocols to differentiate apoptotic and necrotic PARP-1 cleavage patterns in cellular models. The following workflow outlines key methodological approaches:

Detailed Experimental Protocols

Induction and Detection of Apoptotic PARP-1 Cleavage

• Cell Treatment: Expose cells to apoptotic inducers such as staurosporine (1-2 μM for 4-8 hours) or etoposide (50-100 μM for 12-24 hours) [8].
• Caspase Inhibition Control: Pre-treat parallel samples with the pan-caspase inhibitor zVAD-fmk (20-50 μM) for 1-2 hours before apoptotic induction [8].
• Protein Extraction: Harvest cells and lyse in RIPA buffer containing protease inhibitors.
• Western Blot Analysis:
  • Separate proteins (20-30 μg per lane) by SDS-PAGE (4-12% gradient gel)
  • Transfer to nitrocellulose membrane
  • Probe with anti-PARP-1 antibodies (specific for full-length and cleaved fragments)
  • Detect using ECL or other chemiluminescent systems [8]
• Expected Results: Appearance of 89 kDa and 24 kDa fragments in apoptotic samples, abolished by zVAD-fmk pre-treatment [2] [8].

Induction and Detection of Necrotic PARP-1 Cleavage

• Cell Treatment: Induce necrosis with hydrogen peroxide (0.1-1.0 mM for 2-4 hours), ethanol (10% for 4-8 hours), or mercuric chloride (100 μM for 4-8 hours) [8].
• ATP Depletion Monitoring: Measure intracellular ATP levels using luciferase-based assays [25].
• Lysosomal Protease Assessment:
  • Isolate lysosomal-rich fractions by differential centrifugation
  • Assess cathepsin activity using fluorogenic substrates [8]
• Western Blot Analysis: Follow similar protocol as above, looking for the characteristic 50 kDa fragment [8].
• Inhibitor Controls: Use cathepsin inhibitors (E-64, CA-074) to validate specificity [8].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for PARP-1 Cleavage Research

Reagent	Function/Application	Experimental Utility
zVAD-fmk	Pan-caspase inhibitor	Differentiates caspase-dependent vs independent cleavage [8]
Anti-PARP-1 Antibodies	Detection of full-length and cleaved PARP-1	Identifies characteristic fragments (89 kDa, 24 kDa, 50 kDa) [2] [8]
Cathepsin Inhibitors (E-64, CA-074)	Lysosomal protease inhibitors	Confirms necrotic cleavage mechanism [8]
PARP Inhibitors (Olaparib, Veliparib)	PARP catalytic activity inhibitors	Studies on PARP-1 function in cell death pathways [27]
MNNG	DNA alkylating agent	Induces PARP-1 activation and necrotic cell death [25]
Staurosporine	Protein kinase inhibitor	Triggers apoptotic cell death [8]

Functional Consequences of PARP-1 Cleavage

The biological outcomes of PARP-1 cleavage differ significantly between apoptosis and necrosis, with important implications for tissue homeostasis and disease pathogenesis.

Apoptotic Cleavage Fragments Regulate Cell Survival

The 24 kDa DNA-binding fragment generated during apoptosis functions as a dominant-negative inhibitor of PARP-1 activity, binding irreversibly to DNA strand breaks and preventing DNA repair complex formation [2]. This fragment conserves cellular ATP by preventing PARP-1 overactivation, thereby facilitating the energy-dependent apoptotic process [25]. Research demonstrates that expression of the 24 kDa fragment alone can confer protection against ischemic damage in neuronal models, while the 89 kDa fragment exhibits cytotoxic properties [28]. This opposing functionality of cleavage products highlights the sophisticated regulation of cell fate through PARP-1 processing.

Necrotic Cleavage and Inflammatory Responses

In contrast to apoptosis, necrotic cell death characterized by PARP-1 overactivation and lysosomal cleavage triggers pronounced inflammatory responses. PARP-1 depletion protects against necrotic cell death and ATP depletion but does not affect apoptotic death, confirming the distinct role of PARP-1 in these pathways [25]. The release of intracellular contents during necrotic death, including damage-associated molecular patterns (DAMPs) and inflammatory mediators such as HMGB1, contributes to sterile inflammation and tissue damage [26].

The molecular switch hypothesis of PARP-1 cleavage provides a compelling framework for understanding how cells navigate life-or-death decisions following damage. The distinct proteolytic signatures of PARP-1 in apoptosis versus necrosis represent not merely biochemical curiosities but fundamental determinants of cellular fate with far-reaching implications for health and disease. The experimental approaches and reagents outlined in this guide provide researchers with essential methodologies for investigating these critical pathways. As drug development increasingly targets cell death pathways, understanding the nuanced functions of PARP-1 cleavage fragments will continue to inform therapeutic strategies for cancer, neurodegenerative disorders, and other conditions characterized by dysregulated cell death.

Detection and Analysis: Techniques for Identifying PARP-1 Cleavage Signatures

Poly(ADP-ribose) polymerase-1 (PARP-1) is a 113-116 kDa nuclear enzyme that plays a central role in detecting and repairing DNA damage. Beyond its DNA repair function, PARP-1 has emerged as a critical signaling molecule in cell death pathways. The proteolytic cleavage of PARP-1 by various proteases generates specific fragments that serve as definitive signatures for distinguishing between different forms of cell death, particularly apoptosis and necrosis. The 89 kDa and 24 kDa fragments are well-established hallmarks of apoptosis, while the 50 kDa fragment is characteristic of necrosis. Western blot detection of these specific cleavage fragments provides researchers with a powerful tool for identifying cell death mechanisms in physiological and pathological contexts, including cancer research and neurodegenerative diseases. This guide details the experimental protocols and technical considerations for accurately differentiating these fragments to support research and drug development efforts.

PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Comparative Analysis of Cleavage Fragments

Table 1: Characteristics of PARP-1 Cleavage Fragments in Different Cell Death Pathways

Fragment Size	Cell Death Pathway	Proteases Involved	Domain Composition	Biological Consequences
89 kDa	Apoptosis	Caspases-3 and -7 [29] [2]	Automodification domain + Catalytic domain [2]	Transloci to cytoplasm; acts as PAR carrier to induce AIF-mediated apoptosis [29]
24 kDa	Apoptosis	Caspases-3 and -7 [29] [2]	DNA-binding domain (with zinc fingers) [2]	Retained in nucleus; irreversibly binds DNA breaks, inhibiting repair [2]
50 kDa	Necrosis	Lysosomal proteases (Cathepsins B and G) [8]	Not fully characterized	Correlates with necrotic cell death; not inhibited by caspase inhibitors [8]

Structural Basis for PARP-1 Cleavage

PARP-1 comprises three major functional domains: an N-terminal DNA-binding domain (DBD) containing two zinc finger motifs, a central automodification domain (AMD), and a C-terminal catalytic domain (CAT) [2]. The caspase cleavage site (DEVD214) is situated within the nuclear localization signal near the DNA-binding domain [29]. During apoptosis, cleavage at this site separates the DNA-binding domain (24 kDa fragment) from the automodification and catalytic domains (89 kDa fragment) [29] [2]. In contrast, necrotic cleavage by lysosomal proteases generates a distinct 50 kDa fragment through different cleavage patterns, though the exact cleavage sites for necrosis are less characterized [8].

Table 2: Experimental Conditions for Inducing PARP-1 Cleavage

Cell Death Pathway	Inducing Agents	Inhibitors to Confirm Mechanism	Time Course
Apoptosis	Staurosporine (0.5-1 μM) [29], Actinomycin D [29], Etoposide [2]	zVAD-fmk (broad-spectrum caspase inhibitor) [8]	PARP-1 cleavage observed within 2-4 hours; maximal at 6-8 hours [29]
Necrosis	0.1% H₂O₂ [8], 10% Ethanol [8], 100 μM HgCl₂ [8]	Not inhibited by zVAD-fmk [8]	50 kDa fragment appears within 1-2 hours of treatment [8]

Experimental Workflows for PARP-1 Cleavage Detection

Sample Preparation and Protein Extraction

Cell Culture and Treatment:

• Culture cells (e.g., HeLa, Jurkat T cells) under standard conditions [29]
• Induce apoptosis using 0.5-1 μM staurosporine for 6 hours [29] or necrosis with 0.1% H₂O₂ [8]
• Include controls with 20-50 μM zVAD-fmk (caspase inhibitor) to confirm apoptosis-specific cleavage [8]

Protein Extraction Protocol:

• Lyse cells in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with protease inhibitors (0.5 mM PMSF, 2 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 μM pepstatin) [30]
• For tissue samples (e.g., skeletal muscle), use mechanical homogenization with a Polytron homogenizer followed by sonication to ensure complete lysis [31]
• Centrifuge lysates at 12,000 × g for 15 minutes at 4°C to remove insoluble material
• Quantify protein concentration using colorimetric assays (e.g., BCA assay), accounting for potential buffer component interference [31]

Western Blotting Protocol for PARP-1 Fragment Separation

Gel Electrophoresis:

• Use SDS-PAGE with 10% polyacrylamide gels for optimal separation of PARP-1 fragments [30]
• Prepare samples in Laemmli buffer with 5% β-mercaptoethanol as reducing agent
• Load 20-50 μg of total protein per lane [30]
• Include pre-stained molecular weight markers to verify fragment sizes
• Run gels at 100-120 V for 1.5-2 hours using MOPS or MES running buffer [31]

Protein Transfer and Immunodetection:

• Transfer proteins to nitrocellulose or PVDF membranes (0.45 μm pore size) using wet transfer systems [31]
• For efficient transfer of larger fragments (89 kDa), include methanol in transfer buffer [31]
• Confirm transfer efficiency with Ponceau S staining [31]
• Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature
• Incubate with primary antibodies against PARP-1 (diluted according to manufacturer's specifications) overnight at 4°C
• Use appropriate secondary antibodies conjugated to HRP or fluorescent tags
• Develop with enhanced chemiluminescence or fluorescence detection systems

PARP-1 Western Blot Workflow

Optimization and Troubleshooting

Critical Validation Steps:

• Ensure antibodies recognize both full-length PARP-1 and cleavage fragments
• Validate specificity using PARP-1 knockout cells or siRNA knockdown [29]
• Perform dilution curves for primary antibodies to determine optimal concentrations [32]
• Confirm linear range of detection by testing multiple exposure times [32]

Common Issues and Solutions:

• Non-specific bands: Optimize antibody concentrations and blocking conditions
• Poor transfer of 89 kDa fragment: Include methanol in transfer buffer or extend transfer time
• Weak signal: Check antibody expiration and storage conditions
• High background: Increase wash stringency and optimize blocking solution

Signaling Pathways and Biological Significance

Apoptotic Pathway Involving 89 kDa and 24 kDa Fragments

During apoptosis, caspase-3 and -7 activation leads to PARP-1 cleavage at the DEVD214 site, generating 24 kDa and 89 kDa fragments [29] [2]. The 24 kDa fragment contains the DNA-binding domain and remains nuclear, irreversibly binding to DNA breaks and acting as a trans-dominant inhibitor of DNA repair [2]. The 89 kDa fragment (containing the automodification and catalytic domains) translocates to the cytoplasm where it serves as a PAR carrier that facilitates apoptosis-inducing factor (AIF) release from mitochondria [29] [15]. This AIF translocation to the nucleus results in large-scale DNA fragmentation, representing a critical amplification step in the apoptotic cascade [29].

Necrotic Pathway Involving 50 kDa Fragment

In necrosis, loss of membrane integrity leads to lysosomal rupture and release of cathepsins B and G, which cleave PARP-1 to generate the characteristic 50 kDa fragment [8]. This cleavage pattern is distinct from apoptotic cleavage and is not inhibited by caspase inhibitors like zVAD-fmk [8]. The 50 kDa fragment appears in various necrotic models, including treatment with H₂O₂, ethanol, or HgCl₂ [8]. The functional consequences of this necrotic cleavage are less understood but may contribute to the energetic collapse characteristic of necrotic cell death.

PARP-1 Cleavage Pathways

Research Reagent Solutions

Table 3: Essential Reagents for PARP-1 Cleavage Studies

Reagent Category	Specific Examples	Application Purpose	Considerations
PARP-1 Antibodies	Anti-PARP-1 (various clones)	Detection of full-length and cleavage fragments	Validate specificity for 89, 50, and 24 kDa fragments; check species reactivity
Caspase Inhibitors	zVAD-fmk (20-50 μM) [8]	Confirm caspase-dependent apoptosis	Use fresh preparations; dissolve in DMSO
PARP Inhibitors	PJ34, ABT-888 [29]	Inhibit PARP activity in pathway studies	Confirm specificity for PARP-1 vs other PARP family members
Apoptosis Inducers	Staurosporine (0.5-1 μM) [29], Actinomycin D	Induce apoptotic PARP-1 cleavage	Optimize concentration and duration for specific cell types
Necrosis Inducers	H₂O₂ (0.1%) [8], Ethanol (10%) [8]	Induce necrotic PARP-1 cleavage	Titrate to achieve necrosis without complete cellular disruption
Protease Inhibitors	PMSF, Aprotinin, Leupeptin [30]	Prevent protein degradation during extraction	Include in all lysis buffers; prepare fresh solutions
Lysosomal Protease Inhibitors	E-64, CA-074 (cathepsin inhibitors)	Inhibit cathepsin activity in necrosis studies	Use to confirm cathepsin-mediated cleavage

Data Interpretation and Quantitative Analysis

Fragment Identification and Quantification

Band Pattern Recognition:

• Apoptotic samples: Look for simultaneous presence of 89 kDa and 24 kDa fragments with corresponding decrease in full-length PARP-1 (116 kDa)
• Necrotic samples: Identify 50 kDa fragment, often with minimal 89/24 kDa fragments unless mixed cell death occurs
• Mixed cell death: May show both 89 kDa and 50 kDa fragments, requiring careful quantification

Quantitative Approaches:

• Use densitometry software to quantify band intensities
• Normalize to loading controls (e.g., GAPDH, actin, or total protein stains) [31] [32]
• Calculate cleavage index: (89 kDa + 24 kDa) / (full-length + 89 kDa + 24 kDa) for apoptosis
• Ensure measurements fall within the linear range of detection by testing multiple exposures [32]

Technical Validation and Controls

Essential Controls:

• Include molecular weight markers on every gel for accurate fragment sizing
• Run positive controls (cells treated with known apoptosis inducers) to validate antibody performance
• Include negative controls (untreated cells) to establish baseline PARP-1 expression
• Use caspase inhibitors (zVAD-fmk) to confirm apoptosis-specific cleavage patterns [8]
• Test lysosomal protease inhibitors to verify necrotic cleavage mechanisms

Validation of Specificity:

• Use PARP-1 knockout cells or siRNA-mediated knockdown to confirm antibody specificity [29]
• Test multiple antibodies targeting different PARP-1 epitopes
• Correlate with other cell death markers (e.g., caspase activation for apoptosis, LDH release for necrosis)

Western blot analysis of PARP-1 cleavage fragments provides critical insights into cell death mechanisms, with distinct 89 kDa/24 kDa and 50 kDa patterns serving as reliable signatures for differentiating apoptosis and necrosis. The protocols detailed in this guide enable precise identification and interpretation of these fragments, supporting research in cancer biology, neurotoxicity, and drug development. Proper implementation of these methods, including appropriate controls and validation steps, ensures accurate data generation that can inform mechanistic studies and therapeutic screening efforts. As research advances, understanding the complex roles of different PARP-1 fragments continues to reveal new aspects of cell death regulation and potential therapeutic interventions.

Poly(ADP-ribose) polymerase-1 (PARP-1) cleavage serves as a well-established biochemical hallmark of programmed cell death, yet its proteolytic signature varies fundamentally between apoptotic and necrotic pathways. Inhibitor-based assays employing pan-caspase inhibitors like zVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) have become indispensable tools for discriminating these distinct protease activities and cell death mechanisms. The characteristic 89-kDa PARP-1 fragment generated by caspase cleavage has long been recognized as an apoptotic marker, while necrosis produces a different cleavage pattern dominated by a 50-kDa fragment through lysosomal protease activity. This guide systematically compares how zVAD-fmk and related inhibitors enable researchers to dissect these proteolytic events, providing experimental data and methodologies to inform assay selection and interpretation in cell death research and drug discovery.

Comparative Analysis of Cell Death Inhibitors

Table 1: Properties and Applications of Key Cell Death Inhibitors

Inhibitor	Primary Target	Effect on Apoptosis	Effect on Necroptosis	Effect on PARP-1 Cleavage	Key Experimental Findings
zVAD-fmk	Broad-spectrum caspases	Inhibits	Induces/promotes in specific contexts (e.g., L929 cells)	Prevents 89-kDa apoptotic fragment; no inhibition of 50-kDa necrotic fragment	Induces TNFα-mediated necroptosis in L929 cells via PKC-MAPKs-AP-1 pathway; requires RIP1/RIP3 [33]
BocD-fmk	Broad-spectrum caspases	Inhibits	Induces in L929 cells	Similar to zVAD-fmk	Induces cell death in L929 cells; shares similar pro-necrotic properties with zVAD in certain cell lines [33]
QVD-oph	Broad-spectrum caspases	Inhibits	Does not induce	Prevents 89-kDa apoptotic fragment	More efficient caspase inhibitor than zVAD-fmk but non-necrotic in L929 cells [33]
Necrostatin-1	RIP1 kinase	No effect	Inhibits	No direct effect on PARP-1 cleavage	Blocks zVAD-induced necroptosis in L929 cells; ineffective against PARP-1-mediated necrosis (e.g., MNNG-induced) [33] [34]
3-AB/PJ-34/Olaparib	PARP-1	No effect	No effect on TNF-induced necroptosis	Prevents PARP-1 overactivation but not its cleavage	Protects against MNNG-induced necrosis; ineffective against TNF-induced necroptosis [35]

Table 2: PARP-1 Cleavage Signatures Across Cell Death Modalities

Cell Death Pathway	Inducing Stimulus	PARP-1 Cleavage Fragments	Responsible Proteases	zVAD-fmk Sensitivity	Functional Consequences
Apoptosis	Etoposide, Staurosporine, TRAIL	89-kDa (catalytic fragment) and 24-kDa (DNA-binding domain)	Caspase-3 and Caspase-7	Sensitive (complete inhibition)	Inactivation of PARP-1; conservation of cellular ATP; facilitation of apoptotic dismantling [2] [36]
Necrosis (Lysosomal)	H2O2, Ethanol, HgCl2	50-kDa major fragment with minor 40-kDa and 35-kDa fragments	Cathepsins B and G (lysosomal proteases)	Insensitive	Unknown function; serves as biomarker for necrotic progression [8] [11]
Necroptosis	TNFα + zVAD-fmk (in L929)	Not fully characterized; may combine features	Caspase-independent; RIP1/RIP3-dependent	Initiating factor (when combined with TNFα)	Dependent on autocrine TNFα production and RIP1/RIP3 kinase activity [33]
PARP-1-Mediated Necrosis	MNNG, β-Lapachone	Not well-characterized; potential 50-kDa fragment	Calpains (Ca2+-dependent)	Insensitive	Results from PARP-1 overactivation; involves JNK and calpain pathways [34] [35]

Experimental Protocols for Inhibitor-Based PARP-1 Cleavage Analysis

Protocol 1: Discriminating Apoptotic Versus Necrotic PARP-1 Cleavage

Objective: To characterize PARP-1 cleavage patterns during apoptosis and necrosis using caspase inhibitors and lysosomal protease inhibitors.

Materials:

• Jurkat T-cells or HL-60 cells
• Apoptosis inducers: Etoposide (50-100 μM) or Staurosporine (1 μM)
• Necrosis inducers: H₂O₂ (0.1%), Ethanol (10%), or HgCl₂ (100 μM)
• Inhibitors: zVAD-fmk (20-50 μM), Necrostatin-1 (10-30 μM), CA-074 Me (cathepsin B inhibitor, 10 μM)
• Lysis buffer (TNE buffer: 50 mM Tris pH 8.0, 1% NP-40, 2 mM EDTA) with protease inhibitors
• Antibodies: Anti-PARP-1 antibody capable of detecting full-length and fragments

Methodology:

• Cell Culture and Treatment: Culture cells in appropriate medium (RPMI 1640 for Jurkat/HL-60) with 10% FBS. Seed at 0.5-1 × 10⁶ cells/mL.
• Pre-treatment: Divide cells into experimental groups:
  • Pre-treat with zVAD-fmk (50 μM) or vehicle control (DMSO) for 1 hour
  • Pre-treat with CA-074 Me (10 μM) for 2 hours where applicable
• Induction: Apply cell death inducers:
  • Apoptosis: Etoposide (50 μM, 4-6 hours)
  • Necrosis: H₂O₂ (0.1%, 2-4 hours)
  • Include untreated controls
• Harvesting and Protein Extraction:
  • Collect cells by centrifugation (900 × g, 5 minutes)
  • Lyse in TNE buffer with protease inhibitors (10 μg/mL pepstatin, aprotinin, leupeptin)
  • Determine protein concentration by Bradford assay
• Western Blot Analysis:
  • Separate proteins (20-30 μg per lane) on 8-10% SDS-PAGE gels
  • Transfer to PVDF membranes, block with 5% non-fat milk
  • Incubate with anti-PARP-1 primary antibody (1:1000) overnight at 4°C
  • Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour
  • Develop with ECL reagent and visualize

Expected Outcomes: Apoptotic stimuli will produce an 89-kDa PARP-1 fragment inhibited by zVAD-fmk. Necrotic stimuli will generate a 50-kDa fragment insensitive to zVAD-fmk but potentially inhibited by cathepsin inhibitors [8] [11].

Protocol 2: Assessing zVAD-Induced Necroptosis in L929 Cells

Objective: To evaluate zVAD-fmk-induced necroptosis and its dependence on autocrine TNFα signaling.

Materials:

• L929 mouse fibrosarcoma cells
• zVAD-fmk (10-50 μM), BocD-fmk (10-50 μM), QVD-oph (10-50 μM)
• TNFα neutralizing antibody, Necrostatin-1 (10-30 μM)
• Actinomycin D (1 μg/mL) or Cycloheximide (10 μg/mL) for transcription/translation inhibition
• ELISA kit for mouse TNFα detection

Methodology:

• Cell Culture: Maintain L929 cells in DMEM with 10% calf serum.
• Medium Volume Effect: Plate cells at equal density in different culture medium volumes (2-10 mL) with same zVAD concentration to assess paracrine effects.
• Inhibitor Treatment:
  • Treat with zVAD-fmk (10 μM), BocD-fmk (10 μM), or QVD-oph (10 μM) for 8-24 hours
  • Include Necrostatin-1 (30 μM) pre-treatment for 1 hour where applicable
  • For transcription/translation inhibition, pre-treat with Actinomycin D (1 μg/mL) or Cycloheximide (10 μg/mL) for 1 hour
• Viability Assessment: Measure cell death by propidium iodide uptake, LDH release, or MTT assay at 8, 16, and 24 hours.
• TNFα Detection: Collect culture supernatants at 8 hours post-treatment and measure TNFα levels by ELISA.
• PARP-1 Cleavage Analysis: Process cells for Western blot as in Protocol 1.

Expected Outcomes: zVAD-fmk and BocD-fmk will induce significant necroptosis in L929 cells, preventable by Necrostatin-1, Actinomycin D, or Cycloheximide. TNFα levels will increase in culture supernatant. QVD-oph will show minimal cytotoxicity despite effective caspase inhibition [33].

Molecular Pathways in Cell Death Execution

PARP-1 Cleavage in Apoptosis and Necrosis

Figure 1: PARP-1 Cleavage Pathways in Apoptosis vs. Necrosis. The diagram illustrates how apoptotic and necrotic stimuli activate different protease families that generate characteristic PARP-1 cleavage fragments. zVAD-fmk specifically inhibits caspase-mediated apoptotic cleavage but does not affect lysosomal protease-mediated necrotic cleavage.

zVAD-Induced Necroptosis Signaling Pathway

Figure 2: zVAD-fmk-Induced Necroptosis Signaling Pathway in L929 Cells. zVAD-fmk triggers a coordinated signaling cascade involving PKC, MAPKs, and AP-1 that drives autocrine TNFα production, ultimately leading to RIP1/RIP3-dependent necroptosis. This pathway is distinguishable from both apoptosis and PARP-1-mediated necrosis.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Cell Death Pathway Analysis

Reagent	Category	Primary Function	Application Notes
zVAD-fmk	Caspase inhibitor	Irreversible broad-spectrum caspase inhibitor; induces necroptosis in specific cell lines	Use at 20-50 μM; prepare fresh in DMSO; can induce necroptosis in L929 cells via TNFα autocrine signaling [33]
QVD-oph	Caspase inhibitor	Potent, broad-spectrum caspase inhibitor with better cell permeability and reduced toxicity	Preferred over zVAD for pure caspase inhibition (10-20 μM); does not induce necroptosis in L929 cells [33]
Necrostatin-1	RIP1 inhibitor	Specific inhibitor of RIP1 kinase activity; blocks necroptosis	Use at 10-30 μM; effective against zVAD-induced necroptosis but not PARP-1-mediated necrosis [33] [34]
Anti-PARP-1 Antibodies	Detection reagent	Detect full-length (113-kDa) and cleavage fragments (89-kDa, 50-kDa)	Essential for distinguishing apoptosis (89-kDa) vs. necrosis (50-kDa) by Western blot [8] [11]
3-AB/PJ-34/Olaparib	PARP-1 inhibitors	Inhibit PARP-1 enzymatic activity; prevent PARP-1-mediated necrosis	Useful for distinguishing PARP-1-mediated necrosis from other pathways; ineffective against TNF-induced necroptosis [35]
CA-074 Me	Cathepsin B inhibitor	Cell-permeable cathepsin B inhibitor; blocks lysosomal protease-mediated necrosis	Use at 10-20 μM; inhibits generation of 50-kDa PARP-1 fragment in necrosis [8]

Discussion and Research Implications

The strategic application of protease inhibitors, particularly zVAD-fmk, provides critical insights into the complex interplay between different cell death modalities. The paradoxical ability of zVAD-fmk to induce necroptosis in certain cellular contexts like L929 cells, while effectively suppressing apoptosis, highlights the sophisticated compensatory mechanisms that exist within cell death signaling networks. This phenomenon depends on autocrine TNFα production and requires RIP1/RIP3 kinase activity, distinguishing it from both caspase-dependent apoptosis and PARP-1-mediated necrotic pathways.

The differential PARP-1 cleavage signatures—89-kDa fragment in apoptosis versus 50-kDa fragment in necrosis—provide verifiable biomarkers for discriminating these pathways in experimental systems. The resistance of necrotic PARP-1 cleavage to zVAD-fmk confirms the involvement of non-caspase proteases, specifically cathepsins B and G released from damaged lysosomes. This fundamental distinction enables researchers to interpret cell death mechanisms more accurately when employing caspase inhibitors in their experimental designs.

For drug development professionals, these findings highlight the importance of comprehensive cell death pathway screening when evaluating therapeutic candidates, particularly those targeting caspase pathways. The cell-type-specific effects of caspase inhibitors underscore the necessity of testing across multiple model systems to identify potential adverse necroptotic responses. Furthermore, the discrete nature of PARP-1-mediated necrosis versus TNF-induced necroptosis suggests that therapeutic strategies targeting programmed necrosis may require pathway-specific approaches rather than broad anti-necrotic interventions.

Activity-Western Blot Techniques for Non-isotopic Detection of PARP-1 Fragments

The detection and characterization of poly(ADP-ribose) polymerase-1 (PARP-1) cleavage fragments has become a fundamental methodology for distinguishing between different modes of cell death in biomedical research. As a nuclear enzyme with critical roles in DNA repair, transcription regulation, and cell fate decisions, PARP-1 undergoes distinct proteolytic cleavage patterns in response to various cellular insults [37]. The emergence of activity-Western blot techniques for non-isotopic detection has provided researchers with powerful tools to investigate these cleavage events without the safety concerns and regulatory challenges associated with radioactive methods. These techniques are particularly valuable for differentiating between apoptotic and necrotic cell death, as PARP-1 is processed by different proteases in each pathway, generating characteristic fragment signatures [8] [37].

Within the context of drug development and basic research, understanding PARP-1 cleavage patterns provides crucial insights into compound mechanisms, cellular responses to stress, and pathological processes in neurodegeneration, cancer, and ischemia-reperfusion injury [38] [37] [39]. This guide objectively compares the performance of non-isotopic activity-Western blot techniques with alternative methodologies, supported by experimental data from current literature, to assist researchers in selecting appropriate detection strategies for their specific applications in PARP-1 research.

Technical Basis of Activity-Western Blot for PARP-1 Detection

Fundamental Principles and Development

The activity-Western blot technique for PARP-1 detection represents a significant advancement over conventional Western blotting by combining electrophoretic separation with functional activity assessment. Originally described by Shah et al. in 1995, this method enables simultaneous detection of PARP-1 and its apoptosis-specific fragments while providing information about their enzymatic capabilities [40]. The non-isotopic aspect refers to the replacement of radioactive labels with safer detection methods such as chemiluminescence, fluorescence, or colorimetric development without compromising sensitivity.

The technique capitalizes on PARP-1's ability to catalyze the transfer of ADP-ribose units from NAD+ to acceptor proteins, a process known as poly(ADP-ribosyl)ation. In the activity-Western blot protocol, this catalytic activity is harnessed after proteins are separated by SDS-PAGE and transferred to membranes. The membrane is incubated with biotinylated NAD+ or digoxigenin-NAD+, allowing active PARP-1 fragments to incorporate these modified substrates into poly(ADP-ribose) chains, which are then detected with enzyme-conjugated streptavidin or anti-digoxigenin antibodies [40]. This approach provides distinct advantages over conventional antibody-based detection by confirming the functional status of the observed fragments.

Key Advantages for Apoptosis vs. Necrosis Research

The activity-Western blot technique offers several critical advantages for distinguishing apoptotic and necrotic PARP-1 cleavage patterns. First, it allows simultaneous visualization of full-length PARP-1 (113 kDa) and its characteristic proteolytic fragments, including the apoptotic 89 kDa and 24 kDa fragments, and the necrotic 50 kDa fragment [8] [37]. Second, by confirming enzymatic activity, researchers can distinguish between catalytically active and inactive fragments, providing insights into the functional consequences of cleavage. Third, the non-isotopic nature makes the technique accessible to most laboratories without specialized radiation safety protocols.

Most importantly, this method enables discrimination between caspase-dependent apoptosis (producing 89 kDa and 24 kDa fragments) and caspase-independent necrosis (producing 50 kDa fragments) through the characteristic fragment signatures [8]. When combined with caspase inhibitors like zVAD-fmk, which block apoptotic but not necrotic cleavage, the activity-Western blot provides a powerful tool for delineating cell death mechanisms in experimental models [8].

Comparative Analysis of PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Protease-Specific Cleavage Signatures

PARP-1 serves as a substrate for multiple cell death proteases, each generating distinctive cleavage fragments that serve as molecular signatures for specific cell death pathways:

• Caspase-dependent apoptosis: Executioner caspases-3 and -7 cleave PARP-1 at the conserved DEVD214 site, generating 89 kDa and 24 kDa fragments [38] [37]. The 89 kDa fragment contains the automodification and catalytic domains, while the 24 kDa fragment comprises the DNA-binding domain. This cleavage pattern is considered a hallmark of apoptosis and inactivates PARP-1's DNA repair function while conserving cellular energy during programmed cell death.

• Necrotic cleavage: During necrosis, PARP-1 is processed by lysosomal proteases including cathepsins B and G, generating a prominent 50 kDa fragment [8]. This cleavage occurs independently of caspase activation and is not inhibited by broad-spectrum caspase inhibitors like zVAD-fmk. The necrotic cleavage reflects the loss of lysosomal membrane integrity and release of proteases into the cytosol during uncontrolled cell death.

• Alternative proteolytic pathways: Additional proteases including calpains, granzymes, and matrix metalloproteinases can cleave PARP-1 at distinct sites, generating unique fragments such as 40 kDa, 55 kDa, and 62 kDa products [37]. These alternative cleavage events occur in specific pathological contexts and represent non-apoptotic cell death mechanisms.

Table 1: PARP-1 Cleavage Fragments in Different Cell Death Pathways

Cell Death Pathway	Primary Proteases	Characteristic Fragments	Inhibitor Sensitivity	Functional Consequences
Apoptosis	Caspases-3/7	89 kDa + 24 kDa	zVAD-fmk sensitive	Inactivation of DNA repair, energy conservation
Necrosis	Cathepsins B, G	50 kDa	zVAD-fmk insensitive	Lysosomal protease release, uncontrolled degradation
Alternative Death Pathways	Calpains, Granzymes, MMPs	40 kDa, 55 kDa, 62 kDa	Pathway-specific inhibitors	Context-dependent regulation

Experimental Detection and Differentiation

The differentiation between apoptotic and necrotic PARP-1 cleavage relies on both fragment size characterization and inhibitor studies. In a typical experiment, cells treated with apoptotic inducers (e.g., staurosporine, etoposide) or necrotic inducers (e.g., H2O2, HgCl2, ethanol) are analyzed by activity-Western blot to generate distinct fragment patterns [8]. The 89 kDa apoptotic fragment retains catalytic activity and can be detected by activity blotting, while the 24 kDa DNA-binding fragment can be detected with specific antibodies [37].

The use of caspase inhibitors provides further discrimination; pretreatment with zVAD-fmk prevents the appearance of 89 kDa/24 kDa fragments in apoptosis but does not affect the generation of the 50 kDa fragment in necrosis [8]. This experimental approach allows researchers to determine the predominant cell death mechanism in their experimental systems and investigate mixed cell death populations.

Comparison of Detection Methodologies for PARP-1 Cleavage

Technique Performance Metrics

Multiple methodologies are available for detecting PARP-1 cleavage, each with distinct advantages, limitations, and appropriate applications. The following comparison summarizes the key performance characteristics of major detection platforms:

Table 2: Comparison of PARP-1 Cleavage Detection Methodologies

Methodology	Detection Principle	Sensitivity	Information Obtained	Throughput	Key Applications
Activity-Western Blot	Catalytic activity + immunodetection	Moderate (nanogram range)	Fragment size, catalytic activity, cleavage specificity	Low-medium	Mechanism of action studies, apoptosis/necrosis differentiation
Conventional Western Blot	Antibody-based immunodetection	High (picogram-nanogram)	Fragment size, abundance, cleavage specificity	Low-medium	Routine apoptosis detection, cleavage confirmation
ELISA	Solid-phase immunoassay	High (1.81 ng/mL for cleaved PARP-1) [41]	Quantitative fragment measurement	High	Drug screening, high-throughput compound evaluation
Single-Cell Electrophoresis (SEVAP)	Electrophoretic separation + immunoprobing	Single-cell resolution	DNA fragmentation + PARP-1 cleavage at single-cell level	Medium	Heterogeneity analysis, rare cell detection, mechanism validation
In Situ Fractionation + Immunodetection	Cellular fractionation + microscopy	Spatial resolution	Subcellular localization, recruitment to DNA damage	Low	DNA damage response, nuclear localization studies

Technical Considerations for Method Selection

The selection of an appropriate detection methodology depends on multiple experimental factors:

• Sample type and quantity: Activity-Western blot requires sufficient protein for catalytic activity detection (typically 20-50 μg per lane), while conventional Western blot can detect fragments from smaller samples. ELISA offers high sensitivity with minimal sample consumption [41].

• Information requirements: When confirming functional consequences of cleavage, activity-Western blot provides unique information about catalytic competence of fragments. For pure quantification of cleavage extent, ELISA offers superior precision and dynamic range.

• Throughput needs: High-throughput drug screening applications benefit from ELISA platforms (96- or 384-well formats) [41], while mechanism-of-action studies may prioritize the detailed information from blotting techniques.

• Cellular heterogeneity: For mixed cell populations or investigation of rare events, single-cell approaches like SEVAP provide resolution unavailable in bulk measurements [42].

• Spatial information: Techniques incorporating cellular fractionation or in situ detection preserve subcellular localization information critical for understanding PARP-1's nuclear functions [43].

Detailed Experimental Protocols

Non-isotopic Activity-Western Blot Protocol

The following protocol adapts the original activity-Western blot methodology [40] for contemporary laboratory settings:

Sample Preparation:

• Harvest cells and lyse in modified RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1× protease inhibitor cocktail.
• For apoptosis induction, treat cells with 1 μM staurosporine for 4 hours [41]. For necrosis induction, use 0.1% H2O2 for 30-60 minutes [8].
• Determine protein concentration using Bradford or BCA assay and adjust to 1-2 μg/μL.

Electrophoresis and Transfer:

• Separate 20-50 μg total protein per lane on 7-10% SDS-polyacrylamide gels.
• Transfer to nitrocellulose or PVDF membranes using standard wet or semi-dry transfer systems.
• Confirm transfer efficiency with Ponceau S staining.

Activity Blotting Procedure:

• Block membrane with 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.
• Wash membrane with PARP activity buffer (50 mM Tris-HCl pH 8.0, 4 mM MgCl2, 0.3 M NaCl, 0.2 mM DTT).
• Incubate membrane with reaction mixture (PARP activity buffer containing 50 μM biotin-NAD+ or digoxigenin-NAD+) for 1-2 hours at room temperature.
• Terminate reaction by washing with TBST.
• Detect biotinylated or digoxigenin-labeled PAR polymers with horseradish peroxidase-conjugated streptavidin or anti-digoxigenin antibodies (1:5000 dilution).
• Develop with enhanced chemiluminescence substrate and image with digital imaging system.

Immunodetection (Parallel Confirmation):

• Strip membrane (optional) and reprobe with PARP-1 antibodies (e.g., targeting N-terminal or C-terminal epitopes).
• Use species-appropriate HRP-conjugated secondary antibodies.
• Develop with ECL and compare fragment patterns with activity blot.

Apoptosis vs. Necrosis Differentiation Protocol

To specifically differentiate apoptotic and necrotic PARP-1 cleavage:

• Divide cell populations into four treatment groups:

  • Untreated control
  • Apoptosis inducer (1 μM staurosporine, 4 hours)
  • Necrosis inducer (0.1% H2O2, 1 hour)
  • Pretreatment with 50 μM zVAD-fmk (1 hour) followed by apoptosis or necrosis inducer

• Prepare samples and perform activity-Western blot as described above.

• Analyze fragment patterns:

  • Apoptotic signature: 89 kDa and 24 kDa fragments, inhibited by zVAD-fmk
  • Necrotic signature: 50 kDa fragment, not inhibited by zVAD-fmk
  • Mixed death: Combination of fragments

• For confirmation, probe parallel blots with caspase-3 antibodies (apoptosis marker) and LDH release assays (necrosis marker).

Signaling Pathways and Experimental Workflows

The following diagrams illustrate the key signaling pathways in PARP-1 cleavage and the experimental workflow for detection:

PARP-1 Cleavage in Cell Death Pathways

Activity-Western Blot Experimental Workflow

Research Reagent Solutions Toolkit

Table 3: Essential Reagents for PARP-1 Cleavage Detection

Reagent Category	Specific Examples	Function/Application	Technical Notes
PARP-1 Antibodies	Anti-PARP-1 N-terminal, Anti-PARP-1 C-terminal, Anti-cleaved PARP-1 (Gly215)	Fragment detection, cleavage confirmation	Cleavage-specific antibodies require Gly215 epitope [41]
Activity Blotting Reagents	Biotin-NAD+, Digoxigenin-NAD+, HRP-streptavidin, Anti-digoxigenin-HRP	Catalytic activity detection	Biotin-NAD+ preferred for sensitivity; 50-100 μM in reaction
Cell Death Inducers	Staurosporine (apoptosis), H2O2 (necrosis), Etoposide (apoptosis), HgCl2 (necrosis)	Pathway-specific PARP-1 cleavage induction	Use zVAD-fmk controls to confirm caspase-dependence [8]
Protease Inhibitors	zVAD-fmk (caspase inhibitor), E64d (cysteine protease inhibitor), Pepstatin A (aspartyl protease inhibitor)	Pathway inhibition, mechanism elucidation	zVAD-fmk at 50 μM for caspase inhibition [8]
Detection Systems	ECL substrates, Fluorescent secondary antibodies, Colorimetric substrates	Signal generation and detection	Chemiluminescence offers widest dynamic range for quantification
Separation Matrices	SDS-polyacrylamide gels (7-10%), Transfer membranes (nitrocellulose/PVDF)	Protein separation and immobilization	7% gels optimal for 50-100 kDa fragment resolution

The non-isotopic activity-Western blot technique provides researchers with a powerful methodology for detecting PARP-1 cleavage fragments while confirming their functional status through catalytic activity assessment. This approach enables clear differentiation between apoptotic and necrotic cell death pathways based on characteristic fragment signatures - the 89 kDa/24 kDa fragments of apoptosis versus the 50 kDa fragment of necrosis [8] [37]. The technique's compatibility with standard laboratory equipment and avoidance of radioactive materials makes it accessible for most research settings.

For drug development applications, particularly in oncology and neurodegenerative diseases, understanding PARP-1 cleavage patterns provides crucial insights into compound mechanisms and cellular responses to therapeutic interventions [38] [39]. The growing recognition of PARP-1's roles in transcription regulation and inflammation through NF-κB-mediated pathways further expands the utility of these detection methodologies beyond traditional cell death analysis [38] [39]. As research continues to elucidate the complex functions of PARP-1 fragments in cellular signaling, activity-Western blotting and complementary techniques will remain essential tools for mechanistic studies and therapeutic development.

In Vitro Cleavage Assays with Isolated Lysosomal Fractions and Purified Proteases

In vitro cleavage assays are fundamental tools for studying protease function and their role in cellular processes. Within the nucleus, the enzyme poly (ADP-ribose) polymerase-1 (PARP-1) is a critical target for proteases involved in different cell death pathways. Its cleavage produces distinct signature fragments that serve as biomarkers to differentiate between apoptosis and necrosis [37]. This guide provides a detailed comparison of methodologies using isolated lysosomal fractions and purified proteases to study PARP-1 cleavage, offering experimental data and protocols to inform research and drug development.

Experimental Protocols for PARP-1 Cleavage Assays

The following sections detail the core methodologies for conducting in vitro cleavage assays.

Lysosomal Rich-Fraction Isolation and Assay

This method leverages the native mixture of proteases found within lysosomes.

• Lysosome Isolation: Lysosomal-rich fractions can be isolated from cell lines (e.g., Jurkat T cells) using differential centrifugation. This process involves homogenizing cells and separating organelles based on size and density in a sucrose buffer. Purity is confirmed by measuring the activity of acid phosphatase, a classic lysosomal marker [8] [44].
• In Vitro Cleavage Reaction: The affinity-purified PARP-1 protein is incubated with the isolated lysosomal fraction. A typical reaction buffer might consist of 50 mM sodium acetate, pH 5.5, 1 mM DTT, and 1 mM EDTA. The reaction is carried out at 37°C for a defined period (e.g., 30-60 minutes) and is terminated by adding SDS-PAGE loading buffer [8].
• Analysis: The cleavage products are separated by SDS-PAGE and visualized by Western blotting using anti-PARP-1 antibodies. A characteristic 50 kDa fragment is considered a signature of necrotic cleavage mediated by lysosomal proteases [8].

Assay with Purified Lysosomal Proteases

This reductionist approach identifies the contribution of specific proteases.

• Protease Selection: Common lysosomal proteases used include cathepsins B, D, G, and L. These are available commercially as recombinant proteins [8] [45].
• Optimized Reaction Conditions: Each protease has specific activity requirements. Assays are typically performed in 100 mM buffer (e.g., sodium acetate for pH 4.5-5.5, phosphate for pH 6.0-7.0) containing 1 mM DTT and 1 mM EDTA. The reaction is initiated by adding the enzyme to the substrate (PARP-1) and incubated at 37°C [46] [44].
• Analysis: Similar to the lysosomal fraction assay, cleavage is analyzed by Western blot. Cathepsins B and G have been shown to cleave PARP-1 into the 50 kDa necrotic fragment, among others [8].

Fluorogenic Activity-Based Assays

This method provides a quantitative readout of general protease activity, useful for initial characterization.

• Substrate Design: Short peptide substrates linked to a fluorogenic group like 7-amino-4-methylcoumarin (AMC) are used. The sequence is derived from known cleavage sites in natural substrates (e.g., Z-FR-AMC for omni-cathepsin activity or Z-RR-AMC for cathepsin B) [45] [44].
• Reaction Setup: The fluorogenic substrate is added to the protease or lysosomal fraction in the appropriate activity buffer. Upon cleavage, the release of free AMC is monitored in real-time using a fluorometer (excitation ~370-380 nm, emission ~460 nm) [45].
• Data Collection: The increase in fluorescence over time is recorded, and the maximum slope of the curve is calculated to determine enzymatic velocity. This method is ideal for pH profiling and inhibitor studies [44].

Comparative Performance Data

The tables below summarize key experimental data from PARP-1 cleavage studies.

Table 1: PARP-1 Cleavage Fragments as Signatures of Cell Death

Cell Death Pathway	Primary Proteases Involved	Characteristic PARP-1 Fragments	Functional Outcome
Apoptosis	Caspases-3 and -7	89 kDa + 24 kDa	Inhibition of DNA repair; energy conservation [37]
Necrosis	Lysosomal Proteases (e.g., Cathepsins B, G)	50 kDa	Uncontrolled cellular digestion [8] [37]

Table 2: Comparison of In Vitro Cleavage Assay Methods

Assay Parameter	Lysosomal Fractions	Purified Proteases	Fluorogenic Substrates
Physiological Relevance	High (native protease milieu)	Medium (defined system)	Low (activity on short peptides)
Primary Readout	Western Blot (Fragment size)	Western Blot (Fragment size)	Fluorescence (Activity rate)
Key Advantage	Identifies net proteolytic outcome	Identifies specific protease functions	Quantitative and high-throughput
Typical Buffers	Sodium Acetate (pH 5.5) [8]	Enzyme-specific pH optima [46]	Enzyme-specific pH optima [44]
Data Shown	50 kDa PARP-1 fragment generation [8]	Cathepsins B & G produce 50 kDa fragment [8]	Cathepsin activity peaks at pH 5.0 [44]

Signaling Pathways and Experimental Workflows

The following diagrams illustrate the core concepts and methodologies discussed in this guide.

PARP-1 Cleavage in Cell Death. This diagram contrasts the pathways leading to different PARP-1 cleavage signatures. Necrosis involves full lysosomal disruption and cathepsin-mediated generation of a 50 kDa fragment. Limited lysosomal leakage can sometimes initiate apoptosis via caspase activation, producing 89 kDa and 24 kDa fragments [8] [37] [47].

In Vitro Cleavage Assay Workflow. This chart outlines the key steps in a typical cleavage experiment, highlighting the parallel paths of using isolated lysosomal fractions versus purified proteases, converging on Western blot analysis for definitive fragment identification [8] [44].

The Scientist's Toolkit: Key Research Reagents

Successful execution of these assays requires a set of core reagents and materials.

Table 3: Essential Reagents for Lysosomal Cleavage Assays

Reagent / Material	Function / Description	Examples / Notes
PARP-1 Protein	Substrate for cleavage assays.	Affinity-purified bovine or human PARP-1; full-length recombinant protein [8].
Lysosomal Proteases	Effector enzymes.	Recombinant Cathepsins B, D, G, L (available from R&D Systems, Millipore, Sigma-Aldrich) [46] [8].
Protease Inhibitors	Control experiments; pathway validation.	E64d (cysteine cathepsin inhibitor), Pepstatin A (aspartyl protease inhibitor), zVAD-fmk (caspase inhibitor) [48] [47].
Activity Buffers	Maintain optimal protease activity.	Sodium acetate (pH 4.5-5.5), Phosphate (pH 6.0-7.0); often include DTT and EDTA [46] [44].
Fluorogenic Substrates	Quantitative activity measurement.	Z-FR-AMC (broad cathepsin), Z-RR-AMC (Cathepsin B), Ac-DEVD-AMC (Caspase-3/7) [45] [44].
Antibodies	Detection of PARP-1 and its fragments.	Monoclonal anti-PARP-1 for Western blotting [8].
Cell Lines	Source for lysosomal fractions.	Jurkat T cells, MCF-7, SH-SY5Y, and primary fibroblasts [8] [47].

In vitro cleavage assays with lysosomal fractions and purified proteases provide distinct yet complementary data. Lysosomal fractions offer a physiologically relevant system to observe the net outcome of coordinated protease activity, reliably generating the necrotic 50 kDa PARP-1 fragment. In contrast, assays with purified cathepsins are indispensable for deconvoluting the specific role of individual enzymes and establishing direct substrate relationships. The choice between methods depends on the research question—whether it is to observe the global proteolytic landscape or to define precise protease-substrate interactions. Together, these assays are powerful tools for defining biomarkers of cell death and screening potential therapeutic modulators of lysosomal function.

Poly(ADP-ribose) polymerase-1 (PARP-1) plays a complex, dual role in cellular fate, functioning as a critical DNA damage repair enzyme while also serving as a key executioner substrate in programmed cell death. The cleavage of PARP-1 by caspases during apoptosis is a well-established hallmark, generating characteristic 24 kDa and 89 kDa fragments that serve as a definitive biochemical marker for this form of cell death. However, emerging research reveals that PARP-1's role extends beyond apoptosis into other death pathways, including parthanatos, where its overactivation leads to energy depletion-induced necrosis. This guide provides a comprehensive comparison of PARP-1 cleavage patterns across different cell death contexts, with a specific focus on flow cytometric methodologies for correlating these patterns with established cell death markers. By offering detailed experimental protocols and analytical frameworks, we aim to equip researchers with the tools necessary to precisely distinguish between cell death mechanisms in both basic research and drug development applications.

PARP-1 in Cell Death Signaling Pathways

The Dual Role of PARP-1: DNA Guardian and Death Substrate

PARP-1 functions as a primary nuclear DNA damage sensor that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, facilitating DNA repair processes. However, under conditions of severe genotoxic stress, PARP-1 becomes a central player in cell death decision-making. During classical apoptosis, caspase-3 cleaves PARP-1 at aspartic acid residue 214, separating its N-terminal DNA-binding domains from its C-terminal catalytic domain [49]. This cleavage event inactivates PARP-1's DNA repair function while preventing excessive NAD+ consumption, thereby facilitating an orderly apoptotic process. The resulting 89 kDa truncated PARP-1 (tPARP1) translocates to the cytoplasm where it can undertake novel functions, including mediating ADP-ribosylation of RNA polymerase III to potentiate innate immune responses during apoptosis [49].

In contrast to its role in apoptosis, PARP-1 mediates a distinct form of programmed necrosis called parthanatos through excessive activation. When DNA damage is too severe for repair, hyperactivated PARP-1 triggers catastrophic NAD+ and ATP depletion, leading to energy failure and necrotic cell death [50]. Recent research has identified that PARP-1 activation and the resulting poly(ADP-ribose) (PAR) polymers can directly interact with STING (stimulator of interferon genes), promoting apoptosis upon acute ionizing radiation-mediated DNA damage [51]. This PAR-STING interaction represents a novel mechanism through which PARP-1 influences cell fate decisions independent of its cleavage status.

PARP-1 Cleavage as a Hallmark of Apoptosis

The proteolytic cleavage of PARP-1 serves as a definitive biochemical marker for apoptosis, distinguishing it from other forms of cell death. During the execution phase of apoptosis, effector caspases (primarily caspase-3) recognize and cleave PARP-1 at a specific DEVD motif, generating the characteristic 24 kDa and 89 kDa fragments [49] [52]. This cleavage event serves as a molecular switch that terminates DNA repair efforts and permits the apoptotic process to proceed unimpeded. Detection of these cleavage products, particularly the 89 kDa fragment, provides a specific indicator of caspase-mediated apoptotic signaling, as this proteolytic event does not occur during caspase-independent cell death modalities.

The critical positioning of PARP-1 cleavage within the apoptotic cascade makes it an invaluable parameter for flow cytometric analysis of programmed cell death. When correlated with other apoptotic markers, PARP-1 cleavage patterns provide enhanced resolution for distinguishing between apoptosis, necrosis, and hybrid cell death phenotypes, offering critical insights for therapeutic interventions targeting specific death pathways.

Experimental Protocols for PARP-1 Cleavage Analysis

Multicolor Flow Cytometry Panel Design

Designing a robust multicolor flow cytometry panel for correlating PARP-1 cleavage with other cell death markers requires strategic planning to minimize spectral overlap while ensuring detection sensitivity for critical parameters. The following protocol outlines a comprehensive approach for simultaneous detection of PARP-1 cleavage, caspase activation, and membrane alterations:

Panel Configuration:

• Fluorophore Selection: Assign bright fluorophores (PE, APC) to low-abundance targets like cleaved PARP-1 and dim fluorophores (FITC, PerCP) to abundant targets such as Annexin V [53]. Avoid combinations with significant spectral overlap, such as APC and PE-Cy5.
• Compensation Controls: Include single-stained controls for each fluorophore using compensation beads or cells with known marker expression. Ensure the positive population represents at least 10% of the total sample and matches or exceeds the brightness of experimental samples [53].
• Gating Strategy: Begin with forward scatter (FSC) vs. side scatter (SSC) to identify intact cells, excluding debris and apoptotic bodies. Subsequent gating should utilize fluorescence minus one (FMO) controls to establish accurate positive populations for each parameter.

Staining Protocol:

• Cell Preparation: Harvest cells, wash with PBS, and resuspend in Annexin V binding buffer.
• Viability Staining: Add viability dye (e.g., 7-AAD or propidium iodide) and incubate for 5-10 minutes.
• Surface Staining: Add Annexin V conjugate and incubate for 15 minutes in the dark.
• Fixation and Permeabilization: Fix cells with 4% paraformaldehyde for 20 minutes, then permeabilize with ice-cold 90% methanol for 30 minutes.
• Intracellular Staining: Add antibodies against cleaved PARP-1 and active caspase-3, then incubate for 60 minutes.
• Analysis: Wash cells, resuspend in buffer, and acquire data immediately on a flow cytometer with appropriate laser and filter configurations.

Detection of PARP-1 Cleavage in Apoptosis Induction Models

To validate PARP-1 cleavage patterns, researchers can employ established apoptosis induction models with the following experimental setup:

Chemical Induction with Staurosporine (STS):

• Prepare a 1mM stock solution of STS in DMSO and store at -20°C.
• Treat cells at 70-80% confluence with 0.5-1μM STS for 4-6 hours.
• Include a PARP inhibitor control (e.g., 3-aminobenzamide at 5mM) to distinguish PARP-1-dependent effects [52].
• Harvest cells at regular intervals (0, 2, 4, 6, 8 hours) to capture temporal progression of PARP-1 cleavage.

Oxidative Stress Induction with Hydrogen Peroxide (H₂O₂):

• Prepare fresh H₂O₂ dilution in serum-free medium.
• Treat cells with 100-500μM H₂O₂ for 2-4 hours.
• Include antioxidant controls (e.g., N-acetylcysteine) to verify oxidative stress-specific effects.
• Assess PARP-1 cleavage in conjunction with oxidative stress markers like ROS production.

DNA Damage Induction with Ultraviolet (UV) Radiation:

• Culture cells to 60-70% confluence in PBS-covered dishes.
• Expose to 5-20 J/m² UV-C radiation using a calibrated UV source.
• Replace with fresh culture medium and incubate for 4-24 hours before analysis.
• Consider combination treatments with low-dose arsenite (2μM for 24 hours) to examine co-carcinogenic effects on PARP-1 inhibition and apoptosis reduction [50].

For all models, include appropriate controls: untreated cells, vehicle controls (DMSO for STS experiments), and caspase inhibitor controls (Z-VAD-FMK at 20μM) to confirm caspase-dependent PARP-1 cleavage.

Comparative Analysis of PARP-1 Cleavage Across Cell Death Modalities

Correlation of PARP-1 with Apoptotic Markers

The relationship between PARP-1 cleavage and established apoptotic markers provides a framework for definitive identification of apoptosis versus other cell death mechanisms. The following table summarizes key correlative patterns observed in experimental models:

Table 1: PARP-1 Cleavage Correlations with Apoptotic Markers

Cell Death Marker	Detection Method	Correlation with PARP-1 Cleavage	Temporal Relationship	Experimental Context
Caspase-3 Activation	FLICA, anti-active caspase-3 Ab	Strong positive correlation	Caspase-3 activation precedes PARP-1 cleavage by 30-60 minutes	Staurosporine-treated lymphocytes [54] [52]
Phosphatidylserine Externalization	Annexin V binding	Moderate positive correlation	PS externalization occurs concurrently or slightly before PARP-1 cleavage	UV-radiated HaCat cells [50]
Mitochondrial Membrane Potential (ΔΨm)	JC-1, TMRM dye	Inverse correlation	ΔΨm collapse precedes PARP-1 cleavage in intrinsic apoptosis	Cytarabine/idarubicin-treated AML cells [55]
DNA Fragmentation	TUNEL assay, sub-G1 analysis	Moderate positive correlation	DNA fragmentation typically follows PARP-1 cleavage	Hydrogen peroxide-treated sperm fractions [52]
Cytochrome c Release	Immunocytochemistry	Variable correlation	Precedes PARP-1 cleavage in intrinsic pathway only	Ionizing radiation-induced apoptosis [51]

The strong correlation between caspase-3 activation and PARP-1 cleavage makes this combination particularly valuable for definitive apoptosis identification. Researchers should note that during extrinsic apoptosis, PS externalization may occasionally precede detectable PARP-1 cleavage, requiring multiple timepoint analyses for accurate interpretation.

Discriminatory Patterns in Non-Apoptotic Cell Death

PARP-1 exhibits distinct signatures in non-apoptotic cell death pathways, providing critical discriminatory power for cell death classification:

Table 2: PARP-1 in Non-Apoptotic Cell Death Pathways

Cell Death Modality	PARP-1 Status	Key Associated Markers	Differentiating Features from Apoptosis	Therapeutic Context
Parthanatos	Hyperactivation without cleavage	AIF translocation, PAR polymer accumulation	Massive PAR synthesis, caspase-independent	Cytarabine+idarubicin in AML M4/M5 subtypes [55]
Necroptosis	No specific cleavage	RIPK1/RIPK3/MLKL activation, membrane rupture	Phospho-MLKL positivity, caspase-8 inhibition	Caspase-inhibited conditions [26]
Pyroptosis	Caspase-1 mediated cleavage	GSDMD cleavage, IL-1β release, LDH release	Distinct 32 kDa GSDMD fragment, inflammasome activation	Caspase-1/4/5/11 activation [26]
Ferroptosis	No cleavage	Lipid peroxidation, GPX4 inhibition	Caspase-independent, caspase-2 may inhibit	Erastin, RSL3 treatments [26]

The PARP-1 hyperactivation observed in parthanatos represents a particularly important diagnostic pattern, as it associates with favorable outcomes (3-fold improved survival) in acute myeloid leukemia patients treated with cytarabine and idarubicin [55]. This PARP-1 activation signature differs fundamentally from the cleavage pattern of apoptosis, highlighting the critical importance of measuring both PARP-1 quantity and proteolytic status in therapeutic response assessment.

Signaling Pathway Integration

PARP-1 Cleavage in Cell Death Pathways

The diagram above illustrates the central position of PARP-1 in coordinating cellular responses to DNA damage, with distinct pathways leading to either apoptosis or parthanatos. In the apoptotic pathway (blue), caspase-3 activation leads to PARP-1 cleavage, generating the characteristic 89 kDa and 24 kDa fragments that serve as definitive apoptotic markers. In contrast, parthanatos (green) involves PARP-1 hyperactivation, resulting in massive PAR polymer production that triggers both AIF release and STING activation, ultimately leading to caspase-independent cell death [51]. This pathway visualization highlights how PARP-1 processing status provides critical information about the operative cell death mechanism, with cleavage products indicating apoptosis and PAR accumulation indicating parthanatos.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for PARP-1 Cleavage and Cell Death Analysis

Reagent Category	Specific Examples	Application Notes	Detection Method
PARP-1 Antibodies	Anti-PARP-1 full length, Anti-cleaved PARP-1 (89 kDa), Anti-PAR polymer	Use cleavage-specific antibodies for apoptosis; PAR polymer antibodies for parthanatos	Western blot, flow cytometry, immunofluorescence
Caspase Detection Reagents	FLICA assays, anti-active caspase-3, caspase-3 substrate (DEVD-pNA)	FLICA provides live-cell capability; anti-active caspase-3 offers specificity	Flow cytometry, fluorescence microscopy, spectrophotometry
Viability & Membrane Integrity Probes	Annexin V conjugates, PI, 7-AAD, SYTOX dyes	Annexin V requires calcium buffer; viability dyes distinguish necrosis	Flow cytometry, fluorescence microscopy
DNA Damage & Fragmentation Assays	TUNEL assay kits, anti-γH2AX, sub-G1 staining	TUNEL detects late apoptosis; γH2AX indicates early DNA damage	Flow cytometry, microscopy
Mitochondrial Function Probes	JC-1, TMRM, MitoSOX, MitoTracker	JC-1 detects ΔΨm collapse; MitoSOX measures mitochondrial ROS	Flow cytometry, fluorescence microscopy
PARP Inhibitors	Olaparib, Niraparib, 3-aminobenzamide, PJ34	Use as experimental controls to verify PARP-1 specific effects	Combined with cell viability assays
Flow Cytometry Controls	Compensation beads, FMO controls, viability dyes	Essential for multicolor panel validation and accurate gating	Flow cytometry

When selecting reagents for PARP-1 cleavage studies, researchers should prioritize validated antibodies that specifically recognize the 89 kDa cleavage fragment while showing minimal cross-reactivity with full-length PARP-1. For flow cytometric applications, ensure antibody clones have been validated for intracellular staining following fixation and permeabilization protocols. Combination with FLICA caspase assays provides particularly robust apoptosis detection, while PAR polymer antibodies enable discrimination of parthanatos pathways.

Analytical Framework for Data Interpretation

Interpreting flow cytometric data involving PARP-1 cleavage requires a systematic approach that integrates multiple parameters to accurately classify cell death modalities. The following analytical framework provides guidance for robust experimental interpretation:

Quantitative Correlation Analysis:

• Establish correlation coefficients between PARP-1 cleavage and other apoptotic markers (caspase activation, PS externalization) across multiple experimental conditions.
• Calculate the temporal sequence of events through time-course experiments, noting that caspase activation typically precedes detectable PARP-1 cleavage by 30-60 minutes in most apoptotic models.
• Determine population distributions using bivariate gating to identify subpopulations with discordant marker expression (e.g., PARP-1 cleavage without caspase activation), which may indicate alternative cleavage mechanisms or experimental artifacts.

Gating Strategy Optimization:

• Implement fluorescence minus one (FMO) controls for each parameter to establish accurate positive/negative boundaries, particularly for cleaved PARP-1 detection where background autofluorescence may be significant.
• Utilize back-gating techniques to verify that PARP-1 positive populations align with expected light scatter properties of apoptotic cells (initially increased side scatter with decreased forward scatter, followed by reduction in both parameters).
• Apply Boolean gating strategies to quantify the prevalence of specific death signatures (e.g., Annexin V+/Caspase-3+/PARP-1+ for classical apoptosis vs. Annexin V+/Caspase-3-/PARP-1- for primary necrosis).

Validation and Quality Control:

• Confirm flow cytometric findings through orthogonal methods, particularly Western blot analysis for PARP-1 cleavage fragments, which provides definitive molecular weight confirmation.
• Include reference samples with known apoptosis induction (e.g., staurosporine-treated cells) in each experiment to ensure consistent assay performance and enable cross-experiment comparisons.
• Document compensation matrices and fluorescence spillover values to maintain consistency across experimental runs, particularly when analyzing subtle changes in PARP-1 cleavage kinetics.

This analytical approach enables researchers to move beyond simple positive/negative classification to a more nuanced understanding of cell death heterogeneity within samples, providing insights into kinetic transitions between death pathways and potential resistance mechanisms in subpopulations of therapeutic interest.

Resolving Ambiguity: Challenges in Differentiating Apoptosis from Necrosis

In cell death research, poly (ADP-ribose) polymerase-1 (PARP-1) serves as a critical molecular node whose cleavage patterns provide distinctive signatures for differentiating between apoptosis, necrosis, and other forms of programmed cell death. As an abundant nuclear enzyme with approximately 1-2 million copies per cell, PARP-1 accounts for roughly 85% of total cellular PARP activity and functions as a primary DNA damage sensor [37]. During controlled cellular demise, PARP-1 becomes a preferred substrate for various "suicidal" proteases, including caspases, calpains, cathepsins, granzymes, and matrix metalloproteinases, with each protease class generating specific PARP-1 cleavage fragments that serve as recognizable biomarkers [37]. The accurate interpretation of these fragment patterns is essential for understanding cell death mechanisms in diverse pathological contexts, from neurodegenerative diseases to cancer therapeutics.

The functional significance of PARP-1 cleavage extends beyond mere biomarker utility. When cleaved by different proteases, the resulting fragments exhibit distinct biological activities and cellular localizations that can either promote or inhibit downstream death signaling. For example, the 24-kD DNA-binding domain fragment produced by caspase cleavage can act as a trans-dominant inhibitor of intact PARP-1, irreversibly binding to damaged DNA and preventing repair enzymes from accessing strand breaks [37]. This conservation of cellular ATP pools during apoptosis contrasts sharply with the consequences of PARP-1 overactivation in necrotic death, where rampant NAD+ consumption leads to catastrophic energy depletion [6]. Thus, understanding PARP-1 cleavage patterns provides not only diagnostic but also functional insights into cell death pathophysiology.

Comparative Analysis of PARP-1 Cleavage Signatures

Apoptotic Versus Necrotic Cleavage Patterns

The cleavage of PARP-1 follows distinctly different patterns in apoptotic versus necrotic cell death, providing researchers with clear molecular signatures for pathway identification. The following table summarizes the key characteristics of PARP-1 cleavage across major cell death pathways:

Table 1: PARP-1 Cleavage Patterns in Different Cell Death Pathways

Cell Death Pathway	Primary Proteases	PARP-1 Fragments	Functional Consequences	Regulatory Context
Apoptosis	Caspase-3, Caspase-7	89-kD (AMD+CAT), 24-kD (DBD)	Inactivation of PARP-1, conservation of ATP, inhibition of DNA repair	Controlled energy depletion, orderly cellular dismantling [37]
Necrosis	Calpains, Cathepsins	50-kD, 40-kD (various)	Potential dominant-negative effects, incomplete inactivation	Severe energy depletion, inflammatory response [37]
Parthanatos	(PARP-1 dependent)	(Not cleaved)	AIF-mediated chromatin fragmentation	PARP-1 overactivation, massive NAD+/ATP depletion [56]
Other PCD Forms	Caspase-1, Granzymes, MMPs	64-kD, 50-kD, 40-kD, 35-kD	Varied effects on catalytic activity and DNA binding	Context-specific, often inflammatory [37]

Caspase-Specific Cleavage Motifs and PARP-1 Processing

The overlapping substrate specificity among caspases creates both challenges and opportunities for interpreting PARP-1 cleavage patterns. Research has demonstrated that while caspases exhibit preferred substrate cohorts, their cleavage motifs frequently overlap, with caspase-3 able to cleave most substrates more efficiently than other caspases to which the substrates are reportedly specific [57] [58]. This promiscuity necessitates careful experimental design when attributing PARP-1 cleavage to specific caspases in mixed cell death environments.

The primary caspase cleavage site in PARP-1 is located within the aspartate-glutamate-valine-aspartic acid (DEVD) motif, a sequence recognized preferentially by executioner caspases-3 and -7 [6] [37]. This cleavage separates PARP-1's 46-kD DNA-binding domain (containing two zinc finger motifs) from its 54-kD catalytic domain, effectively disabling the enzyme's capacity to respond to DNA damage while conserving cellular energy resources [37]. The 24-kD DBD fragment remains tightly bound to DNA strand breaks, where it may block access by other repair enzymes, while the 89-kD fragment (containing the automodification and catalytic domains) translocates to the cytosol [37].

Table 2: Caspase Specificity in PARP-1 Cleavage

Caspase	Primary Role in Cell Death	Efficiency on PARP-1	Additional Substrates	Inhibitor Sensitivity
Caspase-3	Executioner (apoptosis)	High (primary PARP-1 protease)	Multiple nuclear and cytoskeletal targets	Broad caspase inhibition
Caspase-7	Executioner (apoptosis)	Moderate	PARP-1, other apoptotic substrates	Broad caspase inhibition
Caspase-6	Executioner (apoptosis)	Low	Lamin proteins, caspase activators	Less characterized
Caspase-8	Initiator (extrinsic apoptosis)	Context-dependent	Caspase-3, Bid, gasdermins	Specific inhibitor available

Experimental Approaches for PARP-1 Cleavage Analysis

Standardized Western Blot Protocol for PARP-1 Fragment Detection

The detection and differentiation of PARP-1 cleavage fragments primarily relies on Western blot analysis with specific antibodies targeting different PARP-1 domains. The following protocol represents a standardized approach for unambiguous identification of PARP-1 fragments in mixed cell death scenarios:

Cell Lysis and Protein Extraction:

• Prepare ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitor cocktail
• Harvest cells and incubate in lysis buffer for 30 minutes on ice with occasional vortexing
• Centrifuge at 14,000 × g for 15 minutes at 4°C
• Collect supernatant and determine protein concentration using BCA assay

Electrophoresis and Transfer:

• Load 20-50 μg of protein per lane on 4-12% Bis-Tris polyacrylamide gels
• Include molecular weight markers and appropriate controls (e.g., apoptotic cell lysate)
• Run electrophoresis at 120-150V for 60-90 minutes
• Transfer to PVDF membrane using standard wet transfer protocols

Antibody Detection:

• Block membrane with 5% non-fat milk in TBST for 1 hour
• Incubate with primary antibodies (recommended: anti-PARP-1 antibody targeting N-terminal epitope for full-length and 89-kD fragment detection; anti-C-terminal antibody for catalytic domain localization)
• Wash and incubate with appropriate HRP-conjugated secondary antibodies
• Develop using enhanced chemiluminescence substrate

Fragment Interpretation:

• Full-length PARP-1: ~116 kDa
• Apoptotic fragment: ~89 kDa (C-terminal) + ~24 kDa (N-terminal, often not detected)
• Necrotic fragments: ~50 kDa, ~40 kDa, ~35 kDa (variable based on protease)

This protocol should be supplemented with caspase activity assays using fluorogenic substrates (e.g., DEVD-AFC for caspases-3/7) to confirm apoptotic activation, and viability assays to distinguish primary necrosis from secondary necrosis following apoptosis [37].

Advanced Proteomic Methodologies for Comprehensive Cleavage Mapping

Beyond standard Western blot approaches, advanced proteomic techniques enable comprehensive mapping of PARP-1 cleavage events in complex cell death environments. N-terminomics technologies, including TAILS (Terminal Amine Isotopic Labeling of Substrates) and other N-terminal labeling strategies, allow for system-wide identification of protease cleavage events without presupposition of the proteases involved [59] [60].

For PARP-1-specific analysis, a combination of immunoprecipitation followed by mass spectrometry can identify not only canonical cleavage sites but also novel proteolytic events that might be missed by antibody-based approaches. Recent advances in this field include the development of proteomics strategies tailored to the chemical features of post-translational modifications, including ADP-ribosylation itself, which can influence protease accessibility [61]. These methods are particularly valuable in mixed cell death scenarios where multiple proteases are active simultaneously.

Signaling Pathways in PARP-1-Mediated Cell Death

The following diagram illustrates the key regulatory nodes where PARP-1 cleavage intersects with major cell death pathways:

This pathway diagram illustrates how PARP-1 cleavage patterns are determined by both the severity of initial DNA damage and the specific protease cascades activated in response. The critical regulatory role of cellular energy status in determining death modality highlights the importance of monitoring ATP levels alongside PARP-1 cleavage in experimental systems.

The Scientist's Toolkit: Essential Reagents for PARP-1 Cleavage Research

Table 3: Essential Research Reagents for PARP-1 Cleavage Studies

Reagent Category	Specific Examples	Research Application	Technical Considerations
PARP-1 Antibodies	Anti-N-terminal, Anti-C-terminal, Anti-catalytic domain	Fragment detection via Western blot, immunofluorescence	Epitope mapping critical for fragment identification
Caspase Inhibitors	Z-VAD-FMK (pan-caspase), DEVD-CHO (caspase-3/7)	Pathway inhibition studies, cleavage source identification	Limited specificity at high concentrations [57]
Caspase Substrates	DEVD-AFC, DEVD-AMC (fluorogenic)	Caspase activity measurement in cell lysates	Overlapping specificity requires careful interpretation [58]
PARP-1 Activity Assays	NAD+ consumption assays, PAR polymer detection	Monitoring PARP-1 activation prior to cleavage	Complements cleavage data
Cell Death Inducers	Staurosporine (apoptosis), H₂O₂ (oxidative stress), TNF-α (necrosis)	Controlled induction of specific death pathways	Concentration-dependent effects on death modality
Proteomic Tools	TAILS, N-terminal COFRADIC	Global cleavage site identification	Requires specialized expertise and instrumentation [60]

Interpretation Guidelines for Complex Fragment Patterns

In mixed cell death scenarios, researchers frequently encounter complex PARP-1 cleavage patterns that require careful interpretation. The following guidelines support accurate analysis:

Concurrent Fragment Detection: The simultaneous presence of 89-kD apoptotic fragments and 50-kD/40-kD necrotic fragments suggests either heterogeneous cell populations or sequential activation of different death pathways. Single-cell analysis techniques (e.g., immunofluorescence, flow cytometry) can help distinguish between these possibilities.

Temporal Considerations: Apoptotic PARP-1 cleavage typically occurs early in the death process, while necrotic cleavage appears later. Time-course experiments with frequent sampling provide essential kinetic data for pathway discrimination.

Complementary Assays: PARP-1 cleavage data should always be corroborated with additional death markers:

• Apoptosis: Caspase-3/7 activity, phosphatidylserine exposure (Annexin V), nuclear fragmentation
• Necrosis: Plasma membrane integrity (propidium iodide), ATP depletion, HMGB1 release
• Parthanatos: AIF translocation, extensive PAR synthesis

Quantitative Considerations: While Western blotting is inherently semi-quantitative, densitometric analysis of fragment ratios (e.g., 89-kD:full-length) can provide insights into the predominant death pathway. Mass spectrometry-based proteomics offers more precise quantification for complex mixtures [60].

The complexity of PARP-1 cleavage interpretation is further heightened by the growing recognition of non-apoptotic caspase functions in processes such as cellular differentiation, where caspase activation and substrate cleavage occur without triggering cell death [60]. In these contexts, PARP-1 cleavage may represent regulatory processing rather than a commitment to death, emphasizing the necessity of correlating cleavage patterns with functional cellular outcomes.

The therapeutic inhibition of caspases, initially envisioned as a strategy to suppress apoptotic cell death, presents a significant paradox in cell death research. A growing body of evidence demonstrates that under specific conditions, caspase inhibition can unexpectedly potentiate necrotic cell death through hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1). This review systematically compares PARP-1 cleavage patterns across different cell death modalities and synthesizes experimental data revealing how disrupted apoptotic signaling redirects cells toward PARP-1-mediated necrosis. We examine the molecular mechanisms underlying this phenomenon, detail key experimental methodologies for its investigation, and discuss the implications for therapeutic development in conditions where both apoptosis and necrosis contribute to pathology.

Poly(ADP-ribose) polymerase-1 (PARP-1) functions as a critical molecular switch governing cellular survival and death decisions. As a nuclear enzyme activated by DNA damage, PARP-1 normally facilitates DNA repair through poly(ADP-ribosyl)ation of target proteins [14] [2]. However, excessive activation in response to severe genotoxic stress triggers pathological processes that culminate in cell death. The fate of the cell—apoptosis or necrosis—depends significantly on the post-translational processing of PARP-1, particularly its proteolytic cleavage by specific enzymes [2].

Caspases, a family of cysteine-aspartate proteases, execute the apoptotic program and cleave PARP-1 at specific aspartate residues, generating characteristic 89 kDa and 24 kDa fragments [62] [2]. This cleavage inactivates PARP-1, conserving cellular ATP pools necessary for the energy-dependent apoptotic process [62]. Inhibition of caspases, while intended to block apoptosis, disrupts this regulated process and can unleash an alternative necrotic pathway driven by PARP-1 hyperactivation, leading to compromised cellular integrity and inflammatory cell death [62] [35].

Comparative Analysis of PARP-1 Cleavage Patterns in Cell Death

Proteolytic Signatures of PARP-1 in Apoptosis vs. Necrosis

PARP-1 undergoes distinct cleavage patterns depending on the mode of cell death and the specific proteases activated, producing characteristic fragments that serve as biochemical signatures for different death pathways.

Table 1: PARP-1 Cleavage Fragments in Different Cell Death Pathways

Cell Death Pathway	Primary Proteases	Characteristic PARP-1 Fragments	Functional Consequences
Apoptosis	Caspase-3, Caspase-7	89 kDa + 24 kDa	Inactivation of PARP-1, conservation of ATP for orderly apoptosis [62] [2]
Necrosis (Lysosomal Proteases)	Cathepsins B, D, G	50 kDa, 89 kDa, 40 kDa, 35 kDa	Incomplete inactivation, sustained energy depletion [8] [11]
Parthanatos	Calpains, other PARP-1 dependent proteases	Various, including 55 kDa	AIF-mediated caspase-independent death [14] [2]

The 89 kDa fragment generated during apoptosis contains the auto-modification and catalytic domains but has greatly reduced DNA binding capacity, while the 24 kDa fragment retains the DNA-binding domain but is disconnected from the catalytic domain [2]. This cleavage effectively terminates PARP-1 activity, preventing excessive NAD+ and ATP consumption and allowing the cell to complete the energy-dependent apoptotic program [62].

In contrast, during necrosis, PARP-1 is cleaved by lysosomal proteases such as cathepsins B and G, generating a different pattern of fragments including a prominent 50 kDa fragment [8] [11]. This necrotic cleavage pattern occurs later in the cell death process and does not effectively terminate PARP-1 activity, contributing to the energetic collapse characteristic of necrosis [8].

Molecular Consequences of PARP-1 Cleavage Patterns

The functional outcomes of these distinct cleavage patterns extend beyond mere enzyme inactivation:

• Apoptotic Cleavage (89 kDa/24 kDa): The 24 kDa DNA-binding fragment remains tightly bound to DNA strand breaks, potentially acting as a trans-dominant inhibitor of DNA repair by blocking access of intact PARP-1 and other repair enzymes to damage sites [2]. The 89 kDa catalytic fragment is liberated from the nucleus into the cytosol, where its function remains less defined but may involve non-nuclear signaling roles [2].

• Necrotic Cleavage (50 kDa fragment): This alternative cleavage pattern fails to completely separate the DNA-binding domain from the catalytic domain, potentially allowing residual PARP-1 activity that continues to consume NAD+ and ATP, exacerbating the energetic crisis [8] [11].

The diagram below illustrates the PARP-1 protein domain structure and the cleavage sites associated with different proteases in apoptosis and necrosis:

The Paradox: How Caspase Inhibition Potentiates PARP-1-Mediated Necrosis

Experimental Evidence from Key Studies

Multiple studies have demonstrated the counterintuitive phenomenon where caspase inhibition redirects cell death toward necrosis through PARP-1 dependent mechanisms.

Table 2: Experimental Models Demonstrating Caspase Inhibition Potentiating Necrosis

Experimental System	Caspase Inhibitor	Necrotic Inducer	Key Findings	Reference
L929 fibrosarcoma cells	zVAD-fmk	TNF	zVAD potentiated TNF-induced necrosis; PARP activation and ATP depletion observed	[62]
HL-60 cells	zVAD-fmk	H₂O₂, EtOH, HgCl₂	Necrotic cleavage of PARP-1 (50 kDa fragment) not inhibited by zVAD	[8]
Jurkat T cells	zVAD-fmk	DNA alkylating agents	Necrotic PARP-1 cleavage mediated by lysosomal proteases	[8]
PARP-1(-/-) fibroblasts	zVAD-fmk	TNF	PARP-1 deficiency conferred resistance to TNF-induced necrosis	[62] [35]

In a pivotal study using L929 fibrosarcoma cells, treatment with TNF alone induced necrosis, while CD95 ligation triggered apoptosis. Surprisingly, the caspase inhibitor zVAD-fmk prevented CD95-mediated apoptosis but potentiated TNF-induced necrosis [62]. This enhanced necrosis correlated with PARP activation and profound ATP depletion. Conversely, PARP inhibitors suppressed TNF-induced necrosis and abolished the sensitizing effect of zVAD [62].

Further evidence comes from studies of PARP-1 cleavage patterns. During apoptosis induced by etoposide in HL-60 cells, PARP-1 was cleaved specifically to the 89 kDa fragment, whereas necrosis induced by cytochalasin B or hydrogen peroxide produced a different pattern with major fragments at approximately 89 kDa and 50 kDa [11]. This necrotic cleavage was not inhibited by zVAD-fmk, indicating caspase-independent proteolysis [8].

Molecular Mechanism of the Switch

The molecular basis for this paradoxical effect involves several interconnected pathways:

• Energetic Collapse: PARP-1 overactivation consumes NAD+ during poly(ADP-ribose) synthesis, necessitating ATP-dependent NAD+ resynthesis. This creates a vicious cycle of energy depletion, with ATP levels falling below the threshold required for apoptosis [62] [14].

• Lysosomal Protease Involvement: When caspases are inhibited, alternative proteolytic systems become activated. Lysosomal proteases, particularly cathepsins B and G, are released during necrosis and cleave PARP-1 in a distinct pattern that fails to inactivate the enzyme completely [8].

• Mitochondrial Dysfunction: PARP-1 activation triggers mitochondrial membrane permeabilization and release of apoptosis-inducing factor (AIF), which translocates to the nucleus and mediates caspase-independent chromatin condensation and DNA fragmentation [14] [2].

The diagram below illustrates the molecular switch mechanism between apoptotic and necrotic cell death fates:

Experimental Approaches and Methodologies

Key Protocols for Investigating PARP-1-Mediated Necrosis

Cell Death Induction and Inhibition Protocols

• TNF-Induced Necrosis in L929 Cells: Treat L929 cells with 10-100 ng/mL recombinant mouse TNF in serum-free medium. For inhibition studies, pre-treat cells with 20-50 µM zVAD-fmk (caspase inhibitor) and/or 100-500 µM 3-aminobenzamide (PARP inhibitor) for 1-2 hours before TNF addition [62] [35].

• Chemical Necrosis Induction: Induce necrosis in HL-60 or Jurkat T cells with 0.1% H₂O₂, 10% ethanol, or 100 µM HgCl₂ for 2-6 hours. Include zVAD-fmk (20-50 µM) to confirm caspase-independent death [8].

• DNA Alkylating Agent Treatment: Induce PARP-1 hyperactivation with 100-500 µM MNNG (1-methyl-3-nitro-1-nitrosoguanidine) or 1-5 mM MMS (methyl methanesulfonate) for 15-60 minutes [35].

PARP-1 Cleavage Analysis

• Western Blotting for PARP-1 Fragments: Separate proteins by SDS-PAGE (6-12% gradient gels) and transfer to PVDF membranes. Detect PARP-1 fragments using anti-PARP-1 antibodies that recognize both full-length and cleaved forms. Apoptotic cleavage generates 89 kDa and 24 kDa fragments, while necrotic cleavage produces additional fragments at 50 kDa, 40 kDa, and 35 kDa [8] [2] [11].

• ATP Measurement: Quantify intracellular ATP levels using luciferase-based assays. Lyse cells and mix with luciferin/luciferase reagent, measure luminescence. Normalize to protein content. PARP-1-mediated necrosis typically reduces ATP to <20% of control levels [62].

• PAR Polymer Detection: Immunostain with anti-poly(ADP-ribose) antibodies to visualize PAR accumulation, indicating PARP-1 activation [14].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Studying Caspase Inhibition and PARP-1-Mediated Necrosis

Reagent	Function/Mechanism	Application Examples	Considerations
zVAD-fmk	Broad-spectrum caspase inhibitor (irreversible)	Inhibition of apoptotic pathways to study alternative death mechanisms (20-50 µM)	Can potentiate necrosis in certain models [8] [62]
3-Aminobenzamide (3-AB)	PARP enzyme inhibitor	Protection against PARP-mediated necrosis (100-500 µM)	Moderate potency; may require higher concentrations [62] [35]
PJ34	Potent PARP-1/2 inhibitor (IC₅₀ ~20 nM)	Inhibition of PARP-mediated cell death (1-10 µM)	High potency and selectivity [14] [35]
Olaparib	Clinical PARP inhibitor (IC₅₀ ~5 nM)	Therapeutic targeting of PARP activity (0.1-10 µM)	FDA-approved; useful for translational studies [14] [35]
Anti-PARP-1 Antibodies	Detection of full-length and cleaved PARP-1	Western blotting, immunofluorescence	Should recognize multiple fragments (24, 50, 89, 113 kDa) [8] [2]
Anti-PAR Antibodies	Detection of poly(ADP-ribose) polymers	Assessment of PARP-1 activation	Indicator of PARP-1 enzymatic activity [14]

Discussion and Research Implications

Therapeutic Considerations and Pathophysiological Relevance

The interplay between caspase inhibition and PARP-1-mediated necrosis has significant implications for therapeutic development:

• Neurodegenerative Diseases: PARP-1 overactivation contributes to neuronal death in Parkinson's, Alzheimer's, and Huntington's diseases, and following cerebral ischemia [14] [63]. Therapeutic caspase inhibition in these contexts requires careful evaluation of potential necrotic consequences.

• Cancer Therapy: PARP inhibitors are established in oncology for BRCA-mutated cancers, but their interaction with caspase pathways in non-malignant cells requires consideration [63]. The combination of PARP inhibitors with caspase-modulating agents represents a promising but complex therapeutic approach.

• Inflammatory Pathologies: Since necrosis promotes inflammation through release of cellular contents, the potentiation of necrosis by caspase inhibition could exacerbate inflammatory conditions [62] [64].

Future Research Directions

Key unanswered questions and promising research avenues include:

• Cell-Type Specificity: The paradoxical effect of caspase inhibitors appears more prominent in certain cell types (e.g., L929, HL-60) but not universal across all cellular contexts. Determining the molecular basis for this specificity remains crucial.

• Alternative Proteolytic Pathways: Beyond cathepsins, other proteases like calpains and granzymes also cleave PARP-1 [2]. Their contribution to necrosis when caspases are inhibited requires further investigation.

• Metabolic Adaptations: How cellular metabolic states influence the switch between apoptosis and PARP-1-mediated necrosis represents an important area for future study, particularly in the context of varying microenvironments in diseased tissues.

The paradoxical potentiation of PARP-1-mediated necrosis by caspase inhibition underscores the complexity of cellular death pathways and the risks of therapeutic interventions targeting single mechanisms. The distinct PARP-1 cleavage signatures in apoptosis versus necrosis provide valuable biomarkers for differentiating these pathways in experimental and potentially clinical contexts. Future therapeutic strategies must account for the interconnected nature of cell death mechanisms and consider combinatorial approaches that modulate both apoptotic and necrotic pathways. As research advances, a more nuanced understanding of the molecular switches controlling cell fate will enable more precise manipulation of these processes for therapeutic benefit.

Optimizing Sample Preparation to Prevent Artefactual Proteolysis During Analysis

The analysis of PARP-1 cleavage patterns serves as a critical biomarker for distinguishing between different modes of cell death, primarily apoptosis and necrosis. However, the integrity of this analysis is highly dependent on sample preparation methodologies. Artifactual proteolysis during cell lysis and protein extraction can generate cleavage fragments that are indistinguishable from those produced by endogenous death proteases, leading to misinterpretation of experimental results. This guide provides a standardized framework for sample preparation, comparing common techniques and reagents to preserve native PARP-1 status for accurate identification of cell death pathways.

PARP-1 Cleavage as a Signature for Cell Death

The Role of PARP-1 in Cellular Homeostasis

PARP-1 is a nuclear enzyme with a foundational role in maintaining genome stability. It acts as a primary sensor for DNA strand breaks, initiating the base excision repair (BER) pathway through poly(ADP-ribosyl)ation of itself and other nuclear proteins [65] [66]. Its structure comprises three key functional domains: a DNA-binding domain (DBD), an auto-modification domain (AMD), and a C-terminal catalytic domain (CAT) [6] [66]. This domain architecture contains specific cleavage sites targeted by different proteases activated during cell death.

Distinct Cleavage Patterns in Apoptosis vs. Necrosis

The specific proteolytic cleavage of PARP-1 by different "suicidal proteases" produces signature fragments that serve as biochemical hallmarks for various cell death pathways [37].

• Apoptosis: During caspase-dependent apoptosis, executioner caspases-3 and -7 cleave PARP-1 at the DEVD214↓G215 site within the AMD. This cleavage produces a characteristic 89 kDa fragment (containing the AMD and CAT) and a 24 kDa fragment (the DBD) [37]. This process inactivates PARP-1's DNA repair function, conserving cellular ATP and facilitating the apoptotic cascade.
• Necrosis/Necroptosis: In contrast, necrosis and related pathways like necroptosis are often associated with calpain activation. Calpain cleaves PARP-1 at a different location, generating a specific 50 kDa fragment [37]. Other proteases, including cathepsins, granzymes, and matrix metalloproteinases (MMPs), can also process PARP-1 into unique fragments, creating a complex landscape of proteolytic signatures [37].

The following diagram illustrates the key differences in PARP-1 cleavage during apoptosis and necrosis:

Comparative Analysis of Sample Preparation Methodologies

The following table summarizes the impact of different sample preparation components on the preservation of PARP-1 integrity, based on experimental data.

Table 1: Comparison of Sample Preparation Components for PARP-1 Analysis

Component	Sub-Optimal Condition	Optimal Condition	Effect on PARP-1 Integrity	Experimental Evidence
Lysis Buffer	Mild, non-denaturing buffers (e.g., with 1% Triton X-100)	Strong denaturing buffers (e.g., RIPA with 1% SDS)	High artefactual cleavage in mild buffers due to co-extracted active proteases; >90% full-length PARP-1 preserved in denaturing buffers.	Immunoblotting shows appearance of non-specific fragments in non-denaturing conditions [37].
Protease Inhibitors	Absence or incomplete cocktails	Broad-spectrum cocktail (including Caspase + Calpain inhibitors)	>60% PARP-1 degradation without inhibitors; <5% degradation with complete inhibitors.	Fragment generation is blocked by specific inhibitors (e.g., Calpain inhibitor ALLN) [37].
Temperature	Prolonged handling at 4°C	Immediate denaturation at ≥95°C	Significant cleavage observed even on ice over 30 minutes; instant protease inactivation at high heat.	Time-course Western blots show progressive fragment formation during cold lysis [37].
Cell Disruption	Repeated freeze-thaw cycles, vigorous pipetting	Single-cycle snap-freeze or gentle detergent lysis	Mechanical shear releases lysosomal proteases, increasing calpain-like cleavage fragments.	Comparative analysis shows more 50 kDa fragments in mechanically sheared samples [37].

Detailed Experimental Protocols for PARP-1 Analysis

Optimized Protocol for Preventing Artefactual Proteolysis

This protocol is designed for the preparation of whole-cell protein lysates from cultured cells to accurately capture endogenous PARP-1 cleavage states.

Reagents and Solutions

• Lysis Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% (w/v) Sodium Dodecyl Sulfate (SDS), 5 mM EDTA.
• Protease Inhibitor Cocktail (100X Stock): 1 mM PMSF, 1 mM AEBSF, 10 µM E-64, 1 µM Pepstatin A, 10 mM EDTA, 100 µM Calpain Inhibitor I (ALLN), 20 µM Z-VAD-FMK (caspase inhibitor). Prepare in DMSO or as recommended.
• Phosphatase Inhibitors (Optional): 10 mM Sodium Fluoride, 1 mM Sodium Orthovanadate.
• Benzonase Nuclease (Optional): For reducing sample viscosity from DNA release.

Step-by-Step Procedure

• Pre-chill and Pre-mix: Pre-cool microcentrifuge to 4°C. Prepare fresh, ice-cold lysis buffer and supplement it with 1X concentration of the protease inhibitor cocktail (and phosphatase inhibitors if needed) immediately before use.
• Cell Harvesting: For adherent cells, rapidly aspirate the medium and rinse once with ice-cold PBS. Do not allow the cell monolayer to dry.
• Immediate Denaturation: Add the appropriate volume of hot (95°C) lysis buffer directly onto the cells (or cell pellet). Immediately scrape the cells and transfer the lysate to a microcentrifuge tube.
• Heat Denaturation: Place the tubes in a heat block or boiling water bath at 95-100°C for 10 minutes to ensure complete and instantaneous denaturation of all cellular proteins and proteases.
• DNA Shearing (Optional): If the lysate is highly viscous due to DNA, sonicate on ice for 10-15 seconds with a microtip probe or digest with Benzonase nuclease (25 U/mL) at 37°C for 10 minutes.
• Clarification: Centrifuge the lysates at 16,000 × g for 15 minutes at 4°C to pellet insoluble debris.
• Storage: Carefully transfer the supernatant (cleared lysate) to a new tube. Aliquot and store at -80°C. Avoid repeated freeze-thaw cycles.

Common Sub-Optimal Protocol (For Comparison)

A commonly used but problematic protocol involves lysis with non-denaturing buffers (e.g., NP-40 or Triton X-100-based buffers) supplemented with inhibitors, followed by incubation on ice for 30 minutes. This method allows for the activity of co-extracted proteases during the lysis period, leading to the generation of artefactual PARP-1 fragments that confound the interpretation of the true cell death status [37].

The Scientist's Toolkit: Essential Research Reagents

Table 2: Key Reagents for PARP-1 Cleavage Studies

Reagent Category	Specific Examples	Function & Rationale
Pan-Caspase Inhibitor	Z-VAD-FMK	Inhibits initiator and executioner caspases; validates caspase-dependent PARP-1 cleavage (89 kDa fragment) [37].
Calpain Inhibitor	ALLN (Calpain Inhibitor I)	Specifically inhibits µ- and m-calpain; used to confirm calpain-mediated PARP-1 cleavage (50 kDa fragment) [37].
Broad-Spectrum Protease Inhibitors	AEBSF, E-64, Pepstatin A, PMSF	Targets serine, cysteine, and aspartic proteases to provide a baseline protection against artefactual proteolysis during lysis.
PARP-1 Antibodies	Anti-PARP-1 (full length), Cleaved PARP-1 (Asp214)	Specific antibodies are crucial for detecting full-length (116 kDa) and cleaved fragments (89 kDa, 50 kDa) via Western blot [37].
Positive Control Lysates	Apoptotic (e.g., Staurosporine-treated), Necrotic (e.g., H₂O₂-treated) cell lysates	Essential controls for validating antibody specificity and the experimental setup for distinguishing cleavage patterns.
Strong Denaturant	Sodium Dodecyl Sulfate (SDS)	Immediately denatures all proteases upon cell lysis, representing the single most critical factor in preventing artefacts [37].

Accurate interpretation of PARP-1 cleavage patterns is paramount in cell death research. The data and protocols presented here demonstrate that rigorous sample preparation is not merely a preliminary step but a critical determinant of data fidelity. The adoption of a rapid, heat-denaturing lysis protocol in a strong denaturant like SDS, supplemented with a comprehensive, death-pathway-aware protease inhibitor cocktail, is essential to suppress artefactual proteolysis. By implementing these optimized and compared methodologies, researchers can ensure that the PARP-1 fragments observed are genuine signatures of apoptosis, necrosis, or other cell death pathways, thereby producing more reliable and reproducible results in basic research and drug development.

In the study of cell death mechanisms, the proteolytic cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) serves as a critical molecular switch that directs cellular fate toward fundamentally different energetic outcomes. As a nuclear enzyme with key roles in DNA damage response, PARP-1 activation and its subsequent cleavage patterns provide researchers with distinct biochemical signatures that discriminate between apoptotic and necrotic pathways [37] [6]. These pathways exhibit dramatically different consequences for cellular energy dynamics, particularly regarding ATP depletion rates and metabolic catastrophe. This guide systematically compares the characteristic PARP-1 cleavage fragments, the experimental methodologies for their detection, and their functional implications in the context of cellular energy depletion, providing a framework for interpreting experimental results in cell death research.

Comparative Analysis of PARP-1 Cleavage Signatures

The cleavage pattern of PARP-1 serves as a primary diagnostic tool for distinguishing programmed apoptosis from necrotic cell death, with each pathway generating unique proteolytic fragments through different enzymatic activities.

Table 1: Comparative PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Feature	Apoptosis	Necrosis
Primary Cleavage Fragment	89-kD catalytic fragment + 24-kD DNA-binding domain (DBD) [37]	55-kD and 62-kD fragments (lysosomal proteases/calpains) [37] [16]
Responsible Proteases	Caspase-3 and Caspase-7 [37]	Lysosomal proteases (e.g., cathepsins), calpains [37] [16]
ATP Level Impact	Conservation of ATP pools [37]	Severe ATP depletion [6] [16]
DNA Repair Consequence	Inhibition of repair (24-kD fragment binds DNA) [37]	Not well characterized
Cellular Energy Strategy	Controlled energy utilization	Energy exhaustion leading to metabolic collapse

Apoptotic Cleavage: Caspase-Mediated Regulation

During apoptosis, caspase-3 and caspase-7 cleave PARP-1 at the DEVD214↓G215 site, producing characteristic 89-kD and 24-kD fragments [37]. The 24-kD fragment containing the DNA-binding domain remains tightly associated with DNA strand breaks, where it functions as a trans-dominant inhibitor of DNA repair by blocking access for other DNA repair enzymes [37]. This strategic inhibition conserves cellular ATP pools by preventing energy-intensive DNA repair processes in a cell destined for elimination, representing an energy-efficient shutdown mechanism.

Necrotic Cleavage: Calpain and Cathepsin-Mediated Fragmentation

In contrast, necrosis involves PARP-1 cleavage by non-caspase proteases including calpains, cathepsins, and other lysosomal proteases, generating 55-kD and 62-kD fragments [37] [16]. This cleavage pattern is associated with PARP-1 hyperactivation in response to severe DNA damage, which rapidly depletes cellular NAD+ and ATP pools through excessive poly(ADP-ribose) polymer synthesis [6] [16]. The resulting energy exhaustion prevents execution of the energy-dependent apoptotic program, forcing the cell into a necrotic demise characterized by cellular swelling and membrane rupture.

PARP-1-Mediated Cell Death Signaling Pathways

The decision between apoptotic and necrotic cell death pathways involves complex signaling networks that respond to DNA damage intensity and cellular energy status. The following diagram illustrates the key molecular events in these pathways:

Experimental Protocols for PARP-1 Cleavage Analysis

Cell Treatment and Induction of Cell Death

For apoptosis induction: Treat cells with 1-10 µM staurosporine for 4-24 hours or 50 µM etoposide for 24-72 hours [34] [16]. For necrosis induction: Treat cells with 1-5 µM doxorubicin for 48-72 hours or 100-500 µM MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) for 30-120 minutes [34] [16]. Include control groups with PARP inhibitors (10 µM olaparib or 20 µM 3-aminobenzamide) and caspase inhibitors (20 µM zVAD-fmk) to validate pathway specificity.

Protein Extraction and Western Blot Analysis

Harvest cells and lyse in RIPA buffer supplemented with protease inhibitors. Separate 20-50 µg of total protein on 8-12% SDS-PAGE gels and transfer to PVDF membranes. Probe membranes with anti-PARP-1 antibody (specific for full-length 116-kD protein) and cleavage fragments. Use antibodies against caspase-3 (apoptosis marker) and HMGB1 (necrosis marker) as pathway validation controls [37] [16]. For quantitative analysis, include densitometry measurements of full-length versus cleaved PARP-1 normalized to loading controls.

ATP Depletion Assessment

Measure intracellular ATP levels using luciferase-based ATP assay kits. Lyse cells in ATP assay buffer and mix with luciferin/luciferase reagent. Record luminescence using a plate reader and calculate ATP concentrations against an ATP standard curve. Normalize values to protein concentration. Correlate ATP levels with PARP-1 cleavage patterns observed in western blot analysis [6] [16].

The Scientist's Toolkit: Key Research Reagents

Table 2: Essential Reagents for PARP-1 Cleavage and Energy Dynamics Research

Reagent/Category	Specific Examples	Research Application
PARP Activators	MNNG, β-Lapachone, Doxorubicin [34] [16]	Induce PARP-1 hyperactivation and study necrosis pathways
PARP Inhibitors	Olaparib, Niraparib, 3-Aminobenzamide [67] [65]	Investigate PARP-1 function and validate mechanism
Caspase Inhibitors	zVAD-fmk [34]	Block apoptotic cleavage to study alternative death pathways
Calpain Inhibitors	BAPTA-AM (calcium chelator), Capn4 siRNA [34]	Inhibit calpain-mediated PARP-1 cleavage in necrosis
Cell Death Assays	ATP assays, LDH release, caspase-3/7 activity kits [16]	Quantify cell death and correlate with cleavage patterns
PARP-1 Antibodies	Specific to full-length and cleavage fragments [37]	Detect and distinguish PARP-1 cleavage patterns

Interpretation Framework: Connecting Cleavage Patterns to Energy Status

When interpreting experimental results, researchers should consider the following analytical framework:

• Fragment Pattern Analysis: Identify whether 89-kD (apoptotic) or 55-kD (necrotic) fragments dominate in western blot analysis [37] [16].

• ATP Level Correlation: Correlate cleavage patterns with ATP measurements. Severe ATP depletion (<20% of control) typically associates with necrotic cleavage, while moderate ATP levels (>50% of control) favor apoptotic fragmentation [6] [16].

• Inhibitor Validation: Use pathway-specific inhibitors to confirm mechanistic relationships. PARP inhibitors should attenuate both ATP depletion and necrotic cleavage, while caspase inhibitors block apoptotic fragmentation but may enhance necrosis when ATP is depleted [34].

• Morphological Correlation: Combine molecular data with cellular morphology assessment. Apoptotic cells display shrinkage and chromatin condensation, while necrotic cells exhibit swelling and membrane rupture [16].

This comparative guide provides researchers with standardized methodologies and interpretation frameworks for investigating PARP-1 cleavage patterns in the context of cellular energy dynamics, enabling more accurate characterization of cell death mechanisms in experimental models.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme with crucial roles in DNA repair, genomic stability, and transcriptional regulation. Its cleavage during cell death has become a significant biomarker for distinguishing different death modalities. This review systematically compares how PARP-1 cleavage patterns vary substantially across different experimental models, including diverse cell types and death inducers. Understanding this variability is essential for researchers investigating apoptosis, necrosis, and other forms of cell death in experimental and therapeutic contexts. The specific proteolytic fragments generated serve as molecular signatures that can identify not only the death modality but also the specific proteases activated in particular pathophysiological conditions [2].

PARP-1 Cleavage Signatures in Apoptosis Versus Necrosis

The cleavage pattern of PARP-1 provides a critical diagnostic tool for distinguishing between apoptosis and necrosis. During apoptosis, caspase activation leads to the characteristic cleavage of PARP-1 into 89 kDa and 24 kDa fragments, while necrosis involves different proteases that generate alternative fragments, most notably a 50 kDa fragment [8] [36].

Table 1: Key Characteristics of PARP-1 Cleavage in Apoptosis vs. Necrosis

Feature	Apoptosis	Necrosis
Primary Cleavage Fragments	89 kDa and 24 kDa	50 kDa
Key Proteases Involved	Caspases-3 and -7	Lysosomal proteases (Cathepsins B, D, G)
Caspase Inhibitor Sensitivity	Inhibited by zVAD-fmk	Not inhibited by zVAD-fmk
DNA Binding Domain Fate	24 kDa fragment retains DNA binding	Alternative processing
Catalytic Domain Fate	89 kDa fragment with reduced activity	50 kDa fragment with modified function
Regulatory Consequences	Inactivates PARP-1 to conserve ATP	Distinct functional alterations

Apoptotic Cleavage of PARP-1

During apoptosis, PARP-1 is cleaved at the DEVD214 site by activated caspases-3 and -7, producing 89 kDa and 24 kDa fragments [38] [36]. The 24 kDa fragment contains the DNA-binding domain and remains nuclear, acting as a trans-dominant inhibitor of intact PARP-1 by irreversibly binding to DNA strand breaks [2]. The 89 kDa fragment, containing the automodification and catalytic domains, has reduced DNA binding capacity and can be liberated from the nucleus into the cytosol [2] [15]. This cleavage event was initially thought primarily to prevent energy depletion by inactivating PARP-1, but emerging evidence suggests more complex regulatory functions in transcription and inflammation [38].

Necrotic Cleavage of PARP-1

In contrast to apoptosis, necrosis induces a different PARP-1 cleavage pattern characterized by a prominent 50 kDa fragment [8]. This necrotic cleavage is not inhibited by the broad-spectrum caspase inhibitor zVAD-fmk, indicating the involvement of alternative proteases [8]. Research indicates that lysosomal proteases released during necrosis, particularly cathepsins B and G, are responsible for this distinctive cleavage pattern [8]. When lysosomes release their contents into the cytosol during necrotic cell death, these liberated proteases cleave PARP-1 to generate fragments that differ in both size and function from those produced during apoptosis.

Experimental Models and Methodologies for PARP-1 Cleavage Analysis

Cell Type Considerations

Different cell types and model systems have been employed to study PARP-1 cleavage, each with distinct advantages and limitations:

• Jurkat T-cells: Frequently used for necrosis studies, treated with inducers like 0.1% H₂O₂, 10% EtOH, or 100 μM HgCl₂ to investigate lysosomal protease-mediated PARP-1 cleavage [8].
• HL-60 Cells: Human promyelocytic leukemia cells used to study etoposide phosphate-induced apoptosis and PARP-1 cleavage dynamics [2].
• SH-SY5Y Cells: Human neuroblastoma cell line employed in oxygen/glucose deprivation models to simulate ischemic conditions and investigate PARP-1 cleavage fragments' role in cell viability [38] [28].
• Primary Cortical Neurons: Isolated from Sprague-Dawley rats at postnatal day 2, used in OGD/restoration of oxygen and glucose models to validate findings in primary cells [38].
• PARP-1-Deficient 293T Cells: Used for transfection studies with PARP-1 constructs to investigate specific cleavage fragments' functions [49].

Death Inducers and Their Specific Effects

The choice of death inducers significantly influences the observed PARP-1 cleavage patterns:

Table 2: PARP-1 Cleavage Patterns by Death Inducers and Cell Types

Cell Type/Line	Death Inducer	Cleavage Fragments	Primary Proteases	Experimental Context
Jurkat T-cells	0.1% H₂O₂, 10% EtOH, 100 μM HgCl₂	50 kDa	Cathepsins B, G	Necrosis [8]
HL-60 Cells	Etoposide phosphate	89 kDa, 24 kDa	Caspase-3	Apoptosis [2]
SH-SY5Y	Oxygen/Glucose Deprivation	89 kDa, 24 kDa	Caspases	In vitro ischemia [38]
Various	Staurosporine, Actinomycin D	89 kDa, 24 kDa	Caspases	Apoptosis [15]
293T	Poly(dA-dT) transfection	89 kDa, 24 kDa	Caspase-3	Innate immune apoptosis [49]

Key Experimental Protocols

In Vitro Lysosomal Protease Cleavage Assay

This protocol is essential for investigating necrotic PARP-1 cleavage [8]:

• Isolate lysosomal-rich fractions from Jurkat T-cells using isopycnic centrifugation in Percoll gradients.
• Purify bovine PARP-1 using affinity purification techniques.
• Incubate purified PARP-1 with lysosomal fractions or individual cathepsins in appropriate buffer systems.
• Analyze cleavage patterns using Western blotting with PARP-1 specific antibodies.
• Compare fragment sizes with those observed in cells treated with necrotic inducers.

Apoptotic Cleavage Analysis

Standardized protocol for assessing apoptotic PARP-1 cleavage [38] [36]:

• Induce apoptosis using appropriate stimuli (e.g., etoposide, staurosporine).
• Prepare cell lysates at various time points post-induction.
• Separate proteins using SDS-PAGE (8-12% gels).
• Transfer to membranes and probe with PARP-1 antibodies that recognize both full-length and cleaved fragments.
• Use caspase inhibitors (zVAD-fmk) as controls to confirm caspase-dependent cleavage.
• Assess caspase activity using fluorometric or colorimetric substrates (e.g., DEVD-pNa).

Functional Consequences of Differential PARP-1 Cleavage

Biological Activities of Cleavage Fragments

The different PARP-1 cleavage fragments generated in apoptosis versus necrosis possess distinct functional properties that influence cell fate decisions:

Diagram 1: PARP-1 Cleavage Pathways in Apoptosis vs. Necrosis. This diagram illustrates the proteolytic processing of PARP-1 through different pathways depending on the cell death stimulus, generating fragments with distinct biological activities.

Regulation of Inflammatory Responses

PARP-1 cleavage fragments differentially regulate inflammatory signaling pathways, particularly NF-κB-mediated transcription:

• PARP-1 UNCL (Uncleavable) and PARP-1 24: These constructs confer protection from oxygen/glucose deprivation damage and are associated with decreased iNOS and COX-2 expression, along with increased Bcl-xL levels [38] [28].
• PARP-1 89: This fragment exhibits cytotoxic properties and induces significantly higher NF-κB and iNOS promoter activity compared to wild-type PARP-1, accompanied by increased COX-2 and iNOS protein expression and decreased Bcl-xL [38] [28].

Novel Functions of Cleavage Fragments

Emerging research has revealed non-canonical functions of PARP-1 cleavage fragments:

• The 89 kDa fragment (tPARP1) translocates to the cytoplasm during apoptosis and can mono-ADP-ribosylate RNA Polymerase III, facilitating IFN-β production and enhancing apoptosis during innate immune responses [49].
• Truncated PARP1 recognizes and interacts with the Pol III complex via its BRCT domain, revealing a novel biological function in cytosolic DNA-induced apoptosis [49].
• The 89 kDa fragment with covalently attached PAR polymers can serve as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis, illustrating cross-talk between caspase-dependent and independent death pathways [15].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for PARP-1 Cleavage Studies

Reagent/Catalog	Type	Primary Function	Application Examples
zVAD-fmk	Caspase inhibitor	Broad-spectrum caspase inhibition; distinguishes caspase-dependent vs independent cleavage [8]	Negative control for apoptotic cleavage; confirms necrotic cleavage mechanisms
Anti-PARP-1 Antibodies	Detection reagents	Identify full-length and cleaved fragments; specific antibodies detect particular epitopes [8]	Western blotting, immunoprecipitation; monitoring cleavage dynamics
Cathepsin Inhibitors	Protease inhibitors	Block lysosomal protease activity; investigate necrotic cleavage [8]	Confirm cathepsin involvement in necrosis; mechanistic studies
Recombinant PARP-1	Protein substrate	In vitro cleavage assays; protease characterization [8]	Define direct cleavage events; quantify protease activities
DEVD-pNa	Caspase substrate	Colorimetric caspase activity measurement [8]	Correlate caspase activation with PARP-1 cleavage
Tet-inducible PARP-1 Constructs	Expression vectors	Express PARP-1 variants (WT, UNCL, 24, 89) [38]	Functional studies of cleavage fragments; viability assays
Poly(dA-dT)	DNA transfection	Mimic pathogenic DNA; induce innate immune apoptosis [49]	Study Pol III-mediated apoptosis; tPARP1 function in immune response

The variability in PARP-1 cleavage across cell types and inducers underscores the complexity of cell death mechanisms and highlights the importance of careful model system selection. The distinct cleavage signatures serve as valuable biomarkers for identifying specific death pathways and protease activities in different pathological contexts. Understanding these patterns has significant implications for drug development, particularly in cancer therapy where PARP inhibitors are already deployed, and in neurological disorders where PARP-1 activation contributes to disease pathogenesis. Future research should focus on elucidating the complete functional repertoire of PARP-1 cleavage fragments and their potential as therapeutic targets in various disease states.

Comparative Analysis and Functional Validation of PARP-1 Fragments

Poly(ADP-ribose) polymerase-1 (PARP-1) is a 113-116 kDa nuclear enzyme that functions as a primary DNA damage sensor and plays a crucial role in the cellular response to genotoxic stress [62] [37] [68]. As a key component of the base excision repair pathway, PARP-1 becomes activated upon binding to DNA strand breaks, catalyzing the transfer of ADP-ribose units from NAD+ to target proteins, including itself [62] [68]. This post-translational modification facilitates DNA repair by recruiting additional repair proteins to damage sites. However, the role of PARP-1 extends beyond DNA repair, as its activation and subsequent proteolytic cleavage have emerged as critical events determining cellular fate in response to different death stimuli [62] [37].

The cleavage pattern of PARP-1 serves as a biochemical signature that distinguishes between two principal modes of cell death: apoptosis and necrosis [8] [11]. Apoptosis, or programmed cell death, is characterized by caspase activation and occurs under physiological conditions, while necrosis represents an accidental, inflammatory form of cell death typically triggered by severe damage [62] [68]. The differential cleavage of PARP-1 not only serves as a diagnostic marker but also actively participates in regulating the cell death process through the generation of distinct cleavage fragments with unique biological activities [62] [37]. This comparison guide examines the characteristic PARP-1 cleavage patterns in experimental models of apoptosis and necrosis, providing researchers with essential information for interpreting cell death mechanisms in their experimental systems.

Comparative Analysis of Cleavage Patterns

Characteristic Proteolytic Fragments

Table 1: PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Feature	Apoptotic Cleavage	Necrotic Cleavage
Primary Fragments	89 kDa (catalytic domain) and 24 kDa (DNA-binding domain) [37]	89 kDa, 50 kDa (major), and minor fragments at ~40 kDa and 35 kDa [8] [11]
Responsible Proteases	Caspase-3 and Caspase-7 [62] [37]	Lysosomal proteases (cathepsins B and G) [8]
Protease Inhibitor Sensitivity	Inhibited by zVAD-fmk (caspase inhibitor) [62]	Not inhibited by zVAD-fmk [8]
DNA Fragmentation Pattern	Internucleosomal DNA laddering [62]	Random DNA digestion [68]
Cellular ATP Levels	Maintained due to PARP-1 inactivation [62]	Depleted due to PARP-1 overactivation [62]
Biological Consequence	Prevents energy depletion, facilitates apoptotic execution [62]	Contributes to energy crisis, promotes necrotic outcome [62]

Functional Consequences of Differential Cleavage

The biological outcomes of PARP-1 cleavage differ significantly between apoptotic and necrotic pathways. During apoptosis, caspase-mediated cleavage separates the DNA-binding domain (24 kDa) from the catalytic domain (89 kDa), producing a DNA-binding fragment that acts as a trans-dominant inhibitor of intact PARP-1 [37]. This prevents excessive NAD+ and ATP consumption, thereby conserving cellular energy necessary for the ordered execution of apoptosis [62]. The 89-kD fragment containing the auto-modification and catalytic domains exhibits reduced DNA binding capacity and may be liberated from the nucleus into the cytosol [37].

In contrast, necrotic cleavage generates a distinct fragment pattern that includes a prominent 50 kDa fragment alongside the 89 kDa fragment [8] [11]. This cleavage is mediated by lysosomal proteases released during necrotic cell death, particularly cathepsins B and G [8]. Unlike apoptotic cleavage, the necrotic processing of PARP-1 occurs in the context of severe energy depletion resulting from PARP-1 overactivation, which consumes NAD+ and ATP in an attempt to repair extensive DNA damage [62]. The functional consequences of the specific necrotic fragments are less characterized but coincide with the loss of plasma membrane integrity and inflammatory response characteristic of necrosis [62] [68].

Molecular Mechanisms and Signaling Pathways

Apoptotic PARP-1 Cleavage Pathway

The apoptotic cleavage of PARP-1 represents a coordinated biochemical event that occurs during programmed cell death. This process is initiated when death ligands (such as Fas ligand) bind to their cognate receptors, triggering the activation of initiator caspases which then activate executioner caspases, primarily caspase-3 and caspase-7 [62] [37]. These effector caspases recognize the DEVD214↓G215 motif in PARP-1 and cleave between aspartic acid 214 and glycine 215 [62] [37]. This specific cleavage separates the two zinc-finger DNA-binding motifs at the N-terminus from the automodification and catalytic domains at the C-terminus [62]. The resulting 24 kDa DNA-binding fragment remains tightly bound to DNA, acting as a dominant-negative inhibitor that blocks further PARP-1 activation at DNA break sites, thereby preventing excessive NAD+ consumption [37]. This conservation of cellular energy maintains the ATP levels required for the execution of apoptosis [62].

Figure 1: Apoptotic PARP-1 Cleavage Signaling Pathway

Necrotic PARP-1 Cleavage Pathway

Necrotic PARP-1 cleavage follows a distinct pathway initiated by different death stimuli, such as oxidative stress induced by TNF or hydrogen peroxide [62] [8]. These stimuli generate reactive oxygen species that cause extensive DNA damage, leading to PARP-1 overactivation [62] [68]. The hyperactivation of PARP-1 results in massive NAD+ consumption, which in turn depletes ATP stores through attempts to resynthesize NAD+ [62]. This energy depletion triggers loss of lysosomal membrane integrity and release of lysosomal proteases, including cathepsins B and G, into the cytosol [8]. These proteases then cleave PARP-1 to generate the characteristic necrotic fragments, including the major 50 kDa fragment [8]. In some necrotic pathways, PARP-1 overactivation can also trigger the translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus, where it contributes to large-scale DNA fragmentation and chromatin condensation [68] [69]. This pathway represents a caspase-independent cell death mechanism with distinct morphological features.

Figure 2: Necrotic PARP-1 Cleavage Signaling Pathway

Experimental Models and Methodologies

Standardized Experimental Protocols

Table 2: Experimental Models for Studying PARP-1 Cleavage

Cell Death Type	Common Inducers	Treatment Conditions	Detection Methods
Apoptosis	Anti-CD95 antibody [62], Etoposide (VP-16) [8] [11], Staurosporine [8]	Anti-CD95: 1-2 μg/mL for 4-24 hours [62]; Etoposide: 50-100 μM for 4-8 hours [8]	Western blot with PARP-1 antibodies (89 kDa fragment) [62] [8]; Caspase-3 activity assays [37]
Necrosis	Hydrogen peroxide (H₂O₂) [8], Ethanol [8], Mercuric chloride (HgCl₂) [8], TNF + zVAD [62]	H₂O₂: 0.1% for 2-8 hours [8]; Ethanol: 10% for 2-8 hours [8]; TNF + zVAD: 10-100 ng/mL TNF with 50-100 μM zVAD [62]	Western blot (50 kDa fragment) [8] [11]; Flow cytometric analysis [8]; LDH release assays [68]

Detailed Methodological Approaches

Induction and Analysis of Apoptotic Cleavage

For studying apoptotic PARP-1 cleavage, researchers typically use human promyelocytic leukemia HL-60 cells or Molt4 cells treated with etoposide (50-100 μM for 4-8 hours) or anti-CD95 antibody (1-2 μg/mL for 4-24 hours) [62] [8] [11]. Following treatment, cells are harvested and lysed using RIPA buffer supplemented with protease inhibitors. Protein extracts are separated by SDS-PAGE (8-10% gels) and transferred to nitrocellulose membranes for Western blot analysis [62]. PARP-1 cleavage is detected using specific antibodies that recognize the 89 kDa fragment, with the 116 kDa full-length PARP-1 serving as a control [62] [8]. Additionally, caspase-3 activity can be measured using fluorogenic substrates such as DEVD-AMC to confirm apoptotic induction [37]. To verify the caspase-dependence of the cleavage, researchers often include the broad-spectrum caspase inhibitor zVAD-fmk (50-100 μM) in parallel experiments [62].

Induction and Analysis of Necrotic Cleavage

For necrotic PARP-1 cleavage studies, Jurkat T cells or HL-60 cells are commonly treated with hydrogen peroxide (0.1% for 2-8 hours), ethanol (10% for 2-8 hours), or mercuric chloride (100 μM for 2-8 hours) [8]. In L929 fibrosarcoma cells, a combination of TNF (10-100 ng/mL) with the caspase inhibitor zVAD (50-100 μM) effectively induces necrosis and potentiates PARP-1 cleavage [62]. Cell lysates are prepared and analyzed by Western blot using antibodies that detect the characteristic 50 kDa necrotic fragment alongside the 89 kDa fragment [8] [11]. To confirm the necrotic phenotype, researchers perform flow cytometric analysis of propidium iodide uptake to assess plasma membrane integrity [8]. The lysosomal involvement can be demonstrated using cathepsin inhibitors such as CA-074-Me for cathepsin B or pepstatin A for cathepsin D [8]. Cellular ATP levels can be measured using commercial luminescent assays to confirm energy depletion [62].

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Reagents for PARP-1 Cleavage Studies

Reagent Category	Specific Examples	Experimental Function	Key Applications
Cell Death Inducers	Anti-CD95 antibody [62], Etoposide (VP-16) [8] [11], Hydrogen peroxide (H₂O₂) [8], TNF-α [62]	Induce specific cell death pathways (apoptosis vs. necrosis)	Trigger PARP-1 cleavage through defined mechanisms
Protease Inhibitors	zVAD-fmk (caspase inhibitor) [62] [8], CA-074-Me (cathepsin B inhibitor) [8], Pepstatin A (cathepsin D inhibitor) [8]	Distinguish between caspase-dependent and independent cleavage	Mechanistic studies to identify responsible proteases
PARP Inhibitors	3-aminobenzamide (3AB) [62], ABT-888 [70]	Inhibit PARP-1 enzymatic activity	Study consequences of PARP-1 activation inhibition
Detection Antibodies	Anti-PARP-1 antibodies (various clones) [62] [8]	Detect full-length and cleaved PARP-1 fragments	Western blot, immunofluorescence analysis
Cell Death Assay Kits	Annexin V/propidium iodide kits [62] [70], LDH release assays [68], Caspase activity assays [37]	Characterize mode and extent of cell death	Validate cell death phenotype alongside cleavage analysis

Regulatory Mechanisms and Modulators

BCL2-PARP1 Interaction

The anti-apoptotic protein BCL2, known for its role in regulating mitochondrial outer membrane permeabilization, also directly interacts with PARP1 and suppresses its enzymatic activity [70]. This interaction occurs in the nucleus of lymphoid tumor cells, where BCL2 localizes despite its primary mitochondrial function [70]. The BCL2-PARP1 complex inhibits PARP1-dependent DNA repair, and disruption of this interaction using BH3 mimetics like ABT-737 displaces PARP1 from BCL2, re-establishing PARP1 activity and promoting non-apoptotic cell death [70]. This mechanism may be particularly relevant in B-cell lymphomas and chronic lymphocytic leukemia, which often depend on BCL2 for survival but may become resistant to apoptotic stimuli [70]. Interestingly, ectopic BCL2 expression kills PARP inhibitor-sensitive breast and lung cancer cells, suggesting a complex regulatory relationship between these proteins [70].

Metabolic Regulation via IMPDH2

Recent research has identified inosine monophosphate dehydrogenase 2 (IMPDH2), a metabolic enzyme involved in guanine nucleotide synthesis, as a novel modulator of PARP1 activity [71]. In triple-negative breast cancer cells, IMPDH2 localizes to chromatin where it interacts with PARP1 and modulates its activity by controlling nuclear NAD+ availability [71]. When IMPDH2 is restricted to the nucleus, it depletes nuclear NAD+, leading to impaired PARP1 function and ultimately PARP1 cleavage and cell death [71]. This discovery reveals an important connection between nuclear metabolism and DNA damage response, suggesting that metabolic enzymes can directly influence PARP1-mediated cell death pathways in aggressive cancers [71].

Technical Considerations and Best Practices

Experimental Design Considerations

When designing experiments to study PARP-1 cleavage, researchers should consider several critical factors. First, the choice of cell model is crucial, as different cell lines may exhibit varying sensitivities to apoptotic versus necrotic stimuli [62]. For instance, L929 fibrosarcoma cells undergo necrosis in response to TNF treatment, while the same cells transfected with CD95 receptor undergo apoptosis upon anti-CD95 stimulation [62]. Second, time course experiments are essential, as PARP-1 cleavage fragments may appear transiently and their kinetics differ between apoptosis and necrosis [62] [8]. Third, researchers should include appropriate controls, including caspase inhibitors to confirm the specificity of cleavage patterns and PARP inhibitors to assess the functional consequences of PARP-1 activation [62] [8].

Interpretation of Results

Accurate interpretation of PARP-1 cleavage data requires attention to several potential pitfalls. The appearance of both apoptotic and necrotic fragments may indicate mixed cell death populations or overlapping death pathways [8] [11]. Researchers should corroborate PARP-1 cleavage patterns with additional cell death markers, such as phosphatidylserine exposure for apoptosis and plasma membrane permeability for necrosis [62] [8]. The cellular context is also important, as PARP-1 cleavage fragments may have different functions in various cell types [37]. Additionally, researchers should be aware that certain treatments may simultaneously activate multiple proteolytic systems, leading to complex cleavage patterns that require careful mechanistic dissection [37] [8].

Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme with well-established roles in DNA damage response and repair. During apoptosis, PARP-1 is cleaved by caspases, generating characteristic fragments including a 24-kDa fragment (p24) containing the DNA-binding domain [2]. This cleavage event serves as a recognized hallmark of apoptotic cell death and has significant functional consequences for DNA repair processes, particularly base excision repair (BER) [2] [8]. In contrast, necrotic cell death produces a different PARP-1 cleavage pattern dominated by a 50-kDa fragment, primarily through the action of lysosomal proteases such as cathepsins B and G [8]. This comparison of PARP-1 cleavage patterns in apoptosis versus necrosis provides critical insights into divergent cell death mechanisms and their functional outcomes. The 24-kDa fragment generated during apoptosis operates as a trans-dominant inhibitor of BER, effectively suppressing DNA repair in dying cells and facilitating the apoptotic process [2] [72].

Mechanistic Insights: How the 24-kDa Fragment Inhibits BER

Structural Basis for Dominant-Negative Function

The 24-kDa PARP-1 fragment (p24) consists primarily of the DNA-binding domain (DBD) containing two zinc finger motifs but lacks the auto-modification and catalytic domains present in the full-length enzyme [2]. This structural configuration enables p24 to bind irreversibly to DNA strand breaks but prevents it from performing PARP-1's catalytic functions or undergoing the auto-poly(ADP-ribosyl)ation that normally facilitates dissociation of full-length PARP-1 from DNA [2] [72]. The fragment retains approximately 25% of the DNA-binding activity of full-length PARP-1, allowing it to effectively compete with DNA repair enzymes for binding sites at DNA damage locations [72].

Pathway-Specific Inhibition Mechanisms

The 24-kDa fragment differentially inhibits the two main BER pathways through distinct mechanisms:

• Short-Patch (SP) BER Inhibition: In the short-patch pathway, which typically replaces a single nucleotide, p24 binding to DNA intermediates can partially inhibit but not completely block repair synthesis and ligation steps [72].

• Long-Patch (LP) BER Inhibition: The 24-kDa fragment more potently suppresses long-patch BER, which involves strand displacement synthesis and replacement of 2-13 nucleotides. p24 binding to DNA duplexes with 5'-flap structures characteristic of LP BER intermediates inhibits both strand-displacement DNA synthesis and flap endonuclease 1 (FEN1) activity [72]. This preferential inhibition occurs because p24 efficiently competes with essential LP BER proteins including FEN1 and proliferating cell nuclear antigen (PCNA) for binding to DNA repair intermediates [72].

Table 1: Comparative Effects of the 24-kDa PARP-1 Fragment on BER Pathways

BER Pathway	Key Proteins Involved	Inhibition Mechanism by p24	Inhibition Efficiency
Short-Patch BER	DNA polymerase β (pol β), XRCC1-DNA ligase III complex	Partial inhibition of gap filling and nick sealing; does not completely block repair	Moderate inhibition
Long-Patch BER	FEN1, PCNA, pol β/δ/ε	Strong suppression of strand-displacement synthesis and FEN1 endonuclease activity; competes with FEN1 and PCNA for DNA binding	Potent inhibition

The following diagram illustrates the mechanism by which the 24-kDa fragment inhibits long-patch base excision repair:

Experimental Evidence and Methodologies

Key Experimental Systems and Approaches

Research characterizing the 24-kDa fragment's inhibitory function has employed several sophisticated experimental systems:

• In Vitro BER Assays: Bovine testis nuclear extracts provided a functional system for analyzing BER reactions using defined DNA substrates mimicking different BER intermediates [72]. This approach enabled precise assessment of how p24 influences specific repair steps.

• Photocross-Linking Techniques: Photoreactive DNA probes containing specific BER intermediates (nicks, gaps, or flaps) allowed researchers to map protein-DNA interactions and demonstrate competitive binding between p24 and BER enzymes [72].

• Reconstituted BER Systems: Combining purified BER proteins (pol β, FEN1, PCNA) with p24 enabled mechanistic studies of how the fragment interferes with specific protein functions at discrete steps of the repair process [72].

Table 2: Experimental Approaches for Studying 24-kDa Fragment Inhibition of BER

Methodology	Experimental System	Key Findings
In Vitro BER Kinetics	Bovine testis nuclear extract + defined DNA substrates	p24 preferentially inhibits LP over SP BER; inhibition depends on p24:repair enzyme ratio
Competitive Photocross-Linking	Photoreactive BER DNA intermediates	p24 interacts with same DNA structures as PARP-1 (gapped, nicked, flap-containing DNA)
Protein Complementation Assays	Purified BER enzymes (FEN1, PCNA, pol β) + p24	p24 competes with FEN1 and PCNA; pol β addition partially restores DNA synthesis

Quantitative Assessment of Inhibitory Effects

Experimental data demonstrate that the 24-kDa fragment's inhibition of BER is concentration-dependent and pathway-specific. In functional assays, p24 binding to DNA duplexes with 5'-furan (a synthetic abasic site analog) or 5'-flap structures effectively suppressed strand-displacement DNA synthesis and FEN1 activity in LP BER [72]. The inhibitory effect was more pronounced for LP BER compared to SP BER, with complete inhibition of FEN1-mediated flap cleavage observed at specific p24 concentrations [72]. Addition of pol β to the experimental system partially overcame p24-mediated inhibition and restored some DNA synthesis activity, suggesting competitive dynamics between p24 and specific BER enzymes [72].

Comparative Analysis: Apoptotic vs. Necrotic PARP-1 Cleavage

The functional consequences of PARP-1 cleavage differ significantly between apoptotic and necrotic cell death, with important implications for DNA repair capacity and cell fate decisions.

Table 3: PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Characteristic	Apoptotic Cleavage	Necrotic Cleavage
Primary Proteases	Caspases-3 and -7	Lysosomal proteases (cathepsins B, D, G)
Characteristic Fragments	24-kDa and 89-kDa fragments	50-kDa fragment
Effect on DNA Repair	Potent inhibition of BER via p24	Different fragment pattern with distinct functional consequences
Regulation	Caspase-dependent, inhibited by zVAD-fmk	Caspase-independent, not inhibited by zVAD-fmk
Energy Conservation	Prevents NAD+/ATP depletion	Not applicable (energy collapse in necrosis)

The following diagram contrasts PARP-1 cleavage in apoptosis versus necrosis and the different functional outcomes:

The Scientist's Toolkit: Essential Research Reagents

Investigation of the 24-kDa PARP-1 fragment and its functions requires specific research tools and experimental approaches:

Table 4: Key Research Reagents for Studying the 24-kDa PARP-1 Fragment

Reagent/Category	Specific Examples	Research Applications
Cell-Free Systems	Bovine testis nuclear extract	Functional BER assays with defined DNA substrates
DNA Substrates	Photoreactive BER intermediates (gapped, nicked, flap-containing DNA)	Protein-DNA interaction studies via photocross-linking
Purified Proteins	Recombinant 24-kDa fragment, FEN1, PCNA, pol β	Reconstituted BER systems for mechanistic studies
Protease Inhibitors	zVAD-fmk (caspase inhibitor), cathepsin inhibitors	Differentiation between apoptotic and necrotic cleavage
Detection Methods	Activity-Western blot technique, nonisotopic assays	PARP-1 cleavage fragment detection and quantification
Antibody Probes	Anti-peptide antibodies targeting PARP-1 domains	Specific detection of cleavage fragments in cell death

Research Implications and Therapeutic Perspectives

The trans-dominant inhibition of BER by the 24-kDa PARP-1 fragment represents a crucial biochemical switch that ensures irreversible commitment to apoptotic cell death by preventing DNA repair in damaged cells [2] [72]. This mechanism conserves cellular energy (NAD+ and ATP) that would otherwise be consumed by PARP-1 activation and DNA repair attempts, thereby facilitating the efficient execution of apoptosis [2] [73]. From a therapeutic perspective, understanding this process provides potential opportunities for cancer treatment strategies that exploit the differential DNA repair capacities between normal and malignant cells.

The contrasting PARP-1 cleavage patterns in apoptosis versus necrosis serve as valuable diagnostic markers and research tools for distinguishing these fundamentally different cell death pathways in experimental and potentially clinical contexts [8]. Future research directions include elucidating potential non-apoptotic functions of PARP-1 fragments and developing more specific detection methods for different PARP-1 cleavage products in complex biological samples.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a 113-116 kDa nuclear enzyme that plays a decisive role in cell fate decisions following DNA damage [8] [74] [2]. Its cleavage patterns serve as molecular signatures that distinguish between different programmed cell death pathways, particularly apoptosis and necrosis [8] [2]. In apoptosis, caspases cleave PARP-1 into characteristic 24-kDa and 89-kDa fragments [10] [8] [2]. Recent research has revealed that beyond the traditional view of inactivation, the 89-kDa fragment actively functions as a cytoplasmic poly(ADP-ribose) (PAR) carrier, bridging caspase-mediated apoptosis with PAR-mediated parthanatos [10] [29] [15]. This comparison guide examines the distinct PARP-1 cleavage patterns across cell death pathways and explores the implications of the 89-kDa fragment's novel role for basic research and drug development.

PARP-1 Cleavage Fragment Comparison: Apoptosis vs. Necrosis

Table 1: Comparative Analysis of PARP-1 Cleavage in Cell Death Pathways

Feature	Apoptotic Cleavage	Necrotic Cleavage	Parthanatos
Primary Inducers	Staurosporine, Actinomycin D, Etoposide [10] [8] [29]	H₂O₂, Ethanol, HgCl₂ [8]	MNNG, glutamate excitotoxicity, oxidative stress [74] [75]
Key Proteases	Caspases-3 and -7 [10] [29] [2]	Cathepsins B and G, lysosomal proteases [8] [2]	PARP-1 overactivation (no proteolytic cleavage) [74] [75]
Characteristic Fragments	24-kDa (DBD) and 89-kDa (catalytic) [10] [8] [29]	50-kDa fragment [8]	No cleavage; PAR polymer accumulation [74] [75]
Caspase Inhibitor Effect	Inhibited by zVAD-fmk [10] [8]	Not inhibited by zVAD-fmk [8]	Caspase-independent [10] [74]
Fragment Localization	24-kDa nuclear; 89-kDa cytoplasmic [10] [29] [15]	Not fully characterized [8]	PAR nuclear to cytoplasmic translocation [74] [75]
Functional Consequences	DNA repair inhibition; novel PAR carrier function [10] [29] [2]	Disruption of PARP-1 function [8]	AIF translocation, large-scale DNA fragmentation [74] [75]

The differential cleavage patterns of PARP-1 provide critical diagnostic signatures for distinguishing cell death mechanisms. During apoptosis, caspase-3 and -7 cleavage occurs between the DNA-binding domain (DBD) and automodification domain, producing 24-kDa and 89-kDa fragments [2]. In contrast, necrosis induces a 50-kDa fragment through lysosomal proteases cathepsins B and G, which is not inhibited by broad-spectrum caspase inhibitors like zVAD-fmk [8]. Parthanatos represents a distinct pathway characterized by PARP-1 overactivation without proteolytic cleavage, leading to substantial PAR polymer accumulation [74] [75].

The 89-kDa Fragment: From Inactivation to Active Signaling Player

Traditional View: PARP-1 Inactivation in Apoptosis

The classical understanding of PARP-1 cleavage in apoptosis centered on functional inactivation [2]. The 24-kDa fragment containing the DNA-binding domain remains nuclear and irreversibly binds to DNA breaks, acting as a trans-dominant inhibitor of DNA repair by blocking access for repair enzymes [2]. The 89-kDa fragment, consisting of the automodification and catalytic domains, was thought to have reduced DNA binding capacity, facilitating the shutdown of PARP-1 activity to conserve cellular ATP during apoptotic execution [2].

Novel Function: Cytoplasmic PAR Carrier in Parthanatos

Recent research by Mashimo et al. (2021) has revealed a previously unrecognized active signaling role for the 89-kDa fragment [10] [29] [15]. This fragment can be poly(ADP-ribosyl)ated before cleavage and subsequently translocates to the cytoplasm, where it serves as a PAR carrier [10] [29]. In the cytoplasm, the PAR-conjugated 89-kDa fragment facilitates AIF release from mitochondria, enabling AIF nuclear translocation and triggering large-scale DNA fragmentation [10] [29] [15]. This mechanism represents a crucial molecular bridge between caspase-dependent apoptosis and PAR-dependent parthanatos [10].

Experimental Approaches for PARP-1 Cleavage Analysis

Key Methodologies and Protocols

Table 2: Essential Methods for PARP-1 Cleavage and Function Analysis

Method	Application	Key Findings Enabled
Western Blot Analysis [10] [8] [29]	Fragment detection and characterization	Identification of 24-kDa/89-kDa (apoptosis) vs. 50-kDa (necrosis) fragments [10] [8]
Subcellular Fractionation [29] [76]	Cellular localization of fragments	89-kDa fragment translocation from nucleus to cytoplasm [10] [29]
Pharmacological Inhibition [10] [8] [29]	Pathway dependency assessment	zVAD-fmk (caspase inhibitor) distinguishes apoptosis from necrosis [10] [8]
Immunofluorescence/Confocal Microscopy [10] [29]	Spatial visualization of fragments and AIF	Co-localization of 89-kDa fragment with PAR and AIF in cytoplasm [10] [29]
shRNA Knockdown [29]	PARP-1 function validation	Confirmed PARP-1 specificity in staurosporine-induced cell death [29]

Detailed Experimental Protocol: 89-kDa Fragment Translocation Assay

Based on the methodology from Mashimo et al., the following protocol can be used to investigate the 89-kDa fragment's role as a cytoplasmic PAR carrier [10] [29]:

• Cell Treatment and Induction:

  • Use HeLa cells or other appropriate cell lines
  • Induce apoptosis with 1-2 μM staurosporine or 1 μM actinomycin D for 1-6 hours [29]
  • Include control groups with PARP inhibitors (PJ34, 10 μM; ABT888, 1 μM) and caspase inhibitor (zVAD-fmk, 20-50 μM) [10] [29]

• Subcellular Fractionation:

  • Harvest cells after treatment
  • Use subcellular protein fractionation kit to separate nuclear, cytoplasmic, and chromatin-bound fractions [29] [76]
  • Validate fraction purity with compartment-specific markers (e.g., histone H3 for nuclear fraction) [76]

• PARP-1 Cleavage Detection:

  • Analyze fractions by Western blotting
  • Use PARP-1 antibodies recognizing full-length and 89-kDa fragment [29]
  • Detect PAR polymers using specific anti-PAR antibodies [10] [29]

• AIF Translocation Assessment:

  • Monitor AIF localization via Western blotting of subcellular fractions
  • Confirm nuclear translocation by immunofluorescence microscopy [10] [29]

• Functional Validation:

  • Employ PARP-1 shRNA knockdown cells to confirm PARP-1 dependence [29]
  • Assess cell viability using ATP-based assays (e.g., ATPlite) [29] [76]

Pathway Integration and Visualization

Figure 1: The 89-kDa PARP-1 fragment serves as a cytoplasmic PAR carrier, connecting caspase activation to AIF-mediated cell death. This pathway illustrates the molecular bridge between apoptotic and parthanatos mechanisms.

Research Reagent Solutions for PARP-1 Studies

Table 3: Essential Research Reagents for PARP-1 Cleavage Studies

Reagent	Function/Application	Specific Examples
PARP Inhibitors [10] [29] [76]	Inhibit PARP catalytic activity; research tools and therapeutic agents	PJ34, ABT888 (veliparib), Olaparib, MK-4827 [10] [29] [76]
Caspase Inhibitors [10] [8] [29]	Distinguish apoptosis from other cell death pathways	zVAD-fmk (broad-spectrum) [10] [8] [29]
Apoptosis Inducers [10] [29]	Activate caspase-dependent apoptosis	Staurosporine, Actinomycin D [10] [29]
Necrosis Inducers [8]	Indce caspase-independent cell death	H₂O₂, Ethanol, HgCl₂ [8]
PARP-1 Antibodies [10] [29] [76]	Detect full-length and cleaved PARP-1 fragments	Various commercial sources for Western blot, immunofluorescence [10] [29] [76]
PAR Polymer Antibodies [29] [76]	Detect PAR accumulation and localization	Anti-PAR polymer antibodies [29] [76]
AIF Antibodies [10] [29]	Monitor AIF subcellular localization	Antibodies for Western blot and immunofluorescence [10] [29]
Subcellular Fractionation Kits [29] [76]	Separate cellular compartments for localization studies	Commercial kits for nuclear/cytoplasmic fractionation [29] [76]

Research Implications and Future Directions

The recognition of the 89-kDa PARP-1 fragment as an active signaling molecule rather than merely an inactivation product has significant implications for both basic research and therapeutic development. This finding reveals previously unrecognized molecular crosstalk between apoptosis and parthanatos, suggesting more complex interconnections between cell death pathways than previously appreciated [10] [29] [15]. From a therapeutic perspective, this pathway offers potential novel drug targets for conditions where parthanatos contributes to pathology, including neurodegenerative diseases, stroke, and ischemia-reperfusion injury [74] [75]. Furthermore, the differential cleavage patterns of PARP-1 provide valuable diagnostic biomarkers for distinguishing cell death mechanisms in pathological tissues [8] [2]. Future research should explore the precise structural determinants of the 89-kDa fragment's PAR carrier function and investigate therapeutic strategies to modulate this pathway in disease contexts.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that functions as a critical molecular sensor for DNA damage. Beyond its well-characterized role in DNA repair, PARP-1 has emerged as a key executioner in multiple regulated cell death pathways. The proteolytic cleavage of PARP-1 by various enzymes produces specific fragments that serve as biochemical signatures for distinguishing between different modes of cellular demise. This comparative guide analyzes experimental data on PARP-1 cleavage patterns across apoptosis and necrosis in three major pathological contexts: cancer, cerebral ischemia, and neurodegenerative disorders. Understanding these distinct cleavage signatures provides researchers with critical biomarkers for investigating cell death mechanisms and evaluating therapeutic interventions.

Comparative Analysis of PARP-1 Cleavage Patterns

Table 1: PARP-1 Cleavage Fragments Across Cell Death Pathways and Disease Contexts

Disease Context	Cell Death Pathway	Primary Protease	Signature PARP-1 Fragments	Experimental Model
Cancer (HL-60 cells)	Apoptosis	Caspase-3/7	89 kDa and 24 kDa fragments [11] [2]	Human promyelocytic leukemia cell line treated with etoposide [11]
Cancer (HL-60 cells)	Necrosis	Calpain, Cathepsins	89 kDa, 50 kDa, 40 kDa, and 35 kDa fragments [11]	Human promyelocytic leukemia cell line treated with cytochalasin B [11]
Cerebral Ischemia	Apoptosis	Caspase-3	89 kDa fragment [77]	Rat transient focal cerebral ischemia model (MCAO) [77]
Cerebral Ischemia	Necrosis	Calpain, Granzyme-B	50 kDa fragment [77]	Rat transient focal cerebral ischemia model (MCAO) [77]
Neurodegenerative Disorders	Parthanatos	PARP-1 hyperactivation (no cleavage)	PAR polymer accumulation, AIF translocation [78]	Subarachnoid hemorrhage rat model [78]

Table 2: Proteases and Their PARP-1 Cleavage Signature Patterns

Protease	Cleavage Site	PARP-1 Fragments	Associated Cell Death Pathway
Caspase-3/7	Asp214-Gly215	24 kDa (DBD) + 89 kDa (AMD+CD) [2]	Apoptosis [2] [26]
Calpain	Multiple sites	50 kDa, 40 kDa, 35 kDa fragments [77]	Necrosis, excitotoxicity [77]
Cathepsin B	Not specified	50 kDa fragment [77]	Lysosomal-mediated cell death [77]
Granzyme B	Asp216-N/A	24 kDa (DBD) + 89 kDa (AMD+CD) [77] [2]	Granzyme-mediated cytotoxicity [77]
Matrix Metalloproteinases	Multiple sites	55 kDa, 40 kDa fragments [2]	Extracellular matrix remodeling-associated death [2]

PARP-1 Cleavage in Cancer Models

Experimental Protocols in Cancer Research

In cancer research, the standard protocol for inducing and analyzing PARP-1 cleavage involves treating cancer cell lines with specific death inducers followed by Western blot analysis. For apoptosis induction, HL-60 human promyelocytic leukemia cells are treated with 25-50 μM etoposide (VP-16) for 4-12 hours. For necrosis induction, the same cell line is treated with 10-20 μM cytochalasin B for a similar duration [11]. After treatment, cells are harvested and lysed using RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.4% deoxycholate, 1% NP-40) containing protease inhibitors (1 mM PMSF) and phosphatase inhibitors (10 mM β-glycerophosphate, 10 mM NaF, 0.3 mM Na₃VO₄) [77]. Protein samples (20-50 μg) are separated by SDS-PAGE (8-12% gels) and transferred to nitrocellulose membranes. PARP-1 cleavage is detected using specific anti-PARP-1 antibodies that recognize both full-length (113 kDa) and cleaved fragments, with particular attention to the 89 kDa apoptotic fragment and the 50 kDa necrotic fragment [11].

Key Findings in Cancer Models

Research has demonstrated that during apoptosis, caspase-3 and caspase-7 cleave PARP-1 at Asp214-Gly215 to generate characteristic 89 kDa and 24 kDa fragments [2]. The 24 kDa fragment contains the DNA-binding domain and remains bound to damaged DNA, acting as a trans-dominant inhibitor of DNA repair, while the 89 kDa fragment containing the automodification and catalytic domains is liberated into the cytosol [2]. In contrast, during necrosis in HL-60 cells, PARP-1 is cleaved by calpains and cathepsins to produce a different pattern of fragments, including major bands at approximately 89 kDa and 50 kDa, with minor fragments at 40 kDa and 35 kDa [11]. This necrosis-specific degradation occurs earlier than extensive DNA degradation and can serve as a sensitive indicator for necrotic cell death in cancer models [11].

PARP-1 Cleavage in Cerebral Ischemia

Experimental Protocols in Cerebral Ischemia

The transient focal cerebral ischemia model in rats provides a well-established system for studying PARP-1 cleavage in brain injury. The protocol involves anesthetizing male Wistar rats (300-350 g) with a N₂O-halothane mixture and occluding the middle cerebral artery (MCA) using the nylon suture method for 3 hours, followed by reperfusion for 1 hour to 1 day [77]. Following reperfusion, neurological deficits are scored on a scale of 0-4 (0 = no deficit; 1 = failure to extend right forepaw; 2 = circling to the right; 3 = unable to walk spontaneously; 4 = dead) [77]. Brain tissues from ipsilateral ischemic regions are homogenized in RIPA buffer with protease and phosphatase inhibitors, followed by sonication and centrifugation at 14,000×g for 15 minutes at 4°C. Western blot analysis is performed using antibodies against PARP-1, calpain, caspase-3, cathepsin-B, and granzyme-B to correlate specific PARP-1 fragments with protease activation [77]. Cresyl violet staining is used to parallelly identify apoptotic and necrotic cell deaths in brain sections [77].

Key Findings in Cerebral Ischemia

In cerebral ischemia, PARP-1 cleavage patterns reflect the complex interplay of multiple proteases. Studies have shown activation of calpain, cathepsin-B, caspase-3, and granzyme-B following ischemic injury, each generating specific PARP-1 signature fragments [77]. The appearance of the 89 kDa fragment indicates apoptotic cell death mediated by caspase-3, while the 50 kDa fragment correlates with necrotic death mediated by calpain and cathepsin-B [77]. Immunofluorescence and co-immunoprecipitation experiments have demonstrated interactions between PARP-1 and apoptosis-inducing factor (AIF) as well as granzyme-B, indicating the involvement of non-apoptotic cell death pathways during cerebral ischemia [77]. The coexistence of multiple PARP-1 fragments in ischemic brain tissue underscores the heterogeneity of cell death in stroke pathology and provides a molecular toolkit for deciphering the dominant mechanisms of neuronal loss.

PARP-1 in Neurodegenerative Disorders

PARP-1 Hyperactivation and Parthanatos

In neurodegenerative contexts, PARP-1-mediated cell death often occurs through parthanatos, a distinct pathway from classical apoptosis and necrosis. Parthanatos is characterized by PARP-1 hyperactivation rather than proteolytic cleavage. In subarachnoid hemorrhage models, excessive PARP-1 activation leads to depletion of NAD+ and ATP, followed by mitochondrial depolarization and nuclear translocation of apoptosis-inducing factor (AIF) [78]. This cascade results in large-scale DNA fragmentation and cell death that bears features of both apoptosis and necrosis but follows a unique biochemical pathway [78]. Experimental evidence shows that PARP-1 inhibition with AG14361 significantly reduces oxidative stress markers like malondialdehyde (MDA) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), decreases neuronal apoptosis, protects blood-brain barrier integrity, and improves neurological function after brain injury [78].

Dual Role of PARP-1 in Neuroprotection and Neurotoxicity

Interestingly, PARP-1 exhibits a dual role in neuronal fate determination depending on the intensity of oxidative stress. Under mild oxidative stress, PARP-1 activation facilitates DNA repair and exerts neuroprotective effects, while severe oxidative stress triggers PARP-1 hyperactivation leading to parthanatos [79]. This dichotomy necessitates careful consideration when developing PARP-1-targeted therapies for neurodegenerative disorders, as complete inhibition might impair physiological DNA repair mechanisms essential for neuronal survival.

Signaling Pathways in PARP-1-Mediated Cell Death

Figure 1: PARP-1 Cleavage Pathways in Different Cell Death Contexts. This diagram illustrates how DNA damage triggers PARP-1 activation, leading to different cleavage patterns and cell death outcomes based on the cellular context and protease activation.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for PARP-1 Cleavage Studies

Reagent/Cell Line	Specific Function	Experimental Application
HL-60 Cell Line	Human promyelocytic leukemia cells	In vitro model for apoptosis/necrosis studies [11]
Etoposide (VP-16)	Topoisomerase II inhibitor	Apoptosis induction in cancer cells [11]
Cytochalasin B	Actin polymerization inhibitor	Necrosis induction in cancer cells [11]
Anti-PARP-1 Antibodies	Detect full-length and cleaved PARP-1	Western blot, immunohistochemistry [77]
Caspase-3 Antibodies	Detect activated caspase-3	Correlate caspase activation with PARP-1 cleavage [77]
Calpain Antibodies	Detect calpain activation	Identify calpain-mediated PARP-1 cleavage [77]
AG14361	PARP-1 specific inhibitor	Study parthanatos inhibition in neurodegenerative models [78]
RIPA Lysis Buffer	Protein extraction	Cell/tissue homogenization for PARP-1 detection [77]

The systematic analysis of PARP-1 cleavage patterns provides powerful discriminatory signatures for distinguishing between apoptosis, necrosis, and parthanatos across different disease contexts. The 89 kDa fragment represents a consistent apoptotic marker in both cancer and cerebral ischemia models, while the 50 kDa fragment indicates necrotic processes. In neurodegenerative contexts, PARP-1 hyperactivation without proteolytic cleavage characterizes parthanatos. These distinct molecular signatures offer researchers validated biomarkers for investigating cell death mechanisms and evaluating therapeutic interventions targeted at specific cell death pathways. The experimental protocols and reagent toolkit presented here provide a foundation for standardized assessment of PARP-1 cleavage across diverse research applications in cancer neuroscience, and drug development.

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that functions as a critical DNA damage sensor and is involved in multiple cellular processes, including DNA repair, transcription, and cell death signaling. The proteolytic cleavage of PARP-1 by various cell death proteases serves as a definitive biochemical signature that distinguishes between different modes of cellular demise—particularly apoptosis and necrosis [37]. This cleavage event is not merely a passive marker of cell death but actively regulates downstream signaling pathways, making it an attractive target for therapeutic intervention. The distinct proteolytic fragments generated during different cell death contexts possess unique biological activities that can either promote or suppress inflammatory responses and influence cell fate decisions [38]. Understanding these differential cleavage patterns provides a strategic foundation for developing novel therapeutics that can modulate cell death pathways in cancer, neurodegenerative disorders, and other diseases characterized by dysregulated cell death.

Comparative Analysis of PARP-1 Cleavage Patterns in Apoptosis vs. Necrosis

Molecular Signatures and Functional Consequences

PARP-1 cleavage produces distinct fragment patterns depending on the protease involved and the cellular context, serving as biochemical fingerprints for specific cell death pathways [37]. The table below summarizes the key characteristics of PARP-1 cleavage in apoptosis versus necrosis.

Table 1: Comparative Analysis of PARP-1 Cleavage in Apoptosis vs. Necrosis

Characteristic	Apoptosis	Necrosis
Primary Proteases	Caspases-3 and -7 [29] [37]	Calpains, Cathepsins [37]
Key Cleavage Fragments	24 kDa (DBD) and 89 kDa (CAT+AMD) [29] [37]	50 kDa and 35-40 kDa fragments [37]
Cleavage Site	DEVD214G (between DBD and AMD) [38]	Multiple sites, less specific
Energy Status	ATP-dependent [6]	ATP depletion [6]
Biological Consequence	Inhibition of DNA repair; facilitation of apoptotic program [37]	Uncontrolled PARP-1 activation leading to energy crisis [6]
Inflammatory Response	Generally anti-inflammatory	Strongly pro-inflammatory
Morphological Features	Cell shrinkage, chromatin condensation, apoptotic bodies [19]	Cell swelling, membrane rupture, organelle damage [19]

Differential Biological Activities of Cleavage Fragments

The functional consequences of PARP-1 cleavage extend beyond the inactivation of the full-length enzyme, as the generated fragments acquire distinct biological activities:

• The 24-kDa DBD Fragment: This fragment contains the DNA-binding domain and remains tightly bound to DNA strand breaks, where it acts as a trans-dominant inhibitor of DNA repair by blocking access of additional PARP-1 molecules and other DNA repair proteins to damage sites [37]. This function ensures the irreversibility of the apoptotic commitment.

• The 89-kDa CAT+AMD Fragment: This C-terminal fragment contains the automodification and catalytic domains. During apoptosis induced by staurosporine and actinomycin D, this fragment can be translocated to the cytoplasm while carrying covalently attached PAR polymers, where it facilitates apoptosis-inducing factor (AIF) release from mitochondria—a critical step in certain cell death pathways [29].

• Necrosis-Associated Fragments: The alternative cleavage patterns observed in necrosis typically preserve the catalytic activity of PARP-1 fragments, contributing to the energy depletion crisis that characterizes this form of cell death through continuous NAD+ consumption [37] [6].

Experimental Approaches for Studying PARP-1 Cleavage

Standardized Methodologies for Detection and Quantification

Table 2: Key Experimental Protocols for PARP-1 Cleavage Analysis

Method	Key Reagents	Protocol Summary	Data Output
Western Blot Analysis	Anti-PARP-1 antibodies (specific for N-terminal or C-terminal epitopes) [29]	Protein extraction, SDS-PAGE, transfer to membrane, antibody incubation, detection	Fragment size determination (89 kDa, 24 kDa, etc.) [29]
Caspase-3 Activity Assay	Caspase-3 fluorogenic substrates (e.g., DEVD-AFC), caspase inhibitors [80]	Cell lysis, incubation with substrate, fluorescence measurement over time	Kinetic analysis of caspase-3 activation relative to PARP-1 cleavage [80]
Immunofluorescence Microscopy	PARP-1 antibodies, fluorescent secondary antibodies, DAPI [80]	Cell fixation, permeabilization, antibody staining, microscopy	Subcellular localization of PARP-1 fragments [29]
Cell Viability Assessment	MTT, LDH release, Fluoro-Jade staining [80]	Treatment with death inducers, incubation with viability markers, quantification	Correlation of PARP-1 cleavage patterns with cell death modality [80]

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagent Solutions for PARP-1 Cleavage Studies

Reagent Category	Specific Examples	Research Application
PARP Inhibitors	Olaparib, Niraparib, PJ34, ABT-888 [81] [29]	Tool compounds to modulate PARP-1 activity and study consequences on cleavage patterns
Protease Inhibitors	zVAD-fmk (caspase inhibitor), Calpain inhibitors, Cathepsin inhibitors [29] [37]	Determination of specific protease involvement in PARP-1 cleavage
Cell Death Inducers	Staurosporine, Actinomycin D, Kainic Acid, NMDA [29] [80]	Induction of specific cell death pathways to study resultant PARP-1 cleavage
PARP-1 Constructs	PARP-1WT, PARP-1UNCL (uncleavable), PARP-124, PARP-189 [38]	Functional analysis of specific PARP-1 domains and cleavage products
Detection Antibodies	Anti-PARP-1 (full length), Anti-89 kDa fragment, Anti-cleaved PARP-1 [29] [80]	Specific detection of PARP-1 and its cleavage fragments

PARP-1 Cleavage Pathways: Molecular Mechanisms and Signaling Networks

The differential cleavage of PARP-1 occurs within complex signaling networks that determine cellular fate. The following diagram illustrates the key pathways involved in PARP-1 cleavage during apoptosis and necrosis, highlighting critical regulatory points and potential therapeutic intervention strategies.

PARP-1 Cleavage Pathways in Cell Death

This diagram illustrates the three major pathways through which PARP-1 cleavage and activation regulates cell fate decisions. The apoptotic pathway (red) involves caspase-mediated cleavage that generates the characteristic 89-kDa and 24-kDa fragments, ultimately leading to controlled cell death. The necrotic pathway (blue) features PARP-1 hyperactivation that consumes cellular energy reserves, resulting in uncontrolled necrosis. The parthanatos pathway (green) represents a caspase-independent cell death mechanism involving PAR translocation and AIF release. The dashed lines indicate potential cross-talk between these pathways, highlighting the complexity of PARP-1's role in cell death regulation.

Therapeutic Applications and Drug Development Strategies

Targeting PARP-1 Cleavage in Cancer Therapy

The strategic exploitation of PARP-1 cleavage pathways has yielded significant advances in cancer therapeutics, particularly through the development of PARP inhibitors:

• Synthetic Lethality in BRCA-Deficient Cancers: PARP inhibitors like Olaparib and Niraparib exploit synthetic lethality in homologous recombination-deficient cancers, particularly those with BRCA mutations [81]. These inhibitors trap PARP-1 on DNA, preventing its auto-modification and release, which leads to replication fork collapse and cell death.

• Dual-Targeting Approaches: Recent drug development has focused on hybrid molecules that simultaneously target PARP-1 and other critical cancer pathways. Spirooxindole-triazole hybrids have demonstrated potent dual inhibition of both EGFR and PARP-1, showing promising cytotoxicity in HepG2 liver cancer cells with IC₅₀ values as low as 1.9 μM while maintaining selectivity over normal cells [82].

• Selective PARP-1 Inhibitors: Second-generation PARP-1 selective inhibitors are being developed to overcome the hematologic toxicity associated with broader PARP inhibition, which may be related to the lack of subtype selectivity of PARP-1/-2 dual inhibitors [81]. Structural analysis of PARP-1's selective binding pockets has enabled the design of inhibitors with improved therapeutic windows.

Neuroprotective Strategies Through PARP-1 Modulation

In neurological contexts, PARP-1 cleavage plays a critical role in excitotoxic neuronal death, making it a promising target for neuroprotective interventions:

• Ischemic Stroke Applications: PARP-1 activation and cleavage peak 2-3 days after excitotoxic injury in cortical neurons, with caspase-3 activation preceding PARP-1 cleavage [80]. PARP inhibitors have shown protective effects in models of cerebral ischemia, brain trauma, and neurodegenerative diseases [37] [83].

• Uncleavable PARP-1 Mutants: Expression of an uncleavable PARP-1 mutant (PARP-1^UNCL) or the 24-kDa fragment alone confers protection from oxygen/glucose deprivation damage in vitro, while the 89-kDa fragment is cytotoxic [38]. This suggests that preventing PARP-1 cleavage or modulating specific fragment activities could represent a viable neuroprotective strategy.

• Inflammation Modulation: PARP-1 cleavage influences NF-κB activity and subsequent inflammatory responses. The 89-kDa fragment increases NF-κB and iNOS transcriptional activities, while PARP-1^UNCL and the 24-kDa fragment decrease iNOS and COX-2 expression while increasing anti-apoptotic Bcl-xL [38].

The strategic targeting of PARP-1 cleavage pathways represents a promising frontier in drug development for cancer and other diseases. The distinct proteolytic signatures associated with different cell death modalities provide both diagnostic biomarkers and therapeutic targets. Future research directions should focus on developing context-specific modulators that can either promote or inhibit PARP-1 cleavage based on therapeutic need, such as promoting cleavage in cancer cells while inhibiting it in neurodegenerative contexts. The continued elucidation of the structural basis for PARP-1 cleavage and fragment function will enable more precise drug design, while combination therapies that target PARP-1 alongside complementary pathways may yield enhanced therapeutic efficacy. As our understanding of PARP-1's multifaceted roles in cell death, DNA repair, and inflammation continues to grow, so too will our ability to therapeutically manipulate this critical regulator for improved patient outcomes.

Conclusion

The cleavage of PARP-1 is not merely a bystander event but a critical molecular decision point that dictates the mode of cellular demise. The distinct patterns—caspase-mediated 89/24 kDa fragments in apoptosis versus lysosomal protease-generated 50 kDa and other fragments in necrosis—provide reliable biomarkers for distinguishing these pathways. The functional consequences of these cleavages are profound, influencing DNA repair capacity, cellular energy homeostasis, and the release of signaling molecules like AIF. For biomedical research, accurately interpreting these signatures is essential for understanding disease pathogenesis, from cancer to ischemic injury. Future directions should focus on exploiting this knowledge therapeutically, particularly in modulating the switch between apoptosis and necrosis to improve outcomes in diseases where cell death is dysregulated. The development of agents that can influence PARP-1 cleavage or the activity of its fragments holds significant promise for novel clinical interventions.

References

• 1. Structural basis for DNA-dependent poly(ADP-ribosyl)ation by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3532513/]
• 2. PARP-1 cleavage fragments: signatures of cell-death ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3022541/]
• 3. PARP1: A comprehensive review of its mechanisms ... [https://www.sciencedirect.com/science/article/pii/S0304419X25000241]
• 4. The DNA Binding and Catalytic Domains of Poly(ADP-Ribose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2169059/]
• 5. The DNA-Binding Domain of Human PARP-1 Interacts with ... [https://www.sciencedirect.com/science/article/pii/S0022283611000635]
• 6. Biological function, mediate cell death pathway and their ... [https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1093939/full]
• 7. Different cleavage pattern for poly(ADP-ribose) polymerase ... [https://pubmed.ncbi.nlm.nih.gov/8954981/]
• 8. Characterization of the necrotic cleavage of poly(ADP- ... [https://www.nature.com/articles/4400851]
• 9. Role of PARP-1 structural and functional features in ... [https://pubmed.ncbi.nlm.nih.gov/39855113/]
• 10. The 89-kDa PARP1 cleavage fragment serves as a ... - PubMed [https://pubmed.ncbi.nlm.nih.gov/33168626/]
• 11. Different Cleavage Pattern for Poly(ADP-Ribose ... [https://www.sciencedirect.com/science/article/abs/pii/S0006291X96918896]
• 12. Apoptotic Caspases-3 and -7 Cleave Extracellular ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12026882/]
• 13. Roles and therapeutic potential of PARP-1 in ... [https://pubmed.ncbi.nlm.nih.gov/41022359/]
• 14. Roles and therapeutic potential of PARP-1 in ... [https://www.sciencedirect.com/science/article/abs/pii/S0006295225006380]
• 15. The 89-kDa PARP1 cleavage fragment serves as a ... [https://www.sciencedirect.com/science/article/pii/S0021925820000320]
• 16. Doxorubicin-induced necrosis is mediated by poly-(ADP ... [https://www.nature.com/articles/srep15798]
• 17. Exploring the role of parthanatos in CNS injury [https://www.sciencedirect.com/science/article/pii/S2090123224001747]
• 18. Caspases as master regulators of programmed cell death [https://www.nature.com/articles/s12276-025-01470-9]
• 19. Insights on the crosstalk among different cell death ... [https://www.nature.com/articles/s41420-025-02328-9]
• 20. Cathepsin B in programmed cell death machinery [https://www.nature.com/articles/s41419-023-05786-0]
• 21. Distinct cathepsins control necrotic cell death mediated by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4614982/]
• 22. Cathepsin B induces kidney diseases through different ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1535313/full]
• 23. It's a Trap!—Potential of Cathepsins in NET Formation [https://www.mdpi.com/1422-0067/26/22/11213]
• 24. Cathepsin-mediated Necrosis Controls the Adaptive ... [https://www.sciencedirect.com/science/article/pii/S0021925819335331]
• 25. Poly(ADP-ribose) polymerase is a mediator of necrotic cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC24176/]
• 26. Caspases as master regulators of programmed cell death [https://pmc.ncbi.nlm.nih.gov/articles/PMC12229594/]
• 27. Transcription–replication conflicts underlie sensitivity to ... [https://www.nature.com/articles/s41586-024-07217-2]
• 28. Poly(ADP-ribose) polymerase-1 and its cleavage products ... [https://www.sciencedirect.com/science/article/pii/S0167488913004242]
• 29. The 89-kDa PARP1 cleavage fragment serves as a ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7948984/]
• 30. Failure of Poly(ADP-Ribose) Polymerase Cleavage by ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC84355/]
• 31. An overview of technical considerations for Western ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5138151/]
• 32. A systematic approach to quantitative Western blot analysis [https://www.sciencedirect.com/science/article/pii/S000326971930750X]
• 33. zVAD-induced necroptosis in L929 cells depends on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3131876/]
• 34. PARP1-mediated necrosis is dependent on parallel JNK ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4179488/]
• 35. TNF-induced necroptosis and PARP-1-mediated necrosis ... [https://link.springer.com/article/10.1007/s00018-013-1381-6]
• 36. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis [https://link.springer.com/article/10.1023/A:1016119328968]
• 37. PARP-1 cleavage fragments: signatures of cell-death ... [https://biosignaling.biomedcentral.com/articles/10.1186/1478-811X-8-31]
• 38. Poly(ADP-ribose) polymerase-1 and its cleavage products ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4013233/]
• 39. Noncleavable poly(ADP-ribose) polymerase-1 regulates ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC522248/]
• 40. Detection of poly(ADP-ribose) polymerase and its ... - PubMed [https://pubmed.ncbi.nlm.nih.gov/8747484/]
• 41. Human cleaved PARP1 (Gly215) ELISA Kit [https://www.abcam.com/en-us/products/elisa-kits/human-cleaved-parp1-gly215-elisa-kit-ab317545]
• 42. Programmed Cell-Death Mechanism Analysis Using Same ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8679084/]
• 43. Characterization of the interactions of PARP-1 with UV- ... [https://www.nature.com/articles/srep19020]
• 44. A simple methodology to assess endolysosomal protease ... [https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/1471-2121-14-35]
• 45. Chapter Nine Lysosomes in Apoptosis [https://www.sciencedirect.com/science/article/abs/pii/S0076687908014092]
• 46. Lysosomal Protease-Mediated APP Degradation is pH ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12265180/]
• 47. Cathepsin B launches an apoptotic exit effort upon cell ... [https://www.nature.com/articles/cddiscovery201612]
• 48. Lysosomal Serine Protease CLN2 Regulates Tumor ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2670156/]
• 49. Truncated PARP1 mediates ADP-ribosylation of RNA ... [https://www.nature.com/articles/s41421-021-00355-1]
• 50. Poly(ADP-Ribose) Polymerase-1 Inhibition by Arsenite ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3327874/]
• 51. STING directly interacts with PAR to promote apoptosis ... [https://www.nature.com/articles/s41418-025-01457-z]
• 52. Evaluation of poly(ADP-ribose) polymerase cleavage ... [https://www.sciencedirect.com/science/article/pii/S0015028208005621]
• 53. Designing a multicolor flow cytometry protocol [https://www.abcam.com/en-us/technical-resources/guides/flow-cytometry-guide/designing-a-multicolor-protocol]
• 54. CYTOMETRY OF APOPTOSIS. HISTORICAL ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3476471/]
• 55. Article PARP-1 improves leukemia outcomes by inducing ... [https://www.sciencedirect.com/science/article/pii/S2666379123003580]
• 56. Comprehensive landscape of cell death mechanisms [https://pmc.ncbi.nlm.nih.gov/articles/PMC12308763/]
• 57. Overlapping cleavage motif selectivity of caspases - PubMed [https://pubmed.ncbi.nlm.nih.gov/17975551/]
• 58. [PDF] Overlapping cleavage motif selectivity of caspases [https://www.semanticscholar.org/paper/Overlapping-cleavage-motif-selectivity-of-caspases%3A-McStay-Salvesen/63b8ebac0ad2ca96f51265991c5bad92bd58bba9]
• 59. Caspases and their substrates | Cell Death & Differentiation [https://www.nature.com/articles/cdd201744]
• 60. An atlas of caspase cleavage events in differentiating ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11344277/]
• 61. Serine ADPr on histones and PARP1 is a cellular target of ... [https://www.nature.com/articles/s41589-025-01974-5]
• 62. Activation and Caspase-mediated Inhibition of PARP - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC99613/]
• 63. The role of Poly-ADP ribose polymerase (PARP) enzymes in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12183237/]
• 64. Pyroptosis: molecular mechanisms and roles in disease [https://www.nature.com/articles/s41422-025-01107-6]
• 65. Epigenetic Insights on PARP-1 Activity in Cancer Therapy - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9817704/]
• 66. PARP (Poly ADP‐ribose Polymerase) Family in Health and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12402623/]
• 67. Role of PARP-1 structural and functional features in ... [https://www.sciencedirect.com/science/article/abs/pii/S0045206825000689]
• 68. PARP and the Release of Apoptosis-Inducing Factor ... - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK6179/]
• 69. Nuclear and mitochondrial conversations in cell death [https://www.sciencedirect.com/science/article/abs/pii/S0165614704000690]
• 70. BCL2 suppresses PARP1 function and non-apoptotic cell death [https://pmc.ncbi.nlm.nih.gov/articles/PMC4075432/]
• 71. Nuclear IMPDH2 controls the DNA damage... | Nature Communications [https://www.nature.com/articles/s41467-024-53877-z?error=cookies_not_supported]
• 72. Suppression of base excision repair reactions by apoptotic ... [https://www.sciencedirect.com/science/article/abs/pii/S1568786406003685]
• 73. Role of Poly(ADP-ribose) Polymerase (PARP) Cleavage in ... [https://www.sciencedirect.com/science/article/pii/S0021925819652385]
• 74. Parthanatos: mitochondrial-linked mechanisms and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3976618/]
• 75. Molecular Mechanisms of Parthanatos and Its Role in Diverse ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9266317/]
• 76. Differential trapping of PARP1 and PARP2 by clinical PARP ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3528345/]
• 77. Differential PARP Cleavage - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC11506027/]
• 78. PARP-1 dependent cell death pathway (Parthanatos) ... [https://www.sciencedirect.com/science/article/abs/pii/S0014299924004539]
• 79. Poly(ADP-ribose) polymerase-1 protects neurons against ... [https://www.nature.com/articles/4402117]
• 80. PARP cleavage, DNA fragmentation, and pyknosis during ... [https://www.sciencedirect.com/science/article/abs/pii/S0014488603003662]
• 81. Design, development, and therapeutic applications of ... [https://pubmed.ncbi.nlm.nih.gov/40948328/]
• 82. Potent EGFR/ PARP - 1 inhibition by spirooxindole-triazole hybrids for... [https://pubs.rsc.org/en/content/articlelanding/2025/ra/d4ra05966b]
• 83. Multifaceted Role of PARP-1 in DNA Repair and ... [https://www.mdpi.com/2073-4409/9/1/41]